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Proteins form the basis of life and are designed to perform a variety of functions. The 
function of a protein is largely determined by its amino acid sequence; therefore 
proteins have been studied extensively using molecular biology techniques. Mutation 
of individual residues to achieve altered function or insertion of new functionalities by 
fusing multiple protein segments was accomplished using molecular biology. Although 
impressive results were achieved, the modifications that are possible using these 
techniques are quite limited from a chemical point of view. For this reason chemical 
protein synthesis plays a huge role in the elucidation of protein function.  
Chemical Protein Synthesis 
Total chemical synthesis of proteins opens up a nearly unlimited array of 
modifications once synthetic access to a protein is established. Moreover, there are 
no limitations to the number of or position at which these modifications are 
introduced. The specificity with which this can be achieved is useful for a wide range 
of applications, i.e. fluorescent- or isotope labelling.  
Synthetic access to proteins has become an established technique to study various 
protein functionalities. This was, however, not possible without the development of 
several synthetic pathways. Early work by Fischer led to the synthesis of a tetra 
peptide[1]; this was followed by the introduction of the carboxybenzoyl group (Cbz) as 
an amine protecting group in peptide synthesis.[2] The Cbz group allowed reversible 
N(α) protection, could be deprotected under mild conditions and was protected from 
racemization during carbonyl activation[2], which led to the synthesis of oxytocin[3] 
and later insulin.[4] A second breakthrough came with the introduction of solid phase 
peptide synthesis (SPPS) as introduced by Merrifield.[5] While initially met with 
skepticism, SPPS quickly emerged as a robust technique for the synthesis of peptides 
(Scheme 1). The main advantage lies in the facile purification by filtration and washing 
after each coupling step due to the solid support, which enables the use of large 
excesses of activated amino acids. N(α) protection in SPPS was initially performed 
with the Cbz group, and later optimized to tert-butyloxycarbonyl (tBoc) or 
fluorenylmethyloxycarbonyl chloride (Fmoc)[6], which are still used, decades after 
their introduction. Optimization and automatization of SPPS has led to its widespread 
use beyond the initial chemical settings, into biological laboratories. Although 
optimization of the original protocol led to a vast improvement of yield obtained by 
SPPS, realistically the synthesis is limited to a linear peptide chain of 40 to 60 amino 
acids. This meant that the majority of proteins were out of synthetic reach. This was, 
however, overcome by employing site specific condensation reactions to link two or 
more unprotected peptide fragments. Initial ligation chemistry used a nucleophilic 
reaction of thiocarboxylate with a bromoacetyl to yield two peptide fragments linked 
by a thioester bond.[7] While this technique was successfully applied and originally 
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resulted in active HIV-1 protease, critics argued that such a non-native bond could be 
unstable and not be used when studying the molecular basis of protein function.  
  
Scheme 1: Schematic representation of solid phase peptide synthesis. Steps include the 
deprotection of the Nα protecting group (tBoc in this case) followed by addition of an activated 
amino acid and coupling of this amino acid to the growing chain on the solid support. Steps are 
repeated until chain is completed. 
Native Chemical Ligation 
A method was sought with which unprotected peptide fragments could be ligated to 
result in a native peptide bond.  An extension of the earlier employed thioester-
forming ligation brought the solution.  A reaction was designed in which a thioester 
moiety is reacted with a free thiol present in a cysteine residue to form a reversible 
thioester bond. This thioester can subsequently quickly undergo an S- to N-acyl shift in 
presence of an intramolecular amine to form a native peptide bond (Scheme 2). This 
ligation is now known as native chemical ligation (NCL), and is the basis of chemical 
protein synthesis.[8] Initially, NCL could only be performed at cysteine ligation sites, 
but recent advances in desulfurization and the use of ß-thiol amino acids have made 
NCL possible at virtually any residue.[9, 10]  
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Scheme 2: Schematic representation of native chemical ligation. The reaction starts with two 
unprotected peptide fragments that undergo a transthioesterification reaction that results in a 
thioester link, that subsequently undergoes a S to N acyl shift to result in a native peptide bond.  
The introduction of NCL opened up the possibility to chemically synthesize larger 
proteins. However, site specific bioconjugation methodologies were still necessary to 
modify these synthetic proteins to render them useful for i.e. imaging purposes.  
Bioconjugation 
A number of different techniques for bioconjugation of protein molecules have been 
developed, while keeping selectivity, compatibility and stability of the linkage in mind. 
Widely used are copper catalyzed azide-alkyne cycloadditions (CuAAC)[11, 12], inverse 
electron demand Diels-Alder cycloadditions (DAINV) [13] and reactions at cysteine 
residues. While these reactions all have their advantages, there are some drawbacks; 
CuAAC is restricted by the use of copper as a catalyst, which is furthermore toxic to 
cells, the complexity and instability of the reaction components required for DAINV 
make this reaction less favorable for protein labelling and finally, thiol additions often 
require an additional cysteine to be introduced to the protein, as most naturally 
occurring cysteines are present as disulfides. An often overlooked alternative ligation 
strategy employs an oxime bond to link molecules of interest.[14] This strategy uses 
easy to engineer starting products and the reaction is orthogonal and therefore site 
specific. The oxime bond is the major subject of this thesis and will be explained in 
more detail below. 
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Oxime Ligation 
An oxime is formed by reaction of a ketone or aldehyde with an aminooxy. The oxime 
is part of the imine family, which is formed by reaction of a carbonyl species with an 
amine (Scheme 3). In contrast to an imine which is reversible and readily hydrolyzed, 
an oxime forms a stable bond especially at neutral pH.[15] The difference is ascribed 
to the so-called α-effect; an increased nucleophilic reactivity of the aminooxy moiety, 
because of the presence of an electronegative atom with a free electron pair adjacent 
to the nucleophilic amine.[16, 17] When both an amine and aminooxy are present the 
oxime will readily form a stable bond whereas the imine is not observed. When 
looking more closely at the mechanism of oxime formation, the reaction consists of 
several steps. In the first step the aminooxy adds to the carbonyl compound to form 
tetrahedral addition transition state.[18] This intermediate product then loses water 
to form the final oxime product (Scheme 3).  At neutral pH this acid catalyzed 
dehydration step is rate-determining for the reaction. A decrease in pH, however, 
leads to a change of the rate-determining step to the formation of the tetrahedral 
intermediate state. This is the result of protonation of the aminooxy moiety, which 
results in a slower formation of the intermediate state. For this reason oxime 
formation has an optimum at a pH of approximately 4.5.[18] 
 
Scheme 3: Schematic representation of oxime forming reaction between a ketone and an 
aminooxy. In addition, the tetrahedral transition state and the protonated aminooxy are shown.  
While oxime formation is a suitable chemoselective reaction for a number of 
applications, it was not very popular since the reaction rate was too slow, requiring 
high concentrations of reactants or elevated temperatures. Inspired by catalysis of 
semi-carbazone formation by aniline, nucleophilic catalysis by aniline was discovered 
as a method of catalyzing oxime formation.[19, 20] With the introduction of aniline 
renewed interest for oxime ligation emerged. The mechanism of aniline catalysis is 
based on the formation of a highly reactive protonated Schiff base. Because the 
equilibrium constant for formation of this Schiff base is extremely small, large 
excesses of aniline can be used. In the final step of catalysis the protonated Schiff base 
undergoes a transimination reaction with the desired aminooxy compound to yield an 
oxime.  
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The aim of this thesis is to further develop the design and application of oxime bond 
chemistry for its practical use in peptides and proteins. After obtaining improved 
protocols for the use of oxime ligation, these methods will be applied to the synthesis 
of targets involved in cardiovascular research. 
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Abstract 
Use of oxime forming reactions has become a widely applied strategy for peptide and 
protein bioconjugation. The efficiency of the reaction and robust stability of the oxime 
product has led to the development of a growing list of methods to introduce the 
required ketone or aldehyde functionality site specifically into proteins. Early methods 
focused on site-specific oxidation of an N-terminal serine or threonine and more 
recently transamination methods have been developed to convert a broader set of N-
terminal amino acids into a ketone or aldehyde. More recently, site specific 
modification of protein has been attained through engineering enzymes involved in 
posttranslational modifications in order to accommodate aldehyde containing 
substrates. Similarly, a growing list of unnatural amino acids can be introduced 
through development of selective amino-acyl tRNA synthetase/tRNA pairs combined 
with codon reassignment. In the case of glycoproteins, glycans can be selectively 
modified chemically or enzymatically to introduce aldehyde functional groups. Finally, 
the total chemical synthesis of proteins complements these biological and 
chemoenzymatic approaches. Once introduced, the oxime ligation of these aldehyde 
and ketone groups can be catalyzed by aniline or a variety of aniline derivatives to 
tune the activity, pH preference, stability and solubility of the catalyst.  
Introduction 
Oxime ligation has gained considerable attention over the past decade and is being 
used for a large number of applications, mainly in the field of bioconjugation. 
Examples include synthetic proteins [1-6], bioconjugates [7-11] and multivalent 
constructs [3, 12-14].An oxime bond is the result of a condensation reaction of a 
ketone or aldehyde and an aminooxy moiety to result in a ketoxime or aldoxime 
respectively (Scheme 1). Oximes are part of the imine family with general formula 
R1R2C=NR3 and are also known as Schiff’s bases when all R groups are either an alkyl 
or aryl group.[15, 16] While imines are generally considered to be unstable bonds, the 
α-effect, caused by a heteroatom (oxygen on R3) adjacent to the amine in an 
aminooxy ensures hydrolytic stability of the oxime bond and thus suitability for 
conjugation purposes. [17, 18] A related reaction of a ketone or aldehyde with a 
hydrazine (nitrogen on R3) to yield a hydrazone is significantly less stable, but is useful 
for rapid conjugation for in vitro uses and has been shown to be useful for reversible 
protein conjugates and libraries. [19-22]  
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Scheme 1: Schematic representation of the reaction of a ketone with an aminooxy to yield an 
oxime bond. 
Since a ketone functionality is not present in natural proteins, a suitable method must 
be chosen for its introduction. In this review we highlight several approaches that 
have been utilized for the site specific oxime modification of proteins. Furthermore, 
introduction of aniline as a nucleophilic catalyst [23] for oxime ligations gave rise to a 
number of aromatic amine catalysts, with distinct reaction profiles. The development 
and reactivity of these catalysts will be reviewed in order to provide the reader with a 
more complete picture regarding oxime ligations as a tool in protein chemistry. 
Carbonyl Incorporation 
The introduction of ketones or aldehydes into polypeptides remains a limiting step in 
the use of oxime ligations. In the past decade, a number of new techniques have 
emerged that range from total chemical synthesis approaches to genetic 
incorporation of the desired ketone or aldehyde. Several strategies have been 
developed to introduce ketone/aldehyde moieties by means of chemical treatment, 
enzymatic modification, genetic methods, glycan modification and chemical synthesis. 
One of the biggest advantages of the carbonyl functionality is its absence in normal 
proteins; side reactions are unlikely to occur and modifications can be made site 
specifically without the use of protective groups. However, this also limits the use of 
this functional group as a starting point for modifications. 
Chemical treatment 
Early methods to generate an aldehyde or ketone in a protein were reactions to site 
specifically modify one or more residues in the desired molecule. The most well 
known and most used is the oxidation with sodium periodate. More specifically this 
reaction takes advantage of the extreme selectivity of 1-amino 2-alcohol compounds 
towards hypervalent iodine species such as metaperiodate (Scheme 2). [24] In 
proteins, this functional group is exclusively found at the site of N-terminal serine or 
threonine. [25-27] The selectivity of this reagent, ensures a highly specific reaction 
under conditions that rarely affect amino acids prone to oxidation.  
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Scheme 2:. Schematic representation of sodium periodate oxidation of an N-terminal 
serine. The intermediate periodate ester opens to give a Schiff base of ammonia that 
subsequently hydrolyzes to yield the final glyoxylyl product. 
This oxidative cleavage yields a glyoxylyl product that can be used to react with 
various (aminooxy) functionalized labels. [3, 28-30] The disadvantage of this method is 
the necessity of a serine or threonine at the N-terminal position, which when not 
found naturally, must be introduced through mutagenesis. In order to introduce 
ketones and aldeydes into a wider spectrum of naturally occurring proteins, 
transamination approaches have been developed. In early work, Dixon found that 
proteins treated with glyoxylate, a bivalent metal ion such as Cu(II) at pH 5-7, 
underwent transamination to the desired carbonyl species. [27] The biological 
cofactor frequently involved in transamination reactions, pyridoxal 5’-phosphate (PLP), 
was evaluated but in conjunction with Cu(II) was found to be inferior to glyoxylate. 
Recently metal free transaminations using PLP have found utility for the mild N-
terminal transamination of intact proteins. Francis found that the reaction does not 
require the presence of metal ions and can be performed at neutral pH and 37 °C in 
good yields. [31] The reaction is compatible to some extent with any N-terminal 
amino acid other than Pro and results in the corresponding glyoxylyl (Gly) or 
ketoamide. Reaction yields differ depending on the terminal amino acid, His, Trp, Pro 
and Lys proceed in low yield due to an adduct with PLP itself, in the case of His and 
Trp most likely through a Pictet-Spengler type reaction. [32] Furthermore, caution has 
to be taken when performing a subsequent oxime reaction as yields of this reaction 
also depend on the amino acid used. In the case of glutamine a high yield of 
transamidated product is observed but this product does not react to an oxime, a 
stable intermediate of the ketone with the glutamine side chain is the most likely 
explanation. [32] Optimization of the transamination reaction and subsequent oxime 
ligation is possible by altering the amino acids in position 2 and 3. A lysine in position 
3 leads to high reaction yields, although this does not hold true when combined with 
for example phenylalanine or histidine. The authors conclude that a synergistic effect 
of the internal sequence is the reason for the observed difference in reaction yield. 
[32] 
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Enzymatic modifications 
In order to introduce aldehydes and ketones into internal positions of the protein, 
researchers have leveraged the high specificity of naturally occurring enzymes 
involved in posttranslational modifications. One of the most straightforward 
strategies has been to modify the substrates of specific enzymes to contain aldehydes 
or ketone functional groups. Protein farnesyltransferase (PFTase) has been used for 
this purpose. [33] In nature this enzyme catalyzes the reaction of a farnesyl isoprenoid 
group from farnesyl diphosphate to a sulfur atom present in cysteine. Only cysteines 
present in a recognition site at the C-terminus of a protein will be modified. This 
recognition site consists of 4 amino acids in the so-called CaaX box, where C is the 
cysteine to be prenylated, a is any aliphatic amino acid and X is M, S, Q, A or C in the 
case of PFTase. The farnesyl diphosphate substrate has been modified to contain 
either a simple aldehyde or an aryl aldehyde, both of which are still recognized by 
PFTase. [34] Lipoic acid ligase (LpIA) present in E.Coli can be used for the same 
purpose. The enzyme catalyses the reaction of lipoic acid to a 13 amino acid 
recognition site called LAP (LpIA acceptor peptide). The substrate pocket of the 
enzyme has been shown to accept mutations which can subsequently be used to fit 
modified substrates with unnatural functional groups. [35-37] The addition of an aryl 
aldehyde conjugated to the lipoic acid substrate proved to be possible by mutation of 
Trp 37 in LpIA. Hydrazine probes were used to site specifically label the desired 
protein. [38] An alternative enzyme used is tubulin tyrosine ligase (TTL), which 
normally attaches a tyrosine residue to the carboxy terminal end of α-tubulin. TTL 
accepts very minor changes in its tyrosine substrate, one of which is 3-formyltyrosine. 
The enzyme was used to label α-tubulin in living cells with a hydrazine label. [39] Later 
it was found that the enzyme can be used to introduce 3-formyltyrosine in any protein 
as long as a recognition site was present. The recognition sequence (Tub-tag) consists 
of 14 amino acids and needs to be installed in at the C-terminus of the protein of 
interest. [40] One limitation in the use of co-factor enzymes to introduce a carbonyl 
functionality is the necessity of acceptor sites. 
An alternative approach for enzymatic introduction of a reactive carbonyl group is to 
use enzymes that modify natural amino acid side chains into the reactive group. One 
example is the site specific conversion of Cys into formylglycine. This modification 
occurs co-translationally by the formylglycine generating enzyme (FGE).[41, 42] The 
required consensus sequence was found to be LCXPXR, where X stands for any amino 
acid. FGE will convert the cysteine residue into a formylglycine that can be used for 
subsequent oxime ligation. In one example, the LCXPXR motif was placed at the N- 
and C-terminus of different proteins and the cysteine was shown to be converted into 
a formylglycine. Although a formylglycine generating enzyme is naturally present in 
E.Coli, the yield is best when coexpressed with an additional prokaryotic FGE. [42] 
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Genetic methods 
Enzymatic approaches typically require specific peptide sequences to be introduced 
near the modification site. In order to restrict modifications to just a single amino acid 
residue, codons can be reassigned to recognize a tRNA loaded with the unnatural 
amino acid. This approach can be utilized in cells through the development of 
selective amino-acyl tRNA synthetase/tRNA (aaRS/tRNA) pairs. [43]  Using this 
approach, amino acids that contain an aldehyde or ketone moiety can be introduced 
site selectively into proteins. The most commonly utilized unnatural amino acid for 
oxime ligations has been p-acetyl-L-phenylalanine which introduces an arylketo group 
into proteins at the site of a suppressed amber nonsense codon. [44] The keto group 
can subsequently be used to site specifically label proteins with groups such as a 
fluorophore or biotin, both in vitro and in vivo. An analogue of p-acetyl-L-
phenylalanine, namely m-acetyl-L-phenylalanine was later used for a similar purpose. 
[45] These keto amino acids were used for a number a purposes from PEGylation to 
spin-labelling and the modification of Fab fragments. [46-48] One limitation has been 
that this ketone is quite unreactive, which is a benefit for stability in the cellular 
environment, but oxime ligation typically requires high label concentrations, long 
reaction times at low pH. Other carbonyl containing amino acids have been explored. 
For example a diketone containing amino acid was synthesized and used in a similar 
manner as p-acetyl-L-phenylalanine. [49]  
Another example of introduction of a ketone group by means of genetic modification 
is found in the lanthipeptide family. These small peptides are ribosomally synthesized 
and post-translationally modified to contain thioether bridges. For this purpose serine 
and threonine residues are dehydrated to dehydroalanine and dehydrobutyrine 
respectively. A subsequent reaction with cysteines present in the sequence will form 
the thioether bridges. Some lanthipeptides contain an N-terminal modification in the 
form of a ketone that arises from a dehydrated serine or threonine at position 1 in the 
final sequence that does not form a thioether bridge. The dehydration of threonine 
and removal of the leader peptide in this case leads to spontaneous hydrolysis of the 
N-terminal enamine to a -ketoamide.  It was found that this modification could be 
introduced in a range of lanthipeptides to result in an N-terminal ketone that can be 
modified using an aminooxy. [50] 
Chemical Synthesis 
While ribosomal synthesis has clear advantages for the production of large proteins, 
chemical synthesis and semisynthesis allows protein modifications that are not 
compatible with the biological assembly machinery. Solid phase peptide synthesis 
(SPPS) and chemical ligation can be used for the total synthesis of proteins, in which 
ketones or aldehydes can be incorporated at any desired position. For this purpose, 
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amino acid building blocks containing a ketone can be used. The earlier mentioned 
p-acetyl-L-phenylalanine, used in the genetic approach, is also available for peptide 
synthesis. Additionally, it is possible to site specifically introduce an aldehyde by 
coupling a serine or threonine residue to the side chain of an orthogonally protected 
lysine. Alternatively keto proline can be used, which can be synthesized from the 
commercially available hydroxyproline by Jones oxidation. [51] Keto proline was an 
intermediate product in a study of proline 4-hydroxylase, but was shown to be 
accepted in the triple helix of collagen in a recent study. After incorporation of keto 
proline in the collagen sequence it was used to introduce a biotin tag via oxime 
ligation. [52] Furthermore, aldehydes have been introduced in peptides using a 
glyoxylyl moiety. Approaches have been described for incorporation of the functional 
group at the C-terminus using special peptidyl resins and at the N-terminus using 
newly designed amino acid building blocks. [53, 54] For a more site specific 
modification keto acids can be used. The N-terminus of a protein or alternatively, 
orthogonally protected lysines can be used for site specific ketone incorporation. For 
this purpose pyruvic acid and levulinic acid have been used. [1, 2, 11, 14, 55] However, 
the choice of ketone is not arbitrary; we found that levulinic acid is prone to an 
intramolecular cyclization reaction. [56] This reaction leads to a cyclic species that is 
unable to form an oxime bond when reacted with an aminooxy moiety. In the same 
study alternatives for levulinic acid were investigated. It was found that elongation of 
the carbon chain with only a single carbon atom was sufficient to prevent the 
cyclization reaction. Furthermore, it was found that aromatic ketones are considerably 
less reactive than alkyl ketones. [56] 
Apart from the use of carbonyl containing amino acids, the ketone can be introduced 
into chemically synthesized or ribosomally expressed proteins through reactions at 
specific side chains. Stabilizing elements are often used to overcome the disordered 
nature of short peptide fragments. These elements are mostly inert, but recently it 
was shown that the incorporation of a ketone can be achieved by macrocyclization 
using dichloroacetone (DCA). [57] DCA was shown to react with nucleophiles present 
in the peptide sequence, i.e. cysteines. The resulting product could be modified with 
aminooxy containing compounds, allowing the modification to occur in the middle of 
the crosslink. [57] 
Glycan Modifications 
Previously it was mentioned that ketones are not present within natural proteins, as 
none of the 20 natural amino acids has a carbonyl moiety. Glycosylated proteins, 
however, contain saccharide groups that can be used as starting points for carbonyl 
incorporation. In a synthetic approach, an O-linked glycopeptide was synthesized 
using a Ser/Thr building block modified with GalNac. This galactose derivative could 
be enzymatically converted by galactase into a C-6 aldehyde, which subsequently was 
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used to incorporate an oligosaccharide using oxime ligation. [58] Furthermore, 
advantage can be taken of the naturally occurring open form of saccharides, in which 
an aldehyde is present as opposed to the closed hemiacetal form.  The free aldehyde 
was used for modification using oxime ligation. [59, 60] Interesting to note is the fact 
that the cyclic structure of the saccharide can be conserved after oxime ligation. [60, 
61] In addition, sialic acid has been used to introduce aldehydes into glycan structures. 
Sialic acid contains a diol that can be oxidized using sodium periodate (Scheme 3). [62] 
Oxidation of sialic acid was first used as a means of quantifying sialic acid contents in 
biological mixtures. The obtained aldehyde was used in a condensation reaction with 
resorcinol to yield stable chromogens with which sialic acid could be quantified. [63] 
Later, the site specific glycan modification was used to introduce radioactive labels in 
glycoconjugates. [64, 65] More recently the oxidation of sialic acid was used in 
combination with oxime ligation to introduce new functional groups on proteins. [66] 
The approach could even be used to label live cells which present sialic acid containing 
glycans on their cell surface. [67] Finally, modification of cell surface glycans was 
achieved by presenting cells with an unnatural derivative of N-acetyl-mannosamine 
(ManLev). This glycan contains a ketone group, is converted into an unnatural sialic 
acid and incorporated into glycans present on the cell surface. The ketone groups 
present on the cell surface could subsequently be used to label cells with 
hydrazines.[68]  
 
Scheme 3:. Schematic representation of sodium periodate oxidation of sialic acid through a 
two-step procedure. In the first step, a hydroxy aldehyde is generated. The hydrated form of 
the aldehyde can subsequently be oxidized again by sodium periodate to yield the final product. 
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Table 1: Overview of the different possibilites of carbonyl introduction in proteins and peptides 
Chemical treatment   
Method Conditions Resulting carbonyl moiety ref 
Oxidation of N-
terminal 
Ser/Thr 
Accessible Ser/Thr 
at N-terminus. 
Treatment with 
NaIO4  
 
[3, 
25-
27] 
Transamidation 
of N-terminal 
residue 
Oxidation using 
glyoxylate, 
copper(II)salts, 1M 
pyridine, 1M HOAc. 
Reaction 
conditions are 
quite harsh. 
 
[27] 
Transamidation 
of N-terminal 
residue 
Oxidation using 
pyridoxal 5’-
phosphate. 
Conditions are 
milder 
 
[31, 
32] 
Enzymatic modification   
Prenylation of 
cysteine by 
PFTase  using 
modified 
substrate 
CaaX box present 
in C-terminus of 
protein. Synthesis 
of a modified 
farnesyl substrate 
is required 
 
[33, 
34] 
Lipoic acid 
ligase used to 
ligate modified 
substrate to 
acceptor site   
13 aa LAP site 
present in protein. 
Mutation of Lipoic 
acid ligase. 
Synthesis of 
modified substrate 
 
[38] 
3-
Formyltyrosine 
incorporation 
by Tubulin 
tyrosine ligase 
Tub-tag (14aa) 
required in protein 
to be modified. 
Synthesis of 
tyrosine derivative 
is necessary. 
 
[39, 
40] 
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Table 1 (continued): 
Cysteine is 
enzymatically 
converted into 
formyl glycine 
by FGE 
LCXPXR motif present 
in desired protein. 
Coexpression with an 
additional eukaryotic 
FGE. 
 
[42] 
Genetic methods   
Introduced by 
amber 
suppression 
Use of a modified tRNA 
amino acid complex to 
accept the keto amino 
acid in response to 
amber nonsense 
codon. 
 
[44-
48] 
N-terminal 
ketone in 
lanthipeptides 
by hydrolysis of 
a dehydro 
amino acid. 
Presence of a dehydro 
amino acid at position 
1 of the final 
lanthipeptide  
[50] 
Total chemical synthesis   
Oxidation of a 
serine or 
threonine 
coupled to a 
lysine side 
chain 
An orthogonally 
protected lysine is 
required, which is side 
chain modified with a 
serine or threonine 
residue  
 
 
Solid phase 
peptide 
synthesis using 
keto-proline 
Jones oxidation of 
hydroxyproline and 
subsequent protection 
of amino group with 
Fmoc or Boc. 
 
[52] 
Glyoxylyl 
introduction at 
N-terminus of 
peptide chain 
The Fmoc protected 
α,α’ 
-diaminoacetic acid 
needs to introduced at 
the end of peptide 
chain 
 
[54] 
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Table 1 (continued): 
Macrocyclization 
using DCA. 
Acetone group 
can be used for 
modification 
Nucleophilic 
groups present in 
molecule for 
formation of 
macrocyclic ring 
 
[57] 
Amine 
modification 
using keto-acids 
On resin coupling 
of desired keto-
acid  
[1, 2, 
11, 
14, 
55, 
56] 
Glycan modifications   
Natural open 
state of glycan 
contains an 
aldehyde 
Free saccharide 
needs to be 
present   
[59-
61] 
Modification of a 
Ser/Thr linked 
glycan using 
galactase 
O-linked GalNac 
needs to 
introduced in 
peptide chain and 
subsequently 
treated with 
galactase to 
obtain glycan 
aldehyde 
 
[58] 
Sialic acid 
oxidation 
Oxidation of a 
sialic acid with 
sodium periodate 
leads to a glycan 
aldehyde 
 
[64-
67] 
Metabolic 
oligosaccharide 
engineering using 
unnatural glycans 
Synthesis of an 
unnatural N-
acetylmannosami
ne, which 
subsequently will 
be converted into 
a sialic acid 
incorporated in 
cell surface 
glycans 
 
[68] 
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Catalysis 
In the previous section it was shown that multiple techniques are available for the 
incorporation of ketones or aldehydes in proteins. The high chemoselectivity of the 
oxime bond led to a wide application in bioconjugation.  Furthermore, mild reaction 
conditions can be used, which is particularly important when modifying folded 
proteins. A drawback, however, are the slow kinetics of oxime formation, which 
typically require the use of high concentrations or large excesses of reactants in order 
to obtain high yields of protein conjugation. A breakthrough came with the 
introduction of aniline as a nucleophilic catalyst for oxime formation which was shown 
to enhance oxime ligation significantly. [23] Rate enhancements of 400- and 40-fold at 
pH 4.5 and 7.0 were obtained, respectively. The use of aniline as a nucleophilic 
catalyst was first observed by Jencks in the case of semicarbazone formation. [18, 69]   
Nucleophilic catalysis was explained by the formation of a highly reactive protonated 
aniline Schiff’s base, subsequent transimination leads to the desired oxime bond 
(Scheme 4). [19, 23] It was also found that anisidine (p-MeO-aniline) was highly 
effective at pH 7, as suggested by its higher pKa (aniline has a pKa of 4.6, anisidine 5.3).   
Aniline catalysis has been used widely for conjugation reactions on enzymes, 
antibodies, viral coat proteins and even the surface of human cells and inside bacterial 
cells. [67, 70-72] 
 
Scheme 4: Schematic representation of the mechanism of nucleophilic catalysis by aniline in the 
oxime-forming reaction. 
In recent years, derivatives of aniline have been used to customize aniline catalysis for 
specific uses.  It was found that at high concentrations, 100 mM and long reaction 
times, aniline can destabilize some proteins. [73] For example, tubulin could no longer 
polymerize after treatment with high concentraitons of aniline, thus an alternative 
was sought. A substituted phenylalanine, 4-amino phenylalanine (4a-Phe), showed a 
slightly lower catalytic activity compared to aniline but maintained the polymerization 
activity of tubulin. [73] The catalytic activity of aniline has been tuned through 
neighboring groups on the ring and a number of derivatives have been investigated. 
These mainly focused on altering the pKa value of aniline (4.6) or increasing its water 
solubility by substitution of the benzene ring. In the original description of aniline 
catalysis for oxime ligation, anisidine (p-methoxyaniline, pMeOAn) was shown to be 
highly effective at neutral pH, since pMeOAn has an elevated pKa of 5.3. [23] The 
effect of pMeOAn was subsequently analyzed in more detail and was found to work 
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moderately better than aniline at neutral pH for the conjugation of glycans. [60] The 
water solubility of aniline is limited to 100 mM, and the development of more soluble 
catalysts was addressed by several groups. It was found that some commercially 
available anthranilic acids have both a higher solubility compared to aniline as well as 
an increased catalytic activity at neutral pH. The substituted anthranilic acid, 5-
methoxyanthranilic acid (5-MeO-AA), showed the highest increase in catalytic activity. 
[74] In more recent studies an extensive analysis of substituted anilines was 
performed. Effects of pMeOAn and 5-MeO-AA were confirmed, but were shown to be 
inferior to phenylenediamines, which have two potential Schiff’s base forming 
functionalities. [48, 75] The second amine group makes phenylenediamines 
particularly useful in a broad pH range, since the second amine has a lower pKa (3.29) 
and can thus be used from pH 4 to 7. However, one study found m-phenylenediamine 
to be a superior catalyst, with higher water solubility and increased nucleophilic 
catalysis, whereas a more recent study finds an inhibitory effect of all meta 
substituted anilines and argues p-phenylenediamine is the best choice [75] No 
mechanistic explanation for this observation is given, but the authors speculate that 
their use of a glyoxylyl moiety might be a reason for the observed effect. The recent 
application of phenylenediamines for the introduction of a spin-label, however, found 
a decreased activity of m- or p-phenylenediamine when compared to pMeOAn. [76] 
Overall, aniline and anisidine can be used as catalysts for a wide variety of oxime 
ligations and if rates need to be enhanced, a series of aniline analogs can be tested for 
suitability with the ketone/aldehyde at the pH that is desired.  
Summary 
Incorporation of ketones and aldehydes in proteins of choice has received increased 
attention over the past decade. Methods are now available ranging from amber 
suppression to total chemical synthesis of ketone containing proteins, thus making the 
starting point for oxime ligation available for every lab. Moreover, examples of 
(bio)conjugation in a variety of molecules are now available, demonstrating the wide 
use of the oxime bond. Development of catalysts for oxime ligation has started since 
the introduction of aniline as nucleophilic catalyst. Various substituted anilines are 
used to increase water solubility or increase catalyst activity. Recent examples, 
however, have shown that it is difficult to find a catalyst suitable for the general oxime 
reaction. The optimal catalyst has to be found for every reaction, which most likely 
means new oxime catalysts will keep emerging. This does, however, not mean that 
newer is always better.  
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Table 2: Overview of nucleophilic catalysts used in oxime ligation with their properties 
Catalyst Structure Properties pKa[77] ref 
Aniline 
 
First generation 
nucleophilic catalyst. 
Most active at acidic 
pH. Limited water 
solubility 
4.62 [19, 
23] 
4-amino 
phenylalanine 
 
More biocompatible 
than aniline, slightly 
lower activity. 
 [73] 
p-methoxy aniline 
 
Aniline derivative 
with increased pKa, 
more active at 
neutral pH. 
5.29 [23, 
60] 
5-methoxy 
anthranilic acid 
 
High water 
solubility, increased 
activity at neutral 
pH compared to 
aniline. 
 [74] 
m-phenylenediamine 
 
Two amine groups 
with different pKa 
values, active over 
broad pH range. 
Shown to be 
inhibitory in a 
protein PEGylation 
using an N-terminal 
glyoxylyl group. 
Prone to oxidation 
to quinone species 
4.88, 
2.65 
[48, 
75] 
p-phenylenediamine 
 
Two amine groups 
with different pKa 
values, active over 
broad pH range. 
Prone to oxidation 
to quinone species. 
6.08, 
3.29 
[75] 
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Chemoselective conjugation of proteins and peptides allows the formation of a 
covalent bond without the need of protective group chemistry in labeling or 
assembling macromolecules. Chemical reactions yielding oxime bonds are highly 
suitable for this purpose. The oxime ligation comprises the reaction of a ketone or 
aldehyde (1) with an aminooxy (2) to form a special imine known as an oxime (3) 
(Scheme 1). Advantages of this strategy include its chemoselectivity, since a ketone is 
inert to most other reactions, and the mild conditions in which the reaction can be 
performed. Oxime formation has been thoroughly investigated and was found to 
proceed in a step-wise manner depending on the pH at which the reaction is 
performed. [1, 2] Although the reaction proceeds faster in acidic conditions (pH 4-5) 
oximes will also form at neutral pH. Oxime formation can be accelerated by the 
addition of the catalyst aniline. [3, 4] Furthermore, oximes are stable at neutral pH. [5] 
Altogether, these properties make the oxime linkage one of the preferred methods 
for the chemoselective modification of peptides and proteins. [6] Levulinic acid (LA) is 
one of the most frequently used ketones for oxime formation, and is generally 
introduced by attachment to a lysine side chain ε-NH2 or an N-terminal NH2 moiety. [7, 
8] The reaction between the protein-levulinic acid complex and an aminooxy moiety 
proceeds well at millimolar concentrations. However, the relative low quantity and 
high molecular weight of most proteins result in submillimolar protein concentrations 
and limitations of the oxime reaction. Under those conditions, we and others have 
found that oxime reaction yields are low due to the formation of a levulinoyl derived 
side-product that competes with oxime bond formation. [7] As oxime ligations are still 
an increasingly attractive and orthogonal approach to label proteins, alternative 
ketone moieties for bioconjugation were explored. Our hypothesis is that the 
levulinoyl side-product, corresponding to a differential mass loss of 18 Da, is the result 
of an intramolecular cyclization of levulinic acid, thus preventing the LA ketone group 
from reacting with the aminooxy moiety. The formation of this by-product is mainly 
seen at low concentrations because under those conditions the concentration-
independent cyclization side-reaction will benefit from the slow oxime formation. 
 
Scheme 1: Overall oxime reaction. A ketone or aldehyde (1) will react with an aminooxy (2) to 
form an oxime bond (3) 
To study the molecular mechanism underlying levulinoyl cyclization, a pentapeptide 
LYRAK was synthesized with levulinic acid (LA) coupled to the lysine ε-amine, giving 
LYRAK(LA).  Lyophilized LYRAK(LA) was dissolved in water under acidic conditions (pH 
4.5) and was left to cyclize spontaneously for 72 h at room temperature. The 
conversion to cyclized derivatives was monitored by ESI-MS and NMR (both in DMSO-
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d6 and D2O) and structurally characterized by 2D NMR experiments (SI-1 and SI-2). The 
cyclization of levulinic acid was tested at 3 concentrations and was shown to be 
concentration independent (SI-3).  
 
Scheme 2: Proposed mechanism for the formation of the cyclic species from levulinoyl-peptides 
Based on these results, a reaction mechanism for intramolecular cyclization of the 
levulinoyl moiety is proposed (Scheme 2): The amide nitrogen in the linear levulinoyl 
peptide 4 performs a nucleophilic attack on the ketone carbonyl group resulting in the 
cyclic intermediate 5. This reaction was previously reported to be favored by 
protonation of the carbonyl. [9] Spontaneous dehydration of 5 leads to the iminium 
species 6 which is stabilized by TFA present in solution. Spontaneous isomerization of 
6 leads to 7 and 8 as determined by 2D NMR methods (SI-1). The conversion of the 
exocyclic double bond containing species 7 from 5 has been reported, but not the 
formation of the endocyclic double bond. [10] Here, 8 is observed but is formed as a 
minor product compared to the major exocyclic species 7 (NMR analysis in DMSO-d6 
showed 7/8 ratio of 5:1). In addition to NMR analysis, the formation of the cyclic 
species was deduced from MS data. Both the iminium (6) with a mass difference of -
17 Da and the final cyclic double bond species (7,8) with a mass difference of -18 Da 
were observed (SI-4). Based on our observations and the proposed reaction 
mechanism, we hypothesize that only a small amount of the linear form is present 
after cleavage of the peptide from the resin, the majority being in the cyclized form (5) 
which shows no mass difference when compared to the linear form. Although it 
remains unclear whether the pyrrolidone 5 is formed during TFA treatment, HF 
cleavage, or under aqueous acidic conditions during the oxime ligation, the low oxime 
yields in the early experiments can be explained by the cyclic derivative being unable 
to react with the aminooxy moiety. 
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Name Structure 
Levulinic acid (LA) 
 
 
4-acetylbutyric acid (AB) 
 
 
7-oxooctanoic acid (OOA) 
 
 
4-acetylbenzoic acid (ABA) 
 
 
3-(2-oxopropyl)-benzoic acid (OBA) 
 
 
Scheme 3: Keto-acids used in test oxime ligations 
We selected a small set of commercially available keto-acids and compared these 
against levulinic acid for ketone functionalization and oxime conjugation of peptides 
and proteins. An overview of the different keto-acids used is shown in Scheme 3. 
LYRAK test peptides were used with different keto-acids coupled through the ε-amine 
of the lysine side-chain. A VIPF peptide was synthesized and N-terminally modified 
with aminooxyacetic acid (AO) (SI-11). Each of the ketone derivatives was tested by 
reacting the ketone peptide with the aminooxy peptide at different concentrations (7, 
70 and 700 µM) in ammonium acetate buffer at pH 4.5, being the optimal pH for 
imine reactions. [3] The oxime reactions of the various ketones with aminooxy 
peptides were followed in time using UPLC-MS (220, 280 nm) for 48h at 37°C, 
quantified by peak integration, and the relative intensities fitted to a reversible 
second-order reaction equation (SI and Figure 1).  
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Figure 1: a: LYRAK-VIPF oxime product formation plotted in time at a concentration of 7 μM 
ketone, b: 70 μM ketone, c: 700 μM ketone with ■ LYRAK(ABA), □ LYRAK(AB), ○ LYRAK(OBA), ● 
LYRAK(OOA), ▲ LYRAK(LA). For all concentrations fits by a second order reversible reaction 
equation are shown, No fits could be obtained for LA under any conditions. d: UV (220 nm) 
trace of the reaction of LYRAK peptide (70 μM) modified with ketone AB (1) with the VIPF 
aminooxy peptide (2) to form LYRAK-VIPF oxime product (3). e: UV trace of reaction of peptide 
modified with ketone LA (1). Major cyclic side product (1*) is formed in addition to oxime 
product (3). f: schematic representation of RANTES conjugated to a bimodal rhodamine/DTPA 
label through an oxime bond. 
To validate this method, one of the reactions was repeated and analyzed by real-time 
NMR. Reaction rate constants of oxime ligation at 700 M between LYRAK(AB) and 
AO-VIPF were measured independently by following the oxime reaction in real-time 
(in sodium acetate-d3, pH 4.5 at 37°C) by NMR spectroscopy. Isolated proton signals of 
NH Val1 in AO-VIPF and AB(3-CH2) in LYRAK(AB) were used to integrate the population 
of reactants and final ligated oxime product as a function of time (SI-5, SI-9 and SI-10). 
In each reaction the aminooxy peptide was taken in excess (2 eq. AO to 1 eq. ketone). 
Full conversion to the oxime product was reached for ketones AB, OOA and OBA at 
both 70 and 700 µM with average rate constants of 0.22, 0.33, and 0.33 M-1s-1 
respectively. At a concentration of 7 µM none of the reactions reached completion, 
but rate constants were in agreement with those determined at 70 and 700 µM (Table 
1). In the case of ABA the reaction rate was almost an order of magnitude lower at 
Chemoselective oxime reactions in proteins and peptides 
 
38 
 
0.04 M-1s-1. The oxime formation with levulinic acid did not reach completion in any of 
the tested concentrations, because of the formation of the cyclic pyrrolidone, and the 
oxime product reached a maximum of 5%, 30% or 75% theoretical yield at 
concentrations of 7, 70 or 700 µM respectively. 
Table 1: Determined reaction constants 
   k1 (M
-1 s-1) 
Ketone 700 µM 70 µM 7 µM Average 7 µM + 
10 mM 
aniline 
7 µM + 
100 mM 
aniline 
Levulinic acid (LA) n.d. n.d. n.d. n.d. n.d. n.d. 
4-acetylbutyric acid 
(AB) 
0.19 0.21 0.25 0.22 ± 0.03 0.30 1.56 
7-oxooctanoic acid 
(OOA) 
0.23 0.28 0.49 0.33 ± 0.14 0.66 2.32 
4-acetylbenzoic acid 
(ABA) 
0.03 0.04 0.05 0.04 ± 0.01 0.05 0.17 
3-(2-oxopropyl)-
benzoic acid (OBA) 
0.28 0.32 0.39 0.33 ± 0.06 0.52 1.71 
Reaction constants were determined by fitting data to a second order reversible reaction 
equation (see supplemental information) with or without supplementation of catalyst aniline at 
3 different concentrations. Reaction constants for Levulinic acid could not be determined 
because the progress curves could not be fitted to a second order reversible reaction. Average 
reaction constants ± standard deviation are given. 
Both ABA and OBA ketones have a rigid aromatic ring placed in between the two 
reactive groups and are too strained to allow intramolecular cyclization. In contrast, 
the AB and OOA derivatives can in theory form a 6- and 8-membered heterocycle 
respectively. Nevertheless no cyclization was observed for both AB and OOA. 
The UPLC-MS experiments show formation of the oxime with all ketones (Figure 1). 
The reaction was fastest for ketones OOA or OBA. The slowest reaction rate was 
observed for ABA. The reactivity of ketones in oxime reactions is likely governed by 
the stability of the formed carbocation. In all cases a secondary carbocation is formed, 
whereas in the case of ABA the secondary cation is stabilized by resonance, 
delocalizing the charge and decreasing its reactivity. This effect has also been 
observed for conjugated aldehydes.[11] 
It has been reported that oxime and hydrazone reactions can be catalyzed with aniline. 
[3, 4, 12] The effect of aniline was therefore evaluated by repeating the 7 µM 
reactions in presence of 10 and 100 mM aniline at which a maximal 6-fold increase in 
k1 was observed (SI-6 and Table 1). The reaction rate constants for oxime formation 
were comparable with previously reported values. [13, 14] This resulted in 
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dissociation constants (KD) around 1 μM for the conditions tested. The hydrolysis rate 
was verified by following the rate of dissociation of a formed oxime bond at 7 and 70 
μM in absence and presence of aniline at pH 4.5. At 7 μM, approximately 15% of the 
oxime product was hydrolyzed within 7 days whereas at 70 μM only 2% hydrolysis was 
observed (SI-7). The oxime bond dissociation constants were calculated by fitting the 
data points to the second order reversible reaction and were all around 1 μM at pH 
4.5 (SI, Table S1-4), in agreement with those determined above. Based on previous 
findings, we expect the hydrolysis of oxime bonds at comparable concentrations at 
neutral pH to be negligible making oxime bond formation a useful method for 
chemoselective bioconjugation and assembly of macromolecular complexes.[5] 
The improved oxime ligation strategy was further validated by coupling a bimodal 
rhodamine/DTPA label to the chemokine CCL5/RANTES (Figure 1F). For this purpose, 
LA and OBA were chosen as ketones. LA to illustrate the interference by the unwanted 
side reaction, OBA as the best candidate for the novel oxime ligation strategy. RANTES 
was synthesized by solid phase peptide synthesis (SPPS) and native chemical ligation 
using a synthetic approach used previously in our lab for the synthesis of Nε-
thiaproline modified RANTES, substituting thiaproline for LA or OBA. [15] The 
incorporation of the ketones was done by coupling the keto-acids to the ε-amino of a 
lysine added at the C-terminal end of the protein. Following SPPS, native chemical 
ligation of the two fragments, and oxidative folding of the protein, the ketone 
functionalized chemokine was coupled with a bimodal imaging label containing a 
fluorescent rhodamine and a metal chelating DTPA moiety functionalized with 
aminooxyacetic acid. The oxime ligation was performed at a concentration of 100 μM 
protein and two-fold excess of label. The coupling was followed by UPLC-MS and in 
agreement with results from the test peptides; coupling efficiency of RANTES(LA) was 
lower than that of RANTES(OBA). After 36 hours a coupling yield of 18% was reached 
in the case of RANTES(LA) versus 81% for RANTES(OBA) (SI-8). The resulting labeled 
chemokine was subsequently used to bind to and visualize its native receptor CCR5 
expressed on macrophages. Macrophages were isolated from mouse bone marrow, 
cultured and incubated with the labeled RANTES derivatives. Before visualization, a 
nuclear stain was applied for 1 hour. 3T3 fibroblasts that do not express CCR5 were 
used as a negative control. The macrophages showed a dose-dependent cell surface 
labeling, whereas the 3T3 cells did not show cell surface labelling (Figure 2). 
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Figure 2: Confocal microscopy imaging of mouse bone marrow derived macrophages (BMDMϕ) 
and 3T3 fibroblasts. a: DIC contrast image of BMDMϕ. b: Merge image of cell staining by 
RANTES-rhodamine/DTPA and nuclei staining with SYTO 13. Dimensions 141 x 141 µm c: DIC 
contrast image of 3T3 fibroblasts. d: Merge image of RANTES-rhodamine/DTPA labeling and 
SYTO 13 nuclei staining. Dimensions 144 x 144 µm 
The results show that levulinoylated lysine end groups are prone to intramolecular 
cyclization to a five-membered pyrrolidone ring that interferes with oxime formation 
when oxime formation is slow at low, biologically relevant protein concentrations. The 
current study provides evidence that the reaction rates and efficacy of oxime 
formation in peptides and proteins can greatly be improved by using alternative 
ketones to levulinic acid, aiding in facile synthesis of macromolecules and conjugated 
peptides and proteins. 
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Supporting Information 
Chemistry 
Peptide synthesis. Peptides were synthesized manually by SPPS on a 0.25 mmol scale 
on a MBHA resin. An in situ neutralization/HCTU activation for Boc chemistry was 
used[1]. Each synthetic cycle consisted of the Boc protective group removal by two 1-
minute treatments with TFA followed by a DMF wash, addition of the preactivated 
amino acid in presence of excess DIPEA, followed by another DMF wash. The Boc-
protected amino acids (1.1 mmol) were activated with 1 mmol of HCTU and 3 mmol 
DIPEA. Coupling of Gln residues was followed by a DCM wash before and after TFA 
deprotection to prevent intramolecular pyrrolidone formation. After coupling of the 
final amino acid the resin was dried by wash steps with DCM and DCM/MeOH. 
After completion of the peptide chain, the peptides were deprotected and cleaved 
from the resin by treatment with anhydrous HF for 1 hour at 0°C with 4% p-cresol (v/v) 
as scavenger. Peptides were precipitated in ice-cold diethylether, dissolved in 50% 
acetonitrile in water +0.1% TFA and lyophilized. The crude mixture was subjected to 
semipreparative HPLC and fractions containing the desired product were identified by 
ESI-MS, pooled and lyophilized. 
LYRAK model peptide 
sequence: H2N-Leu-Tyr-Arg-Ala-Lys-CONH2 
VIPF model peptide 
sequence: H2N-(Aminooxy)acetic acid-Val-Ile-Pro-Phe- CONH2 
Murine RANTES C-terminus 
sequence: H2N-Cys-Ser-Asn-Leu-Ala-Val-Val-Phe-Val-Thr-Arg-Arg-Asn-Arg-Gln-Val-Cys-
Ala-Asn-Pro-Glu-Lys-Lys-Trp-Val-Gln-Glu-Tyr-Ile-Asn-Tyr-Leu-Glu-Met-Ser-Lys(Fmoc)-
CONH2 
Murine RANTES N-terminus 
sequence: H2N-Ser-Pro-Tyr-Gly-Ser-Asp-Thr-Thr-Pro-Cys-Cys-Phe-Ala-Tyr-Leu-Ser-Leu-
Ala-Leu-Pro-Arg-Ala-His-Val-Lys-Glu-Tyr-Phe-Tyr-Thr-Ser-Ser-Lys-MPA-Leu-CONH2 
Synthesis of Rhodamine B DTPA dual label. A dipeptide Cys-Lys(Fmoc) was prepared 
via solid phase peptide synthesis as described above. The N-terminal Boc protection 
was removed with 2x1 min TFA treatment after which (Aminooxy)acetic acid (2.2 
mmol) was preactivated using DIC (2.0 mmol) for 2 minutes after which NHS (2.0 
mmol) and DIPEA (0.6 mmol) was added, directly followed by addition to the 
deprotected Cys-Lys (0.25 mmol) and left to react for 1 hour. The Fmoc deprotection 
was achieved by 4x3 min 20% piperidine in DMF followed by a DMF and DCM wash to 
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remove any residual piperidine. 0.5 mL rhodamine B-succinimide (AAT bioquest, 
Sunnyvale CA, USA) (7.5 mg/mL) was added to the resin and the mixture was left to 
react at 37 °C for 4 hours with occasional mixing. The resin was washed with DMF 
followed by N-terminal Boc protection. The dipeptide was cleaved from the resin 
using anhydrous HF, precipitated in diethylether, dissolved in 50% MeCN in H2O + 0.1% 
TFA, purified and lyophilized. The dried peptide (2.4 mg) was dissolved in 1 mL 0.1 M 
NH4OAc (pH 5.7) + 10 % MeCN. Maleimide-DTPA was added in 1.5 times excess and 
left to react at 37 °C for 2.5 hours. The resulting product was purified, analyzed with 
MALDI mass spectrometry and lyophilized. 
Ketone incorporation into chemokine RANTES C-terminus. After completion of the 
peptide chain, the Fmoc protective group on the C-terminal lysine was deprotected 
using 4x3 min treatments with 20% piperidine in DMF. Subsequently, keto-acids LA 
and OBA (2.2 mmol) were preactivated using carbodiimide (2 mmol) (DIC) for 2 
minutes after which N-hydroxysuccinimide (NHS) (2.0 mmol) and N,N-
diisopropyldiamine (DIPEA) (0.6 mmol) was added, directly followed by addition to the 
deprotected RANTES (0.25 mmol) and left to react for 1 hour. Finally the N-terminal 
Boc-protective group was removed by treatment with TFA as described above to 
result in RANTES(LA) and RANTES(OBA) after cleavage from the resin. 
Native chemical ligation of RANTES C- and N-terminus. Both the C- and N-terminus 
were purified before ligation. Equimolar amounts of both parts were mixed in 6 M 
Guanidine (Gdn)-HCl, 0.1 M Tris-HCl, (pH 8) at a concentration of 10 mg/mL. 
Benzylmercaptan and thiophenol were added (1 v-% each). The pH was adjusted to 7 
before the reaction was left to react at 37 °C for 24h with mixing every hour. 
Oxidative folding of RANTES. The ligated peptide was purified using HPLC, desired 
fractions were pooled and lyophilized. The peptide was dissolved in 3 M Gdn-HCl, 0.1 
M Tris-HCl pH 8 at a concentration of 0.2 mg/mL. Cysteine (8 mM) and Cystine (1 mM) 
were added and the protein was left to fold at 4 °C for 24h with continuous mixing. 
The folded protein was purified using HPLC, desired fractions were pooled and 
lyophilized. 
HPLC Analysis and Purification. Analytical HPLC was performed using a Vydac C18 
HPLC column (4.6 mm x 150 mm, 1 mL/min flow rate) connected to a Varian Prostar 
system consisting of two Varian Prostar 215 delivery modules and a Varian Prostar 
320 UV/Vis detector (λ = 214 nm). A linear gradient of 0-67 % buffer B in buffer A over 
30 minutes was used, where buffer A = 0.1 v-% TFA in H2O and buffer B = 0.1 v-% TFA, 
10 v-% H2O in CH3CN.  
Semi-preparative HPLC was performed using Vydac C18 HPLC columns (10 mm x 250 
mm, 5 mL/min flow rate or 22 mm x 250 mm, 15 mL/min flow rate) connected to a 
Waters Deltaprep System consisting of a Waters Prep LC Controller and a Waters 2487 
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Dual wavelength Absorbance Detector (λ = 214 nm). Peptides were eluted using a 
gradient of B in A, based on an analytical HPLC run. Fractions were analyzed by 
Electrospray Ionization Mass Spectrometry (ESI-MS), desired fractions were pooled 
and lyophilized. 
Mass Spectrometry. ESI-MS was performed on an Applied Biosystems SCIEX API 150 
EX electrospray ionization quadrupole (ESI-Q) mass spectrometer. UPLC ESI-MS was 
performed on a Waters UHPLC XEVO-G2QTOF system Peptide masses were calculated 
from the experimental mass to charge (m/z) ratios of all the protonation states 
observed in the ESI-MS spectrum of a peptide using MaxEnt 3. Monoisotopic and 
average theoretical masses of compounds were calculated using Chemdraw 12.0.2. 
UPLC Mass spectrometry. Oxime ligation was monitored on a Waters UHPLC XEVO-
G2QTOF system. Sample (1-10 µL) was introduced to a PST C18 column (130A; 1.7 µm 
particles; column dimension 2.1x50mm, 35°C) by an FTN-autosampler, using 5% 
acetonitrile and 0.1% formic acid (FA) in water as purge-solvent/diluent. A water-
acetonitrile gradient containing 0.1% FA (flowrate 250µL/min) was used to separate 
starting peptides and oxime bound product at baseline level in 25 min. Exact mass 
measurement was performed in resolution mode using ESI-ionisation in positive mode 
(NaFormate-calibrated). Both quad profile and probe settings were optimized for 
small peptide measurement. 
Keto-acid ligation to LYRAK. The Fmoc protective group on the lysine sidechain was 
deprotected by treatment with 20% piperidine in DMF for three minutes repeated 
four times. The different keto-acids (2.2 mmol) were preactivated using carbodiimide 
(2 mmol) (DIC) for 2 minutes after which N¬-hydroxysuccinimide (NHS) (2.0 mmol) 
and N,N-diisopropyldiamine (DIPEA) (0.6 mmol) was added, directly followed by 
addition to the deprotected LYRAK (0.25 mmol) and left to react for 1 hour. Finally the 
N-terminal Boc-protective group was removed by treatment with TFA as described 
above. 
Aminooxy acetic acid ligation to VIPF. The Boc deprotection of the last amino acid 
was performed by treatment with TFA as described above. (Aminooxy)acetic acid (2.2 
mmol) was preactivated using DIC (2.0 mmol) for 2 minutes after which NHS (2.0 
mmol) and DIPEA (0.6 mmol) was added, directly followed by addition to deprotected 
VIPF (0.25 mmol) and left to react for 1 hour. 
Oxime ligations between LYRAK-ketone and aminooxy-VIPF. Peptide stocks were 
prepared fresh in 0.1 M ammonium acetate (pH 4.5). One equivalent of LYRAK-ketone 
was reacted with 2 equivalents of aminooxy-VIPF at 7, 70 and 700 µM of ketone in a 
total reaction volume of 1 mL. In the case of 7 µM reactions, oxime formation was 
monitored in presence of 0, 10 and 100 mM aniline. An aniline stock solution (200 
mM) was prepared fresh in 0.1 M ammonium acetate (pH 4.5) after which the pH was 
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adjusted to 4.5. Reactions were followed on a Xevo Waters UPLC system at 220 and 
280 nm with MS detection. Product formation was followed by absorbance at 280 nm. 
Integration of peaks was used to determine concentration of product formed. Product 
peak area was divided by the total peak area to obtain product concentration. 
Reactions were monitored for 48h with time points every 2.5h. Reaction constants 
were calculated by fitting the data points to equation 3 (see below).  
Oxime hydrolysis of LYRAK-OBA and aminooxy-VIPF. The mixture of oxime and 
residual aminooxy-VIPF was prepared at 700 µM as above and diluted to 70 and 7 µM 
final concentration of oxime. Oxime hydrolysis was monitored in presence of 0, 10 
and 100 mM aniline for both concentrations. Product degradation was followed on a 
Xevo Waters UPLC system at 220 and 280 nm with MS detection. Peak surface at 280 
nm was integrated to determine the concentration of product disappearing. Reactions 
were initially monitored with time points every 3 hours, with the addition of time 
points after 1, 2, 3 and 7 days. Reaction constants were calculated by fitting the data 
points to equation 3 (see below). 
Intramolecular cyclization of LYRAK-LA. Peptide stocks were prepared in fresh 0.1 M 
ammonium acetate (pH 4.5) at 700, 70 and 7 μM. Levulinoyl product forming was 
monitored on a Xevo Waters UPLC system at 220 and 280 nm with MS detection. Peak 
surface at 220 nm was integrated to determine the concentration of product 
formation. Reactions were monitored every 75 minutes for 17 hours. Reaction 
constants were calculated by fitting the data points to equation 6 (see below). The 
cyclization was proven to be concentration independent with rate constants of 3.68E-
05 s-1 and 1.22E-05 for k1 and k-1 respectively.  
RANTES labeling. RANTES(OBA) and RANTES(LA) were prepared as described above. 
RANTES(OBA)/RANTES(LA) (1 equivalent, 280 μg) and 98 μg label (2 equivalents) were 
dissolved in 6M Gdn-HCl 0.1 M acetate pH 4.5. Oxime formation was monitored on a 
Xevo Waters UPLC system at 220 and 540 nm with MS detection. Peak surface at 220 
nm was integrated to determine the concentration of product formation. Reactions 
were monitored for 36 hours with addition of time points at 65 (OBA) and 85 (LA) 
hours. RANTES-OBA-label was purified, analyzed with MALDI mass spectrometry and 
lyophilized. 
Analytical 
Second order reversible rate equation. The analytical solution for this reaction has 
been derived by Korobov[2]. In short, in a second order reversible reaction A1+A2 ↔ 
B, the change in product (x) is given by the differential equation 1.  
))(())())((()( 0220101 txBktxAtxAkdt
tdx
     (Equation 1) 
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The analytical solution for equation 1 is given by equation 2 
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This leads to the following expression for the concentration of product, [P]. 
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In which [P] is the concentration (M) of measured product formation, A10 is the initial 
concentration of ketone (M), A20 is the initial concentration of aminooxy (M), B0 is 
the initial concentration of oxime (M), k1 is the reaction constant in M-1s-1 , k2 is the 
rate constant in s-1 and t is the time in seconds. 
First order reversible rate equation. The analytical solution for this reaction has been 
derived by Korobov[2]. In short, in a first order reversible reaction A ↔ B, the change 
in product (x) is given by the differential equation 4. 
))(())(()( 0201 txBktxAkdt
tdx
      (Equation 4) 
The analytical solution for equation 4 is given by equation 5. 
)1()( )( 21 tkkeq extx
        (Equation 5) 
This leads to the following expression for the concentration of product, [P] 
)1(][ )(0 21
tkk
eq exBP
        (Equation 6) 
With
21
0201
kk
BkAkxeq 

  
In which [P] is the concentration (M) of measured product formation, A0 is the initial 
concentration of A (M), B0 is the initial concentration of B (M), k1 is the reaction 
constant in s-1, k2 is the rate constant in s-1 and t is the time in seconds. 
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Nuclear magnetic resonance  
Instrumentation. NMR experiments on the LYRAK and VIPF peptides were carried on 
Bruker Avance III 600, 700 HD, 750 and 900 MHz spectrometers. With the exception of 
the 750 MHz all other three spectrometers were equipped with TCI cryo probes. 
Proton spectra were recorded at 25 °C, 30 °C or 37 °C, with the temperature 
calibrated using an external ethylene glycol–DMSO-d6 (80%:20% v/v) NMR sample [3] 
and/or by means of an internal T1 temperature sensor that was placed in water at the 
center height of the magnetic coil of the spectrometer. 
Data acquisition and assignments. Chemical shifts of peptides in water are referenced 
to internal DSS samples in DMSO-d6, in particular to the residual proton (2.50 ppm) 
and carbon signal (39.54 ppm) of (partially) protonated DMSO. Chemical shift 
assignments of the levulinoyl peptides were made based on natural abundance 
gradient enhanced 15N-1H HSQC, 13C-1H HSQC, 15N-1H HMBC and 13C-1H HMBC 
heteronuclear 2D experiments in combination with sequential assignments 2D ROESY 
(200 ms mixing time), 2D NOESY (400 ms mixing time), 2D DIPSI (70 ms mixing time) 
spectra in water. Water suppression of NMR samples containing water-based buffer 
was carried by excitation sculpting techniques [4] or in the case of 13C-1H HMBC 
spectra by presaturation of the residual water line. Similar procedures were carried 
out for the assignment of LYRAK(AB), aminooxy-VIPF and its reaction product. Pulse 
sequences were taken from the standard Bruker pulse library, analysis of the NMR 
spectra was done in Sparky 3.114 [5]. 
Cyclization of LYRAK(LA). To follow the spontaneous cyclization of LYRAK(LA) by 
means of NMR, the freeze-dried peptide material, stored at -20 °C, was dissolved in 
500 µl D2O or DMSO-d6 and immediately put in a Wilmad 5 mm NMR tube for quick 
data collection in the spectrometer. No water-based buffer has been used to prepare 
these LYRAK samples, the pH* (uncorrected for isotope effects) was measured 3.0-3.3 
after dissolution in D2O. Figure S1 shows the conversion of LYRAK(LA) to cyclic (6) in 
D2O followed by proton NMR spectroscopy. 
Characterization of the cyclic LYRAK(LA) species. Chemical shift assignments for the 
reference LYRAK peptide, LYRAK(LA) (4) and various isomers of rearranged, Lev-
LYRAK(LA) (6, 7, 8) are summarized in Figure S2. More structural details on the 
rearranged Lev-LYRAK(LA) isomers will be presented in a separate article (to be 
published). 
Characterization of the reaction between LYRAK(AB) and aminooxy-VIPF. The 
reaction between LYRAK(AB) and aminooxy-VIPF was followed in real-time by NMR 
after dissolving lyophilized LYRAK(AB) peptide in 500 µL 100 mM sodium acetate-d3 
buffer (pH 4.5) with added 5% (v/v) D2O. Two peptide concentration ranges were 
tested: 70 µM and 700 µM LYRAK(AB) with two-fold molar excess of aminooxy-VIPF 
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reactant (140 µM and 1.4 mM, respectively). Reactions were monitored at 37 °C in the 
NMR spectrometer over the time course of 24 hour for the 700 µM series and up to 7 
days for the 70 µM sample. The initial time point zero of the reaction coordinate was 
taken as the moment that the NMR tube, containing the freshly mixed solution of 
LYRAK(AB) and aminooxy-VIPF, entered the spectrometer probe preset at a controlled 
temperature of 37 °C. For the 70 µM time series, a new 1D spectrum was started 
approximately every 15 minutes, for the 700 µM series a 1D spectrum was collected 
every 2 minutes. Relaxation delay between successive scans was set to 3 seconds. The 
1D spectra were stored in a pseudo 2D matrix to get identical phase-correction and 
base-line correction of all subspectra. All NMR processing was performed in Bruker 
Topspin 3.2 (Rheinstetten, Germany). Integration of proton signals was done by first 
exporting the data points to ASCII format in MestReC (version 4.9.9.6) [6] and 
summing the intensities of all points that fell in the appropriate chemical shift interval 
of the selected peak to integrate. Figure S5 displays 1H spectra taken at selected time 
points during 20 hour for the oxime reaction between LYRAK(AB) (700 µM) and 
aminooxy-VIPF (1.4 mM) that have been used to determine rate constants. 
In order to characterize the final adduct formed between LYRAK(AB) and aminooxy-
VIPF more easily by NMR, the reaction was also carried out at 37 °C at a near-
equimolar ratio of 1:1.05. This prevents the presence of excess non-reacted 
aminooxy-VIPF in the reaction mixture that would otherwise interfere with the 
resonance assignment of the final adduct. More details on the structural 
characterization of the oxime adduct will be presented in a separate article (to be 
published). 
Validation of peak integration method using NMR. The peak integration method 
used to calculate the amount of oxime product formed was validated by following the 
reaction of LYRAK-AB with aminooxy-VIPF using NMR. 700 μM LYRAK-AB and 1400 μM 
aminooxy-VIPF were dissolved in 100 mM NaOAc-d3 (pH 4.5). Decrease in proton 
signal of the neighboring CH2 or increase in signal of the valine NH was monitored. The 
resulting graphs were fitted to eq (3) and compared to the graphs obtained from the 
UPLC data as described above (Figure S10). 
Biology 
Cell isolation and culture. Murine bone marrow-derived macrophages (BMDMϕ) 
were isolated from the femurs of apolipoprotein E-deficient C57Bl/6 mice according 
to Davies and Gordon[7]. After flushing the marrow from the femurs, the cells were 
dispersed using a 70-μm cell strainer. Macrophages were cultured in bacteriological 
plastic plates in RPMI 1640 containing 10mM HEPES, 10% fetal calf serum and 1.5 
ng/mL macrophage colony stimulating factor. Murine 3T3 fibroblasts were cultured in 
DMEM containing 10% fetal calf serum.  
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Microscopic imaging using RANTES and SYTO-13. One day prior to confocal 
microscopy imaging, the cells were transferred into 4- or 8-chamber IBIDI slides. After 
overnight culture, the cells were washed with PBS and fresh serum-free DMEM or 
RPMI-1640 was added. Cells were incubated with 0, 500, 1000 or 1500 nM RANTES 
and 2 μM SYTO-13 for 1 hour at 37 °C. Visualization of macrophages and 3T3 
fibroblasts was performed using a Zeiss LSM Life-7 confocal microscope system. 
 
Figure S1: Numbering scheme of levulinic derivatives of the LYRAK peptide, together with a 
summary of experimental observed chemical shifts of various characterized isomers of 
LYRAK(LA): 
a: Unstable linear form (4) in D2O; b: Rearranged cyclic isomer (6) in D2O; c: Cyclic isomer (6) in 
DMSO-d6; d: Rearranged cyclic isomer (7) in DMSO-d6 formed after 24 hr; e: Minor cyclic form 
(8) formed after three months in DMSO-d6. Grey numbers indicate atom numbers. 
1H, 15N, and 
13C chemical shift values are color-coded in red, blue or black, respectively. 
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Figure S2: 1H 750 MHz spectra of the time profile of spontaneous cyclization of LYRAK(LA) (4) to 
(6) after freshly dissolving freeze-dried peptide (4) in D2O. Already after 30 minutes of data 
collection significant formation of the cyclic isomer (6) has taken place (1.8 mg/ml peptide 
incubated at 25 °C). The top spectrum of (6) is taken after prolonged pre-incubation (over 
several weeks) on a separate NMR sample. Note that approximately 5% of the original 
population of linear LYRAK(LA) (4) still survives after long incubation times. 
 
 
Figure S3: Measured concentration of levulinoyl side product (1*) formed at 700, 70 or 7 µM. 
Curves were fitted according to a first order reversible reaction as described above. 
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Figure S4: Deconvoluted spectrum of 1* side product. 747.46 corresponds to the linear form of 
levulinic acid. 729.46 corresponds to the cyclic pyrrolidone species with a mass difference of -18 
Da. 730.46 corresponds to the iminium species with a mass difference of -17 Da. 
 
 
Figure S5: Selected 1D NMR spectra taken during the reaction between LYRAK(AB) and AO-VIPF 
at 700 μM concentration LYRAK(AB)  (with two-fold excess of AO-VIPF) and 37 °C. Spectral 
changes over time are indicated. The original AB-CH2-(3) methylene (at 2.55 ppm) and AB-CH3 
methyl in LYRAK(AB)  (at 2.18 ppm) slowly disappeared and transformed into new signals that 
are contributed to the two possible C=N double bond conformational states (E or Z) of the 
1.92.02.12.22.32.42.5 ppm
1H
time
Et
Et (+overlap)
Ec
Ec
Zt
Zt
AcBu-CH (3)2
AcBu-C=N-OR
CH3CH3
AcBu-CH -C=N-OR2
3
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ligation adduct. The ratio of E/Z is approx. 2:1 with E being the conformer having its methyl 
group cis relative to the N-O oxygen atom, while the Z conformer has the methyl group placed 
in a trans configuration relative to the N-O oxygen atom. However, because the VIPF peptide 
part contains a proline that exists in a slow equilibrium between a major trans and cis 
conformer, four non-equivalent states can be discerned in the NMR spectra of the adduct. Et 
corresponds to R-C=N-O (E) with a trans-proline; Ec to R-C=N-O (Z) with a cis-proline; Zt to R-
C=N-O (Z) with a trans-proline and Zc to R-C=N-O (E) with a cis-proline. Peaks belonging to the 
Zc conformer are weak and are not visible in these 1D plots due to spectrum overlap and low 
intensity. More details will be presented in a separate article (to be published). 
 
 
Figure S6: Measured concentration of oxime formed in a reaction of 7 µM ketone with 14 µM 
aminooxy in the absence (a) or presence of 10 mM (b) or 100 mM aniline (c) fitted to a second 
order reversible reaction as described above. Dotted line represents theoretical maximum of 
product. 
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Figure S7: Measured concentration of oxime hydrolyzed in a reaction of 70 µM (a) or 7 µM (b) 
oxime with 7 µM aminooxy in absence and presence of aniline fitted to a second order 
reversible reaction as described above 
 
 
Figure S8: UV spectrum of RANTES(LA) (a) or RANTES(OBA) (b) labeling with Rhodamine B DTPA 
dual label after 36h. Desired product is labeled with *. Inserts show charge envelopes of 
purified RANTES-LA-label (exact mass: 9491.5, observed mass: 9491.8) and purified RANTES-
OBA-label (exact mass: 9553.5, observed mass: 9552.9).  
 
 
Figure S9: Oxime bond formed by reaction of LYRAK(AB) with aminooxy-VIPF. Signals of protons 
highlighted in bold have been integrated over time using NMR spectroscopy and used for the fit 
in Figure S10. 
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Figure S10: Comparison of measured concentration of oxime formed in a reaction of 700 µM 
ketone with 1400 µM aminooxy fitted to a second order reversible reaction as described above, 
either obtained by HPLC peak integration or NMR. NMR 1 represents the data obtained when 
following decrease of CH2 signal upon oxime formation, whereas NMR 2 represents the data 
when following the signal increase of NH upon oxime formation. Dotted line represents 
theoretical maximum of product. 
 
 
Figure S11: Schematic representation of the peptide model system. Peptides LYRAK, modified 
with a ketone (X denotes the different ketones used), and peptide VIPF, modified with an 
aminooxy, were reacted in aqueous buffer pH 4.5 to form an oxime bond 
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Abstract 
Chemical reaction rates are generally decreased at lower temperatures. Here, we 
report that an oxime ligation reaction in water at neutral pH is accelerated by freezing. 
The freezing method and its rate effect on oxime ligation are systematically studied on 
a peptide model system, and applied to a larger chemokine protein, containing a 
single acetyl butyrate group, which is conjugated to an aminooxy-labeled ligand. Our 
improved ligation protocol now makes it possible to efficiently introduce oxime-bond 
coupled ligands into proteins under aqueous conditions at low concentrations and 
neutral pH. 
Introduction 
Oxime ligations have unique properties and provide various linkage possibilities due to 
their orthogonal chemical nature. However, this chemical reaction is not routinely 
employed in bioconjugation strategies, primarily due to the slow rate of oxime 
formation. The reaction between a ketone or aldehyde with an aminooxy moiety 
forming an oxime bond is known to be sluggish especially at neutral pH, but can be 
accelerated by addition of the catalyst aniline or derivatives thereof.[1-5] Although 
the oxime ligation is becoming more popular, other strategies such as the (copper 
catalyzed) click reaction, the Staudinger ligation or Diels-Alder reactions are the 
preferred methods in most laboratories. [6-8]  
Typically, chemical reaction rates gradually decrease with decreasing temperatures, 
an observation which also holds true for the oxime reaction. Here, we show that by 
slowly freezing the reaction mixture in water at -20 °C, the oxime reaction rate can be 
increased up to two orders of magnitude, an enhancement greater than that achieved 
with the usual catalyst aniline. To demonstrate the feasibility and characteristics of 
the freeze-induced oxime ligation method, we show examples of bioconjugation on a 
model peptide system and a larger chemokine protein. 
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Scheme 1: Model peptide LYRAK(AcBu) and AO-VIPF oxime ligation scheme 
Results 
To investigate the freezing effect on the oxime reaction, a model system was used 
that consisted of two modified peptide sequences, LYRAK and VIPF. The lysine side 
chain in the LYRAK peptide was modified with 4-acetylbutyric acid to yield 
LYRAK(AcBu), one of the fastest reacting ketones. [9]  Peptide VIPF was modified with 
an aminooxy group on the N-terminal NH2 group to result in AO-VIPF (Scheme 1). The 
choice for a ketone instead of an aldehyde functionality on LYRAK was made because 
ketones are more widely used in bioconjugation but suffer from lower reactivity as 
compared to aldehydes, thus making it an optimal target for improvement. [3, 10-13] 
In previous studies, catalysis with aniline (or its derivatives) still exhibit relatively long 
reaction times. [2-4] For example, PEGylation of a ketone-containing protein at low 
concentration (7 μM) was performed at pH 7 using a 700-fold excess of aminooxy-
PEG.[3] Even in the presence of 500 mM m-phenylenediamine as catalyst, the reaction 
yield was only ~60% after 20 hours, thus providing impetus for improving ketone-
mediated oxime reactions.[3] 
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Figure 1: a: Oxime ligation progression curve of peptides LYRAK(AcBu) and AO-VIPF at 37 °C. 
Conditions ■ pH 4.5 □ pH 7.0 ● pH 4.5 + 10 mM aniline ○ pH 7.0 + 10 mM p-
pheneylenediamine, b: HPLC chromatogram of the reaction taken after 32h at pH 4.5 or pH 7.0 
in absence of aniline. LYRAK(AcBu) 1, AO-VIPF 2 and oxime product 3 are denoted. 
The oxime reaction involving two test peptides LYRAK(AcBu) and AO-VIPF was 
followed under various experimental conditions (Figure 1, 2).  All reactions with the 
model system were performed at a concentration of 100 µM LYRAK(AcBu) and a two-
fold excess of AO-VIPF (200 µM). 
In the absence of catalyst, the oxime reaction at the optimal pH of 4.5 was completed 
only after 48 hours (k1 0.11 M
-1 s-1). At neutral pH the reaction was much slower and 
did not exceed 20% of maximal product formation over the same period of time (k1 
0.01 M-1 s-1). Catalysis with 10 mM aniline at pH 4.5 resulted in a two fold increase in 
reaction rate (k1 0.19 M
-1 s-1) (Figure 1). At neutral pH the reaction was catalyzed with 
p-pheneylenediamine, which was shown to have increased activity as compared to 
aniline at neutral pH, yielding a two fold increase in reaction rate (k1 0.02 M
-1 s-1). [4] 
These results show that slow reaction rates for oxime bond formation remain a 
problem especially at neutral pH and prompted us to examine experimental 
conditions that would lead to increased oxime reaction rates for more effective 
protein bioconjugation, which ideally requires reactions to be performed at low 
concentration and neutral pH. 
In studying the thermodynamics of the oxime reaction, we observed that upon 
freezing our sample at -20 °C the reaction unexpectedly reached completion. To 
investigate this effect on oxime formation, peptides LYRAK(AcBu) and AO-VIPF were 
ligated under freezing conditions. To ensure a homogenous freezing of the mixture, 
the samples were frozen in an isopropanol bath at temperatures -20 and -80°C, or 
alternatively in liquid nitrogen at -196 °C. The effects of freezing on ligation yields 
were first studied by maintaining the frozen reaction vessel 1, 2 or 3 hours at a 
constant low temperature (Figure 2A). At optimal pH of 4.5 and freezing at -20 °C, the 
reaction reached 85% of oxime product after 1 hour. Prolongation of incubation time 
to 2 and 3 hours resulted in a slight increase in formation of oxime product, likely due 
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to continuation of normal reaction kinetics. Therefore we concluded that a freezing 
time of 1 hour is sufficient to reach a desirable yield. Addition of 100 mM aniline to 
the reaction increased the yield to near completion within 1 hour (Figure 2A). To 
unambiguously prove that freezing of the sample is responsible for the observed 
effect, a sample was measured under similar conditions in presence of 30% methanol, 
to decrease the freezing point to -26 °C. Addition of methanol only mildly reduced k1 
from 0.17 M-1 s-1 to 0.10 M-1 s-1 (Figure S1). Presence of 30% methanol at -20 °C for 1,2 
or 3 hours showed no effect on the reaction rate, indicating that the process of 
freezing caused the observed increase in reaction rate (Figure 2A). 
 
Figure 2: a: Yield of oxime formation between LYRAK(AcBu) (100 μM) and AO-VIPF (200 μM) as 
a function of freezing time at different temperature and solution conditions. Maximum 
theoretical yield is 100 μM. b: Effect of the number of freeze/thaw cycles (duration of one hour) 
on the final yield of the oxime product formed between LYRAK(AcBu) (100 μM) and AO-VIPF 
(200 μM) in sodium phosphate buffer pH 7. 
In our experimental setup the time for complete freezing of the sample at -20 °C was 
~1 hour. To study the influence of freezing rate on oxime formation, the reaction 
mixture was frozen at lower temperatures of -80 or -196 °C, respectively, to decrease 
the time until a fully frozen state was reached. Notably, the fast freezing procedure 
barely increased oxime reaction rates or yields (Figure 2A). This indicated that -20 °C is 
an optimal temperature and suggested that slow growing ice crystals likely produce 
locally high concentrations of reactants favoring more rapid oxime bond formation. In 
the case of freezing at -80 or -196 °C the short freezing time likely prevents reactant 
exclusion and therefore will not influence oxime formation to a large extent.   
Even though freezing at pH 4.5 was promising, it provided no great advantage 
compared to reaction catalysis with aniline (Figures 1A; 2A). For this reason, we 
decided to assess effects on the reaction at neutral pH where oxime reactions occur 
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very slowly even in the presence of catalysts. Freezing of the sample at pH 7 saw an 
oxime yield of approximately 50%, which is a 25 fold increase in comparison to the 
control reaction at 37 °C that reaches 2% in 1h (Figure 1A). In an attempt to increase 
the oxime formation yield above 50% under these conditions, repeated freeze/thaw 
cycles were performed. In each cycle the samples were slowly frozen at -20 °C for 55 
minutes and subsequently thawed.  After one thermal cycle, the oxime yield was 50% 
(Figure 2B). A second cycle increased the yield to 75%, and the maximum yield was 
obtained after a third cycle. 
To put these results in a more biological and practical context, we applied our freezing 
protocol to protein labeling, at low concentrations and neutral pH. For this purpose, 
the 68 amino acid chemokine CCL5 obtained by chemical synthesis and derivatized 
with a ketone moiety on Lys69 was conjugated with a bimodal label containing 
diethylenetriamine pentaacetic acid (DTPA) and tetramethyl rhodamine (TAMRA) and 
an aminooxy group (Figure 3A). The protein concentration was lowered to 10 µM to 
mimic a more realistic protein bioconjugation situation, with the aminooxy label 
present in three-fold excess.  As a control the reaction was followed at 37 °C which 
showed slow progression of the oxime reaction at neutral pH with a yield of 10% 
reached after 48h. In contrast, after a single freeze/thaw cycle the same reaction 
reached a 77% yield and conversion was near complete after 3 cycles (Figure 3C). To 
compare the freezing procedure with the continuous reaction at 37 °C, data are 
presented as three successive freeze cycles of 1 hour each (Figure 3C). 
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Figure 3: a: Schematic representation of the RANTES synthesis and subsequent labelling with a 
bimodal label. b: Mass spectrum of 9, HPLC graph after a single freeze/thaw cycle of reaction of 
7 and 8 to yield 9 c: Labelling of CCL5 with an aminooxy label. Reaction followed over time. ■ 
Freeze/thaw cycles -20 °C □ reacƟon progression at 37 °C. Insert shows a ribbon representaƟon 
of 9 
Here, we demonstrated that under aqueous conditions, the oxime reaction between a 
ketone and aminooxy group can be readily catalyzed by freezing of the reaction 
mixture. The effects are largest at neutral pH, at which uncatalyzed oxime ligations 
are usually unreactive. The observation that chemical reactions are accelerated by 
freezing was first observed in the ‘60s.[14-16] The explanation for this interesting 
phenomenon rests in several factors.[17] First, freezing induces a concentration effect 
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that can account for most reaction rate accelerations. In addition, a catalytic effect of 
the fine-structured growing ice crystals might play a role. Finally, the increase in salt 
concentration and associated change in pH and ionic strength were mentioned as 
reasons for rate acceleration. The basis for the observed effect in case of the oxime 
reaction most likely lies in the concentration effect, which supports our reactant-
exclusion theory. However, since the effect seen at pH 7.0 is larger than at pH 4.5, we 
cannot exclude that one of the other freezing effects might play a role in rate 
acceleration at neutral pH. 
Overall, we have presented a simple procedure to significantly enhance oxime 
reaction rates without the addition of catalyst. One limitation of our study might lie in 
the repetitive freezing protocol, which would make the procedure less attractive for 
proteins that destabilize and aggregate during freezing. However, in comparison to 
catalysis of the oxime reaction with aniline (or derivatives) the presented increase in 
reaction rate by freezing has a number of advantages. Firstly, the catalysis with aniline 
will also accelerate the backward hydrolysis reaction.[9] Secondly, catalysis with 
aniline requires a purification step following conjugation to remove the catalyst. 
Finally, in comparison to protein labeling reactions catalyzed by anilines, reaction 
times can be even further reduced. For example, the latest reported derivative of 
aniline, p-phenylenediamine, requires 20h reaction time to reach 90% conversion 
(conditions: 91 μM protein 5-fold excess label, 10 mM catalyst, 4 °C) whereas our 
method saw similar yields after only 3 hours with 10 fold lower protein 
concentrations.[4] 
This procedure offers a quick and facile procedure to label proteins via oxime 
chemistry without the need to use large excesses of label, catalysts, or purification. 
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Supporting Information 
Peptide synthesis. Peptides were synthesized manually by SPPS on a 0.25 mmol scale 
on a MBHA or PAM resin. An in situ neutralization/HCTU activation for Boc chemistry 
was used. Each synthetic cycle consisted of 1. removal of the Boc protective group by 
two 1-minute treatments with TFA, followed by a DMF wash; 2. addition of the 
preactivated amino acid in the presence of excess DIPEA, followed by another DMF 
wash. The Boc-protected amino acids (1.1 mmol) were activated with 1 mmol of HCTU 
and 3 mmol DIPEA. Coupling of Gln residues was followed by a DCM wash, before and 
after TFA deprotection, to prevent intramolecular pyrrolidone formation. After 
coupling of the final amino acid, the resin was dried by wash steps with DCM and 
DCM/MeOH. 
After completion of the peptide chain, the peptides were deprotected and cleaved 
from the resin by treatment with anhydrous HF for 1 hour at 0°C, using 4% p-cresol 
(v/v) as scavenger Peptides were precipitated in ice-cold diethylether, dissolved in 50% 
acetonitrile in water containing 0.1% TFA, and lyophilized. The crude mixture was 
subjected to preparative HPLC and fractions containing the desired product were 
identified by ESI-MS, pooled and lyophilized. 
LYRAK model peptide 
sequence: H2N-Leu-Tyr-Arg-Ala-Lys(Fmoc)-CONH2 
VIPF model peptide 
sequence: H2N-(Aminooxy)acetic acid-Val-Ile-Pro-Phe- CONH2 
RANTES C-terminus peptide 
sequence: H2N-Cys-Ser-Asn-Pro-Ala-Val-Val-Phe-Val-Thr-Arg-Lys-Asn-Arg-Gln-Val-Cys-
Ala-Asn-Pro-Glu-Lys-Lys-Trp-Val-Arg-Glu-Tyr-Ile-Asn-Ser-Leu-Glu-Met-Ser-Lys(Fmoc)-
COOH 
RANTES N-terminus peptide 
sequence: H2N-Ser-Pro-Tyr-Ser-Ser-Asp-Thr-Thr-Pro-Cys-Cys-Phe-Ala-Tyr-Ile-Ala-Arg-
Pro-Leu-Pro-Arg-Ala-His-Ile-Lys-Glu-Tyr-Phe-Tyr-Thr-Ser-Gly-Lys-MPAL-COOH 
Synthesis of Rhodamine B DTPA dual label. A dipeptide Cys-Lys(Fmoc) was prepared 
via solid phase peptide synthesis as described above. The N-terminal Boc protection 
was removed with 2x1 min TFA treatment after which (Aminooxy)acetic acid (2.2 
mmol) was preactivated using DIC (2.0 mmol) for 2 minutes. NHS (2.0 mmol) and 
DIPEA (0.6 mmol) was added to the mixture, directly followed by addition to the 
deprotected Cys-Lys (0.25 mmol) and left to react for 1 hour. The Fmoc deprotection 
was achieved by 4x3 min 20% piperidine in DMF. Any unreacted, residual piperidine 
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were removed by a DMF and DCM wash step. 0.5 mL rhodamine B-succinimide (AAT 
Bioquest, Sunnyvale CA, USA) (7.5 mg/mL) was added to the resin and the mixture 
was left to react at 37 °C for 4 hours with occasional mixing. The resin was washed 
with DMF followed by N-terminal Boc deprotection. The dipeptide was cleaved from 
the resin using anhydrous HF, precipitated in diethylether, dissolved in 50% MeCN in 
H2O + 0.1% TFA, purified and lyophilized. The dried peptide (2.4 mg) was dissolved in 
1 mL 0.1 M NH4OAc (pH 5.7) + 10 % MeCN. Maleimide-DTPA was added in 1.5 times 
excess and left to react at 37 °C for 2.5 hours. The resulting product was purified, 
analyzed by MALDI mass spectrometry and lyophilized. 
Ketone incorporation into chemokine RANTES C-terminus peptide. After completion 
of the peptide chain, the Fmoc protective group on the C-terminal lysine was 
deprotected using 4x3 min treatments with 20% piperidine in DMF. Subsequently, 
keto-acid 4-acetylbutyric acid (2.2 mmol) was preactivated using carbodiimide (2 
mmol) (DIC) for 2 minutes after which N-hydroxysuccinimide (NHS) (2.0 mmol) and 
N,N-diisopropyldiamine (DIPEA) (0.6 mmol) was added. This mixture was directly 
added to the deprotected RANTES (0.25 mmol) and left to react for 1 hour. Finally the 
N-terminal Boc-protective group was removed by treatment with TFA as described 
above to result in RANTES(AcBu) C-terminal peptide after cleavage from the resin. 
Native chemical ligation of RANTES C- and N-terminus peptides. Both the C- and N-
terminal peptides were purified using HPLC before ligation. Equimolar amounts of 
both peptides were mixed in 6 M Guanidine (Gdn)-HCl, 0.1 M Tris-HCl, (pH 8) at a 
concentration of 10 mg/mL each , and thiophenol was added (2 vol-%). The pH was 
adjusted to 7 before the reaction was left to react at 37 °C for 4h with occasional 
mixing. 
Oxidative folding of RANTES. After native chemical ligation RANTES was purified using 
HPLC, desired fractions were pooled and lyophilized. The peptide was dissolved in 3 M 
Gdn-HCl, 0.1 M Tris-HCl pH 8 at a concentration of 0.2 mg/mL. Cysteine (8 mM) and 
Cystine (1 mM) were added and the protein was left to fold at 4 °C for 24h with 
continuous stirring.  The folded protein was purified using HPLC, and desired fractions 
were pooled and lyophilized. 
UPLC Mass spectrometry. Analysis of oxime reactions and HPLC fraction analysis were 
performed on a Waters UHPLC XEVO-G2QTOF system. Samples (1-10 µL) were loaded 
using a FTN-autosampler on a PST C18 column (130A; 1.7 µm particles; column 
dimension 2.1x50mm, 35°C). 5% acetonitrile and 0.1% formic acid (FA) in water was 
applied as purge-solvent. A water-acetonitrile gradient containing 0.1% FA (flowrate 
250µL/min) was used to separate starting peptides and oxime bound product at 
baseline level in 14 min Exact mass measurement was performed in resolution mode 
using ESI-ionisation in positive mode detection (NaFormate-calibrated). Both quad 
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profile and probe settings were optimized for small peptide measurementin the case 
of analysis of the model system reactions or optimized for large peptide 
measurements in the case of analysis of RANTES fragments. 
HPLC Purification. (Semi-)preparative HPLC was performed using Vydac C18 HPLC 
columns (10 mm x 250 mm, 10 mL/min flow rate or 22 mm x 250 mm, 20 mL/min flow 
rate) connected to a Waters Deltaprep System consisting of a Waters Prep LC 
Controller and a Waters 2487 Dual wavelength Absorbance Detector (λ = 214 nm). 
Peptides were eluted using a gradient of B(90% MeCN in H2O with 0.1% TFA) in A (100% 
H2O with 0.1% TFA) based on an analytical UPLC run. Fractions were analyzed by 
UPLC-MS, desired fractions were pooled and lyophilized. 
Keto-acid ligation to LYRAK. The Fmoc protective group on the lysine sidechain was 
deprotected by treatment with 20% piperidine in DMF for three minutes, and 
repeated four times. 4-acetylbutyric acid (AcBu) (2.2 mmol) was preactivated for 2 
minutes using carbodiimide (2.0 mmol) (DIC) after which N-hydroxysuccinimide (NHS) 
(2.0 mmol) and N,N-diisopropyldiamine (DIPEA) (0.6 mmol) were added. This mixture 
was directly added to deprotected LYRAK (0.25 mmol) and left to react for 1 hour. 
Finally, the N-terminal Boc-protective group was removed by treatment with TFA as 
described above. 
Aminooxy acetic acid ligation to VIPF. The Boc deprotection of the first amino acid 
(Valine) was performed by treatment with TFA as described above. Boc-
(Aminooxy)acetic acid (2.2 mmol) was preactivated for 2 minutes using DIC (2.0 mmol) 
after which NHS (2.0 mmol) and DIPEA (0.6 mmol) was added. this mixture was 
directly added to deprotected VIPF (0.25 mmol) and left to react for 1 hour. 
Control oxime ligation experiments. Peptides LYRAK(AcBu) and AO-VIPF were 
dissolved in freshly made buffer to a final concentration of respectively 100 µM and 
200 µM. Experiments done at pH 4.5 were performed in 100 mM sodium acetate 
buffer, experiments at pH 7.0 were carried out in 100 mM sodium phosphate buffer. 
An additional control reaction, where 30% v/v methanol was added to the pH 4.5 
buffer, was also studied (supplemental Figure 1). Oxime formation was monitored by 
integration of the two HPLC chromatogram peaks, absorbing at 280 nm, that 
correspond to starting material and peptide end product. The integrated peaks as a 
function of reaction time were fitted to an kinetic equation describing a 2nd order 
reversible reaction.   
Freeze-induced oxime ligation experiments. Peptides LYRAK(AcBu) and AO-VIPF were 
dissolved in freshly made buffer to a final concentration of respectively 100 µM and 
200 µM. Experiments done at pH 4.5 were performed in 100 mM sodium acetate 
buffer, experiments at pH 7.0 were carried out in 100 mM Sodium phosphate buffer. 
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All freeze experiments were performed in triplicate. Samples were frozen in a bath of 
isopropanol at temperatures -20 °C and -80 °C, or in liquid nitrogen at -196 °C. Oxime 
conversion yields were determined by integration of HPLC chromatogram peaks, 
absorbing at 280 nm, that correspond to starting material and peptide end product.  
RANTES(AcBu) conjugation with AO-dual label. 10 µg RANTES(AcBu) was dissolved in 
95 µL buffer (100 mM sodium phosphate pH 7.0), 5 µL AO-dual label was added from 
a 705 µM stock solution to reach final concentrations of 12 µM and 35 µM for 
respectively RANTES(AcBu) and AO-dual label. The reaction mixture was slowly frozen 
at -20 °C in an isopropanol bath, kept at constant temperature for 55 minutes and 
subsequently thawed. After thawing the reaction mixture was placed back in the 
isopropanol bath for a second freeze/ thaw cycle, etc. In total 3 freeze/thaw cycles 
were applied. The experiments were repeated four times and the final results were 
averaged. 
The control experiment without freezing was performed at the same concentration 
and in the same buffer. The samples were placed at 37 °C and measured for 48h. 
Oxime yield was determined by integration of peaks in the HPLC spectrum at 220 nm. 
 
Figure S1: Reaction of LYRAK(AcBu) and AO-VIPF followed over time. Solution conditions used 
were: 100 mM sodium acetate buffer pH 4.5 (■), 100 mM sodium acetate buffer + 100 mM 
aniline pH 4.5 (▲), 100 mM sodium phosphate buffer pH 7 (▼) and in 30% (v/v) MeOH plus 70% 
100 mM sodium acetate water buffer pH 4.5 (●). The addition of 30% MeOH to the buffer 
lowers the freezing temperature to -26 °C and consequently does not freeze in the model 
system at -20 °C 
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Abstract 
Protein-protein interactions (PPIs) govern most processes in living cells. Current drug 
development strategies are aimed at disrupting or stabilizing PPIs, which require 
thorough understanding of PPI mechanisms. Examples of such PPIs are heteromeric-
chemokine interactions that are potentially involved in pathological disorders such as 
cancer, atherosclerosis and HIV. It remains unclear whether this functional 
modulation is mediated by heterodimer formation or by additive effects of mixed 
chemokines on their respective receptors. To address this issue, we report the 
synthesis of a covalent RANTES-PF4 heterodimer (termed OPRAH) by total chemical 
synthesis and oxime ligation, with an acceleration of the final ligation step driven by 
PPIs between RANTES and PF4. Compared to mixed separate chemokines, OPRAH 
exhibited increased biological activity, thus providing evidence that physical formation 
of the heterodimer indeed mediates enhanced function. 
Introduction 
Chemokines are small chemotactic cytokines that mediate leukocyte trafficking, which 
makes them interesting pharmaceutical targets to antagonize inflammatory diseases 
such as rheumatoid arthritis, Crohn's disease and atherosclerosis.[1, 2] By binding to 
their cognate G protein-coupled receptors, they can rapidly trigger leukocyte 
chemotaxis and adhesion, and thus regulate a variety of cellular processes e.g. 
angiogenesis, embryonic development and cell homeostasis.[3]  
The structure of chemokine monomers is characterized by a disordered N-terminus 
and three-stranded antiparallel -sheets onto which a C-terminal -helix is folded. 
Based on the spacing between conserved N-terminal cysteine residues, chemokines 
are divided into 4 groups, with the major ones being CC- and CXC-type. Although 
being small (<10 kDa), most chemokines have the propensity to form homodimers or 
higher-order multimeric structures (>200 kDa).[4] While the monomeric structures of 
all chemokines are highly conserved, there are notable differences between their 
(oligomeric) quaternary structures. For example, CC-type chemokine dimers, formed 
by interactions between their N-termini, are elongated and dumbbell shaped, 
whereas CXC-type chemokine dimers are formed by interactions between their 
central -sheets making them more globular in structure. 
The chemokines RANTES (CCL5) and platelet factor 4 (PF4, CXCL4) are stored in the -
granules of platelets. While RANTES is a potent attractant of mononuclear cells, PF4 
lacks classical chemo-attractant functions.[5] However, the presence of PF4 can 
synergistically enhance RANTES-mediated cell-recruitment mediated by heterophilic 
interactions between chemokines.[5] In fact, pharmacologic inhibition of RANTES and 
PF4 heterodimer formation inhibits monocyte recruitment and attenuates 
progression of atherosclerosis, lung injury and aneurysm formation in mice.[6-8] 
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Heterophilic chemokine interactions have also been reported for CXCL4 and CXCL8[9], 
CCL19 and CCL22[10], CCL2 and CCL8[11], as well as other chemokines.[12] These 
studies support the proposal that heterophilic interactions between different 
chemokines are relevant for many physiological and pathological processes.  
Although current evidence suggests that physical formation of chemokine 
heterodimers mediates their observed functional modulation, the possibility remains 
that this could simply be due to combined receptor stimulation by the respective 
chemokines. Therefore, the aim of the present study is to generate an obligate 
RANTES-PF4 heterodimer by means of total chemical synthesis in order to address this 
crucial mechanistic question. 
Results 
Based on the observation that RANTES and PF4 interact via their N-termini as a CC-
type dimer,[6] we used this model as a starting point to assess optimal coupling 
strategies for the protein pair (Figure 1). Because oxime ligation can be performed 
with folded proteins in aqueous buffer at neutral pH, we chose it to be a suitable 
reaction to covalently link the two proteins. Oxime ligation requires the incorporation 
of a ketone in one protein and an aminooxy moiety in the other. Due to limitations in 
the ketone functionality of the widely-used levulinic acid, we used 5-ketohexanoic 
acid because of its high reactivity and conformational flexibility.[13] 
 
Figure 1: Schematic representation of a covalently linked dimer of PF4 (left) and RANTES (right). 
The termini of the two chemokines are labeled. The oxime connection between the two 
proteins is shown. 
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The proposed heterodimer consists of a RANTES monomer (68 aa) that is covalently 
linked to a PF4 monomer (76 aa) (Figure 3). The chemokines were each assembled by 
two subsequent native chemical ligations (NCL)[14], followed by oxidative folding, and 
joined by oxime ligation. Positions suitable for covalent linkage of the two proteins 
were based on the proposed heterodimer structure observed by NMR.[6] 
Furthermore, the N-terminus of RANTES was required to remain unrestricted to allow 
interactions with its receptor (CCR5).[15] In addition, amino acids crucial for RANTES–
PF4 interaction were left untouched, leaving Thr7 in RANTES and Leu8 in PF4 as a site 
for crosslinking (Figure 1). Therefore, Thr7 and Leu8 were replaced by orthogonal 
protected lysines to provide a handle for introducing the ketone or aminooxy moiety. 
All reactions were followed by HPLC-MS. After oxidative folding of the chemokines to 
obtain modified RANTES (16) and PF4 (8), oxime linkage between the two proteins 
was obtained by reacting equimolar quantities of the two modified chemokines (200 
µM) in aqueous buffer at pH 4.5. This led to the desired Obligate PF4-RANTES 
Heterodimer (OPRAH: 17) with a 60% yield after 12 hours (Figure 3; SI1; SI2). A 
functional negative control (nOPRAH) was established by linking Ser1 of RANTES to 
Glu1 of PF4 through an identical oxime linker by which the N-terminal interaction of 
RANTES with its receptor CCR5 was blocked. 
 
Figure 2: Oxime formation between 8 and 16 followed over time in 0.1 M NaOAc without 
additions (■), the addition of 6 M Gn.HCl (□) or 100 mM aniline (●). 
In an effort to improve the reaction rate we observed only minor enhancement by 
addition of aniline as catalyst.[16] To rule out that homomeric interactions between 
folded chemokines would impair heteromeric oxime formation, we performed oxime 
ligation in the presence of a denaturing agent (6 M Gn.HCl). Surprisingly, in contrast to 
accelerating heteromeric oxime formation, the presence of Gn.HCl slowed down 
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oxime ligation 5-fold, while it only had a minor effect on the reaction rate in a model 
system (Figure 2; SI3). This observation indicated that the rate of formation of the 
oxime bond between RANTES and PF4 was accelerated by heterophilic chemokine 
interactions which bring the two reactive species into close proximity (Figure 2). In 
retrospect, the proposed conformation-assisted ligation was supported by the lower-
than-expected catalytic effect by aniline. Eventually, using slow freezing catalysis,[17] 
we were able to achieve complete oxime reaction within 2 hours. 
To assess the folded states of modified PF4 and RANTES, as well as OPRAH we applied 
NMR spectrometry. NMR spectra show that modified PF4 and RANTES are well folded. 
However, modified PF4 could still form tetramers like wild type PF4, whereas modified 
RANTES with its N-terminally positioned lysyl-linker showed markedly attenuated 
dimer formation. Compared to NMR spectra of the non-ligated proteins, OPRAH 
appears to contain two correctly folded domains of the respective chemokines (Figure 
4, Figure SI4). The resolved Trp57 Hε resonance in the spectrum of 16 is a 
good indicator of the folding preference of the RANTES subunit in OPRAH. In non-
ligated RANTES, Trp57 Hε resonances are observed for monomer (m) and homodimer 
(d) states (insert to Figure 4). Upon covalent dimerization of 16 and 8 to form OPRAH 
(17), the RANTES homodimer “d” state peak is reduced in intensity, whereas the “m” 
peak is increased in intensity and slightly chemically shifted consistent with a change 
in chemical environment likely due to formation of the linked heterodimer. The 
remaining RANTES “d” peak intensity in 17 may arise from some homodimerization of 
two RANTES domains in OPRAH. 
We also followed real time oxime formation between 8 and 16 using NMR analysis 
(Figure SI4-6). These NMR spectra show overall resonance broadening, which we 
attribute to transient formation of the OPRAH heterodimer. This is supported by our 
observations with the Hε resonances of Trp57 which is an indirect structural probe 
due to its distance from the modified N-terminus of 16. Overall, we conclude that the 
general folds of the two protein domains, PF4 and RANTES, are maintained in OPRAH, 
and resonance broadening of residues at the oxime ligation site suggests dynamic 
interactions between the two covalently-linked domains. 
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Figure 3: Schematic representation of the obligate PF4-RANTES heterodimer (OPRAH) synthesis 
route. Insert showing the mass-to-charge distribution of 17 (left) and the UV detected LC 
chromatogram of 17 (right). Both C-terminal peptides (3 and 11) were synthesized using 
standard tBoc solid phase peptide chemistry protocols.[18] Sequential NCL required N-terminal 
encrypted cysteines (thiaprolines) to be used in the middle fragments (2 and 10).[19]  
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Figure 3 (continued): Both N-terminal fragments (1 and 9) contain a thioester for NCL and 
require an orthogonally protected (N-Alloc) lysine for incorporation of the ketone or aminooxy 
functional group. Deprotection of the Alloc group was performed on resin using Pd(PPh3)4, and 
the ketone (5-ketohexanoic acid) and aminooxy (Boc-(aminooxy)acetic acid) moieties were 
introduced to obtain 5 and 13, respectively. Following synthesis and purification, all peptide 
fragments were ligated sequentially with the use of 1-2% thiophenol and benzylmercaptan as 
catalysts. 
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Figure 4: Comparison between 700 MHz 1D proton spectra (amide region) of PF4 (8), RANTES 
(16), OPRAH (17) and a 1:1 complex of wtRANTES and Met-PF4, under similar conditions. Top 
spectrum: overlay of experimental proton spectrum of OPRAH (black) and the sum spectra of 
free RANTES (16) and PF4 (8) (broken line) The agreement between experimental spectrum 17 
and the summed spectra 8+16 shows that globally OPRAH consists of two natively folded PF4 
and RANTES protein domains. Local differences are however apparent and these regions 
correspond to sharp amide peaks in the N-terminus region (2-7) of free PF4 that seem to 
broaden out significantly in OPRAH. Insert: Trp57 Hε signal is indicated for free RANTES(16), the 
1:1 complex and OPRAH(17).  
We next investigated biological activity of OPRAH in a monocyte arrest assay. Here, a 
monolayer of endothelial cells was pre-treated with chemokines or heterodimers, 
after which monocytes were passed over the surface.[5] The presence of chemokines 
triggered monocyte arrest, and the number of arrested monocytes was recorded as 
measure of activity (Figure 5A). Three different conditions were tested; OPRAH, the 
negative control nOPRAH, in which the N-termini were blocked by oxime linkage at 
positions 1 in RANTES and PF4, and a non-covalent dimer-mix of RANTES and PF4. 
OPRAH (17) recruited twice the amount of monocytes than the non-covalent mixed 
PF4 and RANTES chemokines (Figure 5B). Furthermore, the negative control nOPRAH 
showed a decrease in activity, proving the importance of the free N-terminus of 
OPRAH for receptor-mediated monocyte recruitment.[15] Peptide CKEY, that was able 
to disrupt non-covalent PF4-RANTES heterodimers and that led to a decrease in 
atherosclerosis in a mouse model,[6] was able to reduce monocyte adhesion with 
non-covalent PF4-RANTES heterodimers, but not with OPRAH  (Figure 5C). 
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Figure 5: a: Microscopy images showing monocyte arrest by (n)OPRAH and non-covalent 
RANTES-PF4 mixtures on endothelial cells. b: Monocyte arrest by (n)OPRAH (1.9 nM; n=6 ± 
SEM) and non-covalent RANTES-PF4 mixtures (3.8 nM each; n=3 ± SEM). C Effect of CKEY on 
chemokine-mediated monocyte arrest (n=6 ± SEM). 
In summary, we have provided strong evidence that synergism in monocyte 
recruitment by the PF4-RANTES complex proceeds through a 1:1 heterodimeric 
fashion. Proof of this concept through chemical synthesis of a covalent PF4-RANTES 
heterodimer (OPRAH) in addition offers synthetic access to multiple chemokine 
heteromers that can unambiguously prove functional enhancement through 
heteromerization within this novel area of chemokine biology. 
  
Kissing Chemokines 
 
82 
 
References 
1. Schall, T.J. and A.E. Proudfoot, Overcoming hurdles in developing successful drugs 
targeting chemokine receptors. Nat Rev Immunol, 2011. 11(5): 355-363. 
2. Koenen, R.R. and C. Weber, Therapeutic targeting of chemokine interactions in 
atherosclerosis. Nat Rev Drug Discov, 2010. 9(2): 141-153. 
3. Raman, D., T. Sobolik-Delmaire, and A. Richmond, Chemokines in health and disease. 
Exp Cell Res, 2011. 317(5): 575-589. 
4. Allen, S.J., S.E. Crown, and T.M. Handel, Chemokine: receptor structure, interactions, 
and antagonism. Annu Rev Immunol, 2007. 25: 787-820. 
5. von Hundelshausen, P., R.R. Koenen, M. Sack, S.F. Mause, W. Adriaens, A.E. Proudfoot, 
T.M. Hackeng, and C. Weber, Heterophilic interactions of platelet factor 4 and 
RANTES promote monocyte arrest on endothelium. Blood, 2005. 105(3): 924-930. 
6. Koenen, R.R., P. von Hundelshausen, I.V. Nesmelova, A. Zernecke, E.A. Liehn, A. Sarabi, 
B.K. Kramp, A.M. Piccinini, S.R. Paludan, M.A. Kowalska, A.J. Kungl, T.M. Hackeng, K.H. 
Mayo, and C. Weber, Disrupting functional interactions between platelet chemokines 
inhibits atherosclerosis in hyperlipidemic mice. Nat Med, 2009. 15(1): 97-103. 
7. Grommes, J., J.E. Alard, M. Drechsler, S. Wantha, M. Morgelin, W.M. Kuebler, M. 
Jacobs, P. von Hundelshausen, P. Markart, M. Wygrecka, K.T. Preissner, T.M. Hackeng, 
R.R. Koenen, C. Weber, and O. Soehnlein, Disruption of platelet-derived chemokine 
heteromers prevents neutrophil extravasation in acute lung injury. Am J Respir Crit 
Care Med, 2012. 185(6): 628-636. 
8. Iida, Y., B. Xu, H. Xuan, K.J. Glover, H. Tanaka, X. Hu, N. Fujimura, W. Wang, J.R. 
Schultz, C.R. Turner, and R.L. Dalman, Peptide inhibitor of CXCL4-CCL5 heterodimer 
formation, MKEY, inhibits experimental aortic aneurysm initiation and progression. 
Arterioscler Thromb Vasc Biol, 2013. 33(4): 718-726. 
9. Dudek, A.Z., I. Nesmelova, K. Mayo, C.M. Verfaillie, S. Pitchford, and A. Slungaard, 
Platelet factor 4 promotes adhesion of hematopoietic progenitor cells and binds IL-8: 
novel mechanisms for modulation of hematopoiesis. Blood, 2003. 101(12): 4687-4694. 
10. Sebastiani, S., G. Danelon, B. Gerber, and M. Uguccioni, CCL22-induced responses are 
powerfully enhanced by synergy inducing chemokines via CCR4: evidence for the 
involvement of first beta-strand of chemokine. Eur J Immunol, 2005. 35(3): 746-756. 
11. Crown, S.E., Y. Yu, M.D. Sweeney, J.A. Leary, and T.M. Handel, Heterodimerization of 
CCR2 chemokines and regulation by glycosaminoglycan binding. J Biol Chem, 2006. 
281(35): 25438-25446. 
12. Nesmelova, I.V., Y. Sham, J. Gao, and K.H. Mayo, CXC and CC chemokines form mixed 
heterodimers: association free energies from molecular dynamics simulations and 
experimental correlations. J Biol Chem, 2008. 283(35): 24155-24166. 
13. Agten, S.M., D. Suylen, H. Ippel, M. Kokozidou, G. Tans, P. van de Vijver, R.R. Koenen, 
and T.M. Hackeng, Chemoselective oxime reactions in proteins and peptides by using 
an optimized oxime strategy: the demise of levulinic acid. Chembiochem, 2013. 14(18): 
2431-2434. 
14. Dawson, P.E., T.W. Muir, I. Clark-Lewis, and S.B. Kent, Synthesis of proteins by native 
chemical ligation. Science, 1994. 266(5186): 776-779. 
15. Proudfoot, A.E., C.A. Power, A.J. Hoogewerf, M.O. Montjovent, F. Borlat, R.E. Offord, 
and T.N. Wells, Extension of recombinant human RANTES by the retention of the 
initiating methionine produces a potent antagonist. J Biol Chem, 1996. 271(5): 2599-
2603. 
16. Dirksen, A., T.M. Hackeng, and P.E. Dawson, Nucleophilic catalysis of oxime ligation. 
Angew Chem Int Ed Engl, 2006. 45(45): 7581-7584. 
Kissing Chemokines 
 
83 
 
5 
17. Agten, S.M., D.P. Suylen, and T.M. Hackeng, Oxime Catalysis by Freezing. Bioconjug 
Chem, 2016. 27(1): 42-46. 
18. Schnolzer, M., P. Alewood, A. Jones, D. Alewood, and S.B. Kent, In situ neutralization 
in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult 
sequences. Int J Pept Protein Res, 1992. 40(3-4): 180-193. 
19. Bang, D. and S.B. Kent, A one-pot total synthesis of crambin. Angew Chem Int Ed Engl, 
2004. 43(19): 2534-2538. 
20. Hackeng, T.M., J.H. Griffin, and P.E. Dawson, Protein synthesis by native chemical 
ligation: expanded scope by using straightforward methodology. Proc Natl Acad Sci U 
S A, 1999. 96(18): 10068-10073. 
 
 
  
Kissing Chemokines 
 
84 
 
Supporting Information 
Peptide synthesis. Peptides were synthesized manually by SPPS on a 0.25 mmol scale 
on a MBHA or PAM resin. An in situ neutralization/HCTU activation for Boc chemistry 
was used[18]. Each synthetic cycle consisted of the Boc protective group removal by 
two 1-minute treatments with TFA followed by a DMF wash, addition of the pre-
activated amino acid in presence of excess DIPEA, followed by another DMF wash. The 
Boc-protected amino acids (1.1 mmol) were activated with 1 mmol of HCTU and 3 
mmol DIPEA. Coupling of Gln residues was followed by a DCM wash before and after 
TFA deprotection to prevent intramolecular pyrrolidone formation. After coupling of 
the final amino acid, the resin was dried by wash steps with DCM and DCM/MeOH. 
After completion of the peptide chain, the peptides were deprotected and cleaved 
from the resin by treatment with anhydrous HF for 1 hour at 0° C with 4% p-cresol 
(v/v) as scavenger. Peptides were precipitated in ice-cold diethylether, dissolved in 50% 
acetonitrile in water + 0.1% TFA and lyophilized. The crude mixture was subjected to 
preparative HPLC and fractions containing the desired product were identified by ESI-
MS, pooled and lyophilized. 
Human RANTES C-term 
sequence: H2N-Cys-Ser-Asn-Pro-Ala-Val-Val-Phe-Val-Thr-Arg-Lys-Asn-Arg-Gln-Val-Cys-
Ala-Asn-Pro-Glu-Lys-Lys-Trp-Val-Arg-Glu-Tyr-Ile-Asn-Ser-Leu-Glu-Met-Ser-COOH 
Human RANTES middle (M) fragment 
sequence: H2N-Thz-Phe-Ala-Tyr-Ile-Ala-Arg-Pro-Leu-Pro-Arg-Ala-His-Ile-Lys-Glu-Tyr-
Phe-Tyr-Thr-Ser-Gly-Lys-MPAL-COOH 
Human RANTES N-term 
sequence: H2N-Ser-Pro-Tyr-Ser-Ser-Asp-Thr-Thr-Pro-Cys-MPAL-COOH  
Human PF4 C-term 
sequence: H2N-Cys-Pro-Thr-Ala-Gln-Leu-Ile-Ala-Thr-Leu-Lys-Asn-Gly-Arg-Lys-Ile-Cys-
Leu-Asp-Leu-Gln-Ala-Pro-Leu-Tyr-Lys-Lys-Ile-Ile-Lys-Lys-Leu-Leu-Glu-Ser-COOH 
Human PF4 middle (M) fragment 
sequence: H2N-Thz-Leu-Cys-Val-Lys-Thr-Thr-Ser-Gln-Val-Arg-Pro-Arg-His-Ile-Thr-Ser-
Leu-Glu-Val-Ile-Lys-Ala-Gly-Pro-His-MPAL-COOH 
Human PF4 N-term 
sequence: H2N-Glu-Ala-Glu-Glu-Asp-Gly-Asp-Leu-Gln-MPAL-COOH 
Residues in bold were changed into Boc-Lys(alloc) to accommodate for ketone or 
aminooxy incorporations in the different constructs. Thz denotes a cysteine protected 
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as a thiazolidine. MPAL denotes a leucine to which a mercaptopropionic is coupled 
after which the sequence is continued as normal.[20] 
Ketone or aminooxy incorporation into chemokine N-termini. After completion of 
the peptide chain, the Alloc protective group on the N-terminal lysine was 
deprotected using 2 x 30 min treatments with 0.25 eq. Pd(PPh3)4 in DCM using 
PhSiH3 (24 eq.) as a scavenger. Subsequently, the keto-acid (4-acetyl butyric acid) or 
Boc (aminooxy)acetic acid (2.2 mmol) were preactivated using carbodiimide (2 mmol) 
(DIC) for 2 minutes after which N-hydroxysuccinimide (NHS) (2.0 mmol) and N,N-
diisopropyldiamine (DIPEA) (0.6 mmol) was added, directly followed by addition to the 
deprotected peptide chain (0.25 mmol) and left to react for 1 hour. Finally the N-
terminal Boc-protective group was removed by treatment with TFA as described 
above to result in the peptide chain modified with a ketone or aminooxy after 
cleavage from the resin. Alternative orthogonal protection using Fmoc was 
unsuccessful because of low yields obtained by deprotection with 20% piperidine 
(nucleophilic attack on thioester moiety) or with DBU/HOBt. 
Native chemical ligation of RANTES C-terminus and middle fragment (10+11). Both 
the C-terminus and middle fragment (M) were purified before ligation. Equimolar 
amounts of both parts were mixed at a concentration of 10 mg/mL in 0.1 M Tris-HCl 
pH 8, containing 6 M Guanidine (Gdn)-HCl, . Thiophenol was added (2% v/v). The pH 
was adjusted to 7 before the reaction was left to react at 37 °C for 7h with mixing 
every 30 minutes. 
Thiazolidine deprotection RANTES CM ligation product (12→14). After ligation of the 
C and M fragments the N-terminal thiazolidine was deprotected. The ligation mixture 
was diluted 5 times in 0.1 M Acetate pH 4 containing 6 M Guanidine (Gdn)-HCl,. 
MeONH2 (0.2 M) and TCEP (30 eq.)  were added and the deprotection reaction was 
left at RT for 12h. 
Native chemical ligation of RANTES CM- and N-terminus (13+14). Both the CM and 
N-terminus were purified before ligation. The N-terminus was taken in 2 times excess, 
both parts were mixed at a concentration of 10 mg/mL in 0.1 M Tris-HCl pH 8, 
containing 6 M Guanidine (Gdn)-HCl, . Thiophenol was added (2% v/v). The pH was 
adjusted to 7 before the reaction was left to react at 37 °C for 1h with mixing every 5 
minutes. 
Oxidative folding of RANTES (15→16). The ligated peptide was purified using HPLC, 
desired fractions were pooled and lyophilized. The peptide was dissolved at a 
concentration of 0.2 mg/mL in 0.1 M Tris-HCl pH 8 containing 3 M Gdn-HCl, . Cysteine 
(8 mM) and cystine (1 mM) were added and the protein was left to fold at 4 °C for 24h 
with continuous mixing. The folded protein was purified using HPLC, desired fractions 
were pooled and lyophilized. 
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Native chemical ligation of PF4 C-terminus and middle fragment (2+3).Both the C- 
and Middle (M) fragments were purified before ligation. Equimolar amounts of both 
parts were mixed at a concentration of 10 mg/mL in 0.1 M Tris-HCl, pH 8 containing 6 
M Guanidine (Gdn)-HCl, . Thiophenol and benzylmercaptan were added (1% v/v each). 
The pH was adjusted to 7 before the reaction was left to react at 37 °C for 6h with 
mixing every 30 minutes. 
Thiazolidine deprotection PF4 CM ligation product (4→6). After ligation of the C and 
Middle (M) fragments the N-terminal thiazolidine was deprotected. The ligation 
mixture was diluted 5 times using 0.1 M Acetate, pH 4 containing 6 M Guanidine 
(Gdn)-HCl, 0.2 M MeONH2  and TCEP (30 eq.)  The deprotection reaction was left at 
RT for 12h. 
Native chemical ligation of PF4 CM- and N-terminus (5+6). Both the CM and N-
terminus were purified before ligation. The N-terminus was taken in 2 times excess, 
both parts were mixed at a concentration of 10 mg/mL in 0.1 M Tris-HCl, pH 8 
containing 6 M Guanidine (Gdn)-HCl,. Thiophenol and benzylmercaptan were added (1% 
v/v each). The pH was adjusted to 7 before the reaction was left to react at 37 °C for 
8h with mixing every 30 minutes. 
Oxidative folding of PF4 (7→8). The ligated peptide was purified using HPLC, desired 
fractions were pooled and lyophilized. The peptide was dissolved at a concentration of 
0.2 mg/mL in 0.1 M Tris-HCl pH 8 containing 1 M Gdn-HCl, . Cysteine (8 mM) and 
cystine (1 mM) were added and the protein was left to fold at 4 °C for 24h with 
continuous mixing. The folded protein was purified using HPLC, desired fractions were 
pooled and lyophilized. 
HPLC analysis and purification. Analytical HPLC was performed using a Vydac C18 
HPLC column (4.6 mm x 150 mm, 1 mL/min flow rate) connected to a Varian Prostar 
system consisting of two Varian Prostar 215 delivery modules and a Varian Prostar 
320 UV/Vis detector (λ = 214 nm). A linear gradient of 0-67 % buffer B in buffer A over 
30 minutes was used, where buffer A = 0.1 v-% TFA in H2O and buffer B = 0.1 v-% TFA, 
10 v-% H2O in CH3CN.  
Semi-preparative HPLC was performed using Vydac C18 HPLC columns (10 mm x 250 
mm, 10 mL/min flow rate or 22 mm x 250 mm, 20 mL/min flow rate) connected to a 
Waters Deltaprep System consisting of a Waters Prep LC Controller and a Waters 2487 
Dual wavelength Absorbance Detector (λ = 214 nm). Peptides were eluted using a 
gradient of B in A, based on an analytical HPLC run. Fractions were analyzed by 
Electrospray Ionization Mass Spectrometry (ESI-MS), desired fractions were pooled 
and lyophilized. 
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Mass spectrometry. UPLC ESI-MS was performed on a Waters UHPLC XEVO-G2QTOF 
system. Peptide masses were calculated from the experimental mass to charge (m/z) 
ratios of all the protonation states observed in the ESI-MS spectrum of a peptide using 
MaxEnt 3. Monoisotopic and average theoretical masses of compounds were 
calculated using Chemdraw 12.0.2. 
UPLC mass spectrometry. Ligation reactions and preparative HPLC fractions were 
monitored on a Waters UHPLC XEVO-G2QTOF system. Sample (1-10 µL) was 
introduced to a PST C18 column (130A; 1.7 µm particles; column dimension 
2.1x50mm, 40°C) by an FTN-autosampler, using 5% acetonitrile and 0.1% formic acid 
(FA) in water as purge-solvent/diluent. A water-acetonitrile gradient containing 0.1% 
FA (flowrate 250µL/min) was used to separate peptides and ligation products at 
baseline level in 14 min. Exact mass measurement was performed in resolution mode 
using ESI-ionisation in positive mode (sodium formate-calibrated). Both quad profile 
and probe settings were optimized for large peptide measurement. 
Oxime ligation of PF4 and RANTES. The chemokines were dissolved in 100 mM 
NaOAc (pH 4.5) in equimolar amounts (200 μM) and left to react for 48h at 37 °C. 
Reactions were followed using UPLC-MS. Freeze catalysis was performed in identical 
conditions; proteins were mixed, frozen at -20 °C for 1 hour and subsequently thawed. 
This procedure was repeated twice. 
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Figure SI 1: Overview of PF4 synthesis: first column shows ligation of the C-terminal with the 
middle fragment followed over time, with subsequent thiaproline deprotection and 
purification. Middle column shows NCL of the ligated product with the N-terminal fragment. 
The final column shows oxidative folding of PF4 
Kissing Chemokines 
 
89 
 
5 
 
Figure SI 2: Overview of RANTES synthesis: first column shows ligation of the C-terminal with 
the middle fragment followed over time, with subsequent thiaproline deprotection and 
purification. Middle column shows NCL of the ligated product with the N-terminal fragment. 
The final column shows oxidative folding of RANTES 
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Figure SI 3: Oxime forming reaction of LYRAK(AcBu) and AO-VIPF followed over time in different 
conditions.  All reaction were performed in 100mM NaOAc pH 4.5 or in 100mM NaPhos pH 7.0, 
concentrations were 100 µM for LYRAK(AcBu) and 200 µM for AO-VIPF. Conditions: ■pH 4.5 
●pH 7.0 ▲pH 4.5 +100 mM aniline ▼pH 4.5 + 6M Gdn-HCl 
NMR spectroscopy. NMR samples of OPRAH, modified RANTES and modified PF4, 
were prepared as 0.2 mM solutions made from freeze-dried protein buffer exchanged 
into 25 mM deuterated NaAc-d3 buffer (pH 3.60) containing 0.1 mM EDTA, 0.2 mM 
sodium azide. 5% (v/v) D2O was added for deuterium lock. Initial buffer exchange 
steps were carried out by ultracentrifugation (in four to five steps) using pre-washed 
Amicon Ultra-4 ultra-centrifugaton devices with a filter cutoff of 3kDa. Final NMR 
solutions were prepared in Wilmad 3 mm NMR tubes (160 µl volume), containing a 
tiny trace of DSS for internal chemical shift calibration (0 ppm 1H). 
NMR spectra were recorded on a Bruker Avance III HD 700 MHz spectrometer, 
equipped with a cryogenically cooled TCI probe. Internal temperature was set to 37 °C, 
with the probe temperature calibrated using a thermocouple inside a NMR tube that 
was inserted into the probe. One dimensional proton spectra were recorded using 
excitation sculpting to suppress residual water. Two-dimensional DIPSI (70 ms mixing 
time) and 2D NOESY spectra (150 ms mixing time) were recorded using the same 
water suppression technique. Typically 32 scans over 600 increments were collected 
per spectrum. In addition, natural abundance heteronuclear 13C-1H HSQC spectra were 
acquired for better comparison to known assignments of free RANTES and PF4. 
The oxime reaction between RANTES and RANTES to form OPRAH was followed in 
real-time by 1D NMR inside the NMR tube at 50 °C. The reaction proceeds relatively 
slowly, so for that reason the reaction was also studied by freezing the NMR sample at 
-20 °C for one hour in the freezer, and slowly warm up the sample back to room 
temperature. Spectra processing was performed by Bruker Topspin3.2 and Sparky 
3.114 software. 
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Figure SI 4: Comparison between the DIPSI spectra (70 msec mixing time) of 0.2 mM OPRAH 
(17), RANTES(16) PF(8) and a 1:1 complex of wtRANTES + Met-PF4 measured under the same 
conditions (700 MHz, 37 °C in 25 mM NaAc-d3 buffer (pH 3.60), 0.1 mM EDTA, and 0.2 mM 
sodium azide). Assignments for native tetrameric PF4 are incomplete, mostly due to severe 
dynamic chemical shift broadening of proton resonances, N-terminal amide resonances of 
PF4(2-7) are however sharp and sequentially assigned from NOESY spectra. Analysis show that 
the DIPSI spectrum of OPRAH (black) mostly corresponds to a superposition of the spectra of 
two separately folded domains. Signals for important residues connected just around the linker 
region are however missing in OPRAH, most likely due to dynamic repositioning between the 
two domains on an intermediate millisecond time scale. 
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Figure SI 5: Bottom spectrum: Comparison of 1H NMR 700 MHz spectra (amide region) 
monitoring the oxime reaction between 0.2 mM RANTES (16) and 0.2 mM PF4 (8) yielding 
OPRAH. Reaction times were +24 hour at 50 °C (red), and +2 hr at -20 °C, followed by thawing 
and a warm up of the frozen NMR sample (blue).  Top spectrum: reference spectrum of free 0.2 
mM RANTES (16) taken at time zero (black) and +24 hours at 50 °C (broken line). Changes have 
been contributed to side reactions of the aminooxy group in free RANTES (16) and gradually 
appear in both the spectrum of RANTES and OPRAH after keeping the sample for several hours 
at 50 °C (broken line). 
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Figure SI 6: a: Top spectrum: methyl groups in the reference RANTES (16) protein. Two different 
conformational states of the RANTES domain are present: m = monomeric; d = dimeric (top) in 
both RANTES and OPRAH. Peaks denoted “aged” have been contributed to side reactions of the 
aminooxy group of free RANTES (16) and gradually appear in both the spectrum of RANTES and 
OPRAH after keeping the sample for several hours at 50 °C (broken line). Most prominent 
change of conformational state in RANTES (16) is the diminished dimer population compared to 
native RANTES, due to steric hindrance of the introduced oxime bridge involving lysine 
sidechain at RANTES position T7K. Bottom spectrum: Comparison of 1H NMR 700 MHz spectra 
(methyl region) monitoring the oxime reaction between 0.2 mM RANTES (16) and 0.2 mM PF4 
(8) yielding OPRAH. Reaction times were +24 hour at 50 °C (red), and +2 hr at -20 °C, followed 
by thawing and a warm up of the frozen NMR sample (blue). After freezing the reaction NMR 
mixture for an additional +2 hours at -20 °C, mass spectra indicate near-complete conversion to 
OPRAH, and the population of homodimer RANTES states decrease even more compared to 
free RANTES (16), in agreement with competitive formation of heterodimers formed between 
RANTES and PF4 in OPRAH. b: Enlarged section of Figure SI5 showing the comparison of 1H NMR 
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700 MHz spectra (Trp sidechain amino region) monitoring the oxime reaction between 0.2 mM 
RANTES (16) and 0.2 mM PF4 (8) yielding OPRAH. Reaction times were +24 hour at 50 °C (red), 
and +2 hr at -20 °C, followed by thawing and a warm up of the frozen NMR sample (blue). Top 
spectrum: Peaks of RANTES Trp57 Hε in the reference RANTES (16) protein. Two different 
conformational states of the RANTES domain are present: m = monomeric; d = dimeric (top) in 
both RANTES and OPRAH. Peaks denoted “aged” have been contributed to side reactions of the 
aminooxy group of free RANTES (16) and gradually appear in both the spectrum of RANTES and 
OPRAH after keeping the sample for several hours at 50 °C (broken line). Bottom spectrum: 
Comparison of 1H NMR 700 MHz spectra (aromatic region) monitoring the oxime reaction 
between 0.2 mM RANTES (16) and 0.2 mM PF4 (8) yielding OPRAH. Reaction times were +24 
hour at 50 °C (red), and +2 hr at -20 °C, followed by thawing and a warm up of the frozen NMR 
sample (blue) 
Monocyte arrest assay. CD14+ human monocytes were isolated from peripheral blood 
mononuclear cells (PBMC), which were separated from human whole blood (see 
above), and purified by negative selection using the “Monocyte Isolation Kit II” 
according to the manufacturers protocol (Miltenyi Biotec GmbH, Bergisch Gladbach, 
Germany). Human aortic endothelial cells (HAoEC) were cultured and activated with 
IL-1ß for 4 hours prior to incubation for 30 minutes with chemokines (CXCL4+CCL5 3.8 
nM) or synthetic obligate chemokine (1.9 nM) heterodimers and peptide interfering 
with heterodimerization inhibitor (CKEY). Monocytes (0.7×106/ml) were applied onto 
the activated endothelium shear stress (1.5 dyn/cm2) using a syringe pump (WPI, 
Berlin, Germany) in a laminar flow chamber for 2 min and flushed with assay medium 
thereafter. Cells were visualized and recorded using a phase contrast microscope 
(Olympus IX 50, Shinjuku, Japan) connected to a CMOS camera (ids, Obersulm, 
Germany). For quantification, tightly adherent leukocytes were manually counted in 
10 fields of view per dish. Experiments were performed n=3 for (CXCL4+CCL5) or n=6 
for OPRAH and nOPRAH. Presented data were subtracted with monocyte adherence 
in absence of chemokines. Data are presented as mean +SEM. 
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Abstract 
Chemokines orchestrate leukocyte trafficking and function in health and disease. 
Heterophilic interactions between chemokines in a given microenvironment may 
amplify, inhibit or fine-tune their activity; however, a systematic evaluation of the 
chemokine interactome has not been achieved. We used immuno-ligand blotting and 
surface plasmon resonance to obtain a comprehensive map of chemokine-chemokine 
interactions and confirm their specificity. Structure-function analyses revealed that 
chemokine activity was enhanced by CC-type heterodimers but inhibited by CXC-type 
heterodimers. Functional synergy was achieved through receptor heteromerization 
(for CCL5-CCL17) or receptor retention by auxiliary proteoglycan binding (for CCL5-
CXCL4), whereas inhibition was due to conformational changes affecting receptor 
activation. Obligate CC-type heterodimers showed high efficacy/potency and drove 
acute lung injury and atherosclerosis, processes abrogated by specific CCL5-derived 
peptide inhibitors or knock-in of an interaction-deficient CXCL4 variant. 
Atheroprotective effects of CCL17 deficiency were pheno-copied by a CCL5-derived 
peptide disrupting CCL5-CCL17 heterodimers, whereas a CCL5 α-helix-peptide 
mimicked inhibitory effects on CXCL12-driven platelet aggregation. Thus, formation of 
specific chemokine heterodimers differentially dictates functional activity and can be 
exploited for therapeutic targeting. 
Introduction 
Chemokines regulate leukocyte activation and coordinate their trafficking to sites of 
inflammation or during immune surveillance. The G-protein-coupled receptor-binding 
and function of chemokines are governed by their interaction with cell surface 
proteoglycans, oligomer formation, naturally occurring antagonists, and proteolytic 
processing. [1, 2] Recent studies unveiled that heteromeric interactions between 
chemokines modify their biological activities and provide structural insight into 
underlying mechanisms. Consequently, we hypothesized that a functional chemokine 
interactome comprised of pairwise heteromeric interactions explains how signals 
conferred by individual chemokines can be integrated to control leukocyte responses. 
[3, 4] 
Many chemokines form homodimers or oligomers based on two modes to support 
interfaces: CC-type or CXC-type. [5] Dimerization in a CC-type occurs via interaction of 
the flexible N-termini to form a two-stranded anti-parallel β-sheet, whereas in a CXC-
type chemokines interact by anti-parallel extension of preformed β-strands. [5] In 
addition, their structural similarity allows chemokines to form unique hetero-dimers 
to shape the overall signaling response of their receptors, and homo- and 
heteromerization of some chemokines is linked to glycosaminoglycan (GAG) binding. 
[4-7] Molecular dynamics simulations (MDS) for selected chemokine homo- and 
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hetero-dimer pairs predict that association free energies depend upon the particular 
chemokine combination and dimer-type (CC or CXC), some of which are energetically 
favored over others. [8] MDS suggests that CC chemokines preferably engage in CC-
type interactions, CXC chemokines favor a CXC-type, while both interactions can occur 
in mixed CC-CXC heteromers. Preferred modes of interaction have been validated 
experimentally for some chemokine pairs, but have not been extensively explored or 
linked to differential functions. Nuclear magnetic resonance (NMR) analyses revealed 
that CC chemokine receptor 2 (CCR2) ligands form CC-type heteromers, and that CCL5 
forms a mixed CC-type heteromer with the CXC chemokine CXCL4. [6, 7] The CXC-type 
heterodimer CXCL4-CXCL8 inhibits CXCL8-mediated endothelial cell activation and 
proliferation, binding CXCR2 less strongly than CXCL8 alone. [9, 10] Peptide-mediated 
disruption of the CCL5-CXCL4 heteromer revealed that this interaction enhances CCL5-
mediated leukocyte recruitment, acute lung injury and atherosclerosis [7, 11]; 
however, other heteromers have not been evaluated in disease models. 
Among the interactions between platelet-derived chemokines identified by mass 
spectrometry, MDS revealed that CXCL4 can undergo conformational changes to align 
its α-helix with that of CXCL12 to form a CXC-type dimer. [12] Without providing clues 
towards the type of interaction, screening for synergistic effects on leukocytes 
showed that combinations of CCR7 agonists with some non-agonist chemokines led to 
formation of heteromers that enhance T-cell migration and CCR2 ligand activity in 
monocytes. [13, 14] Such evidence of functional synergy implied that heteromers may 
act as amplifiers in chemokine-rich tissues; however, a systematic and in-depth 
approach to map interactions between chemokines and to verify their functional 
specificity has not been undertaken. 
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An unbiased, bidirectional immunoblot chemokine screening in which one partner 
was immobilized on a nitrocellulose membrane and the other remained in solution 
(Fig. S1) identified heteromeric interactions between pairwise combinations of all 
known human chemokines. Interactions were considered positive when they 
exceeded a densitometry threshold of 5% (on average) relative to positive controls in 
either direction (Fig. 1A, Table S1). The full interactome matrix revealed hotspots of 
heteromeric interactions (mostly for inflammatory pairs) and large areas devoid of 
interactions (Fig. 1A). Neither CC chemokines that adopt unusual polymeric or unique 
monomeric states (CCL3, CCL4, CCL18) [15, 16] nor transmembrane chemokines 
(CX3CL1, CXCL16) formed heteromers. Only few plasma chemokines activated by N-
terminal cleavage or non-mucosal homeostatic chemokines [1] engaged in 
interactions, with the exception of CCR7 ligands. 
Aiming at the design of disease-specific peptide therapeutics, we focused on 
chemokines involved in atherosclerosis. CCL2 interacted with CCL5, CXCL8 and other 
CCR2 ligands (Fig. 1A). The atherogenic CCR1/3/5 agonist CCL5 was the most 
promiscuous chemokine, forming heteromers with 24 partners (Fig. 1A). Various 
CXCR2 and CXCR3 ligands [2] interacted with each other, with CCL2, CCL5 or CCL11. 
We did not consider CCR7 ligands, because of their inconclusive role in atherosclerosis 
models. [17] The atypical chemokine CXCL4 interacted with CXCL12 and many 
atherogenic chemokines. CXCL4L1, a CXCL4 variant that differs at three C-terminal 
residues [18], primarily interacted with CCL19/21/25/27 and CXCL12, thus displaying a 
more homeostatic profile. 
The multiple interactions observed for CCL5 and CXCL4 were validated by surface 
plasmon resonance (SPR), which also confirmed the interactions of atheroprotective 
CXCL12, e.g. with CCL5 and CXCL4, and a more selective interaction pattern of CCL17 
(Fig. 1B-E). Thresholds for SPR and densitometry were defined so as to minimize the 
number of non-validated interactions. In addition to positive signals in ligand blots 
and/or in previous assays, interactions were considered bona fide when they passed 
these thresholds or had good affinity (Kd<10
-6 M) despite sub-threshold SPR responses 
(Fig. 1A-E, Table S2). 
Figure 1: Mapping of the chemokine interactome. a: Chemokine-chemokine interactions were 
detected by bidirectional immuno-ligand blotting. Known atherogenic chemokines are 
highlighted in orange and non-mucosal homeostatic chemokines are shaded in grey. Chemokine 
interactions were considered positive (cyan) if the densitometric signal exceeded that of the 
positive control by 5% (on average) on either side of the blot (n=2-4 independent experiments). 
Chemokine interactions previously identified and experimentally confirmed by other techniques 
are indicated in dark blue. b–e: Binding of soluble chemokines (100 nM) to immobilized CCL5 (b), 
CXCL4 (c), CXCL12 (d) and CCL17 (e) was assessed by surface plasmon resonance (SPR). 
Response units (RU) were compared after the association phase. SPR thresholds optimally 
delineating binders (black bars) and non-binders (white bars) were based on median values 
derived from all tested interactions of CCL5, CXCL4 and CXCL12 (b–d), or were set at 300 RU by 
interpolation with immuno-blotting for CCL17. Data represent mean±SEM (n=3-5 experiments). 
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To elaborate interactions of interest, we performed kinetics analyses (Fig. S2). 
Dissociation constants revealed that CCL5 had high affinity for CCL17 and CXCL4 
(KD<10
-8 M), intermediate affinity for CCL2 and CXCL7 (KD<10
-7 M), and lower affinity 
for CXCL12 (Table S2). The affinities of CCL5 for CXCL4 and CXCL4R>Q mutant (with 
attenuated heparin binding [19]) were similar, whereas CXCL4L1 did not bind CCL5 but 
retained affinity for CXCL12. Conversely, CCL5 and the mutant CCL5E66S had high 
affinity for CXCL4, whereas mutation of the basic BBXB cluster (CCL544AANA47) or E26 
(CCL5E26A) resulted in no or impaired binding, identifying residues critical for the 
interaction. CCL5 and CCL5E66S showed similar affinities for CCL17 and CXCL12. 
Monomeric CCL5MT7 (N-methylated T7) did not bind CXCL4 and bound CCL17 with 17-
fold lower affinity, consistent with a role of the CCL5 N-terminus in CC-type 
interactions. CCL5E26A but not CCL544AANA47 had high affinity for CCL17, implying a 
specific role of E26 in binding to CXCL4, with the BBXB motif also involved in binding 
to CCL17. 
Formation of different types of chemokine heterodimers 
We focused our NMR structural studies on CCL5 and partners selected for their range 
of interactions and inflammatory relevance. To avoid higher-order aggregation [20] 
and poor spectral characteristics of native CCL5 [21], we used CCL5E66S. The CXCL4K50E 
mutant was applied to attenuate CXCL4 tetramer formation and to allay concerns 
about broadening of NMR spectra due to chemical exchange. [22] Heteronuclear 
single quantum coherence with 15N-enriched CCL5E66S is exemplified by CXCL4K50E and 
CCL17 (Fig. 2A,B, full spectra in Fig. S3). Significant resonance broadening and minimal 
chemical shift (Δδ) changes indicated heteromeric interactions in the intermediate 
exchange regime. Changes in resonance intensity (ΔIntensity) and Δδ of the CCL5E66S 
monomer were plotted versus its sequence (Fig. 2C-F). Because CCL5E66S dimer 
resonances were much less perturbed (Fig. S4A-D), we concluded that heteromeric 
interactions occur between monomers and not dimers. This was supported by 
comparing Δδ and ΔIntensity changes for native CXCL4 interactions with monomeric 
and dimeric CCL5E66S (Fig. S4E-H). 
The type of heterodimer formed (CC or CXC) was elucidated by analyzing spectral 
changes (Δδ; Δintensity). The most perturbed CCL5E66S monomer resonances belong to 
residues (7-14, 30-33, 47-50) involved in CC-type dimers (Fig. 2C-F, Fig. S4E,F). In both 
hetero-pairs, residues 7-11 at the primary CC-type dimer interface displayed relatively 
large changes. In CCL5E66S, residues 47-50 (corresponding to β-strand 3) were more 
perturbed by interactions with CCL17, whereas residues 30-33 were more affected by 
interactions with CXCL4K50E or CXCL4. As compared to CCL17, smaller spectral effects 
observed for CXCL4 indicate slightly weaker interactions with CCL5E66S, confirming that 
heterodimer stability depends on residue composition and inter-subunit orientation 
at the interface. [8] Although formation of both heterodimer types is possible with 
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varying molar ratios (Fig. S5), our data show that these two chemokine pairs prefer to 
form CC-type heterodimers (Fig. 2G,H). 
As evidenced by CCL5E66S-induced 15N-CXCL12 spectral changes that reflect 
intermediate exchange, CXCL12 and CCL5 also form heterodimers (Fig. S6A,B). The 
most perturbed 15N-CXCL12 resonances belong to residues in β-strand-1 and the C-
terminal helix, which are involved in the CXC-type dimer interface. Combining 15N-
CCL5E66S and unlabeled CXCL12 was also indicative of an interaction but inconclusive in 
terms of heterodimer-type formed (Fig. S6C,D). Other chemokines, e.g. CXCL10, 
induced relatively non-specific and moderate spectral changes that are likely 
attributable to their propensity for homo-aggregation (as seen for CXCL10 tetramers 
[23]) and increased viscosity at higher concentrations (Fig. S6E). Weighted averaging 
of ΔIntensity changes and MDS-based in silico modeling supported that CXCL12 
prefers to form CXC-type interactions with CCL5 and CXCL4, whereas CCL2, CCL17 and 
CXCL4 favor formation of CC-type hetero-dimers with CCL5 (Table S3). 
To exploit our structural models for the design of peptide-based inhibitors, we next 
generated three CCL5-derived peptides (CKEY, CAN, VREY), which form part of the 
heterodimer interfaces with CXCL4, CCL17, and CXCL12, respectively (Table S4). 
Modeled CCL5-CCL17 (CC-type) and CCL5-CXCL12 (CXC-type) heterodimers are 
illustrated in Fig. S7A,B. Cyclic CKEY (containing N-loop and β-sheet 2, residues K25-
R44 [7]) partially reversed CXCL4-induced changes in Δδ and broadening of 15N-
CCL5E66S monomer (but not homodimer) resonances (Fig. S7C). Cyclic CAN comprising 
CCL5 β-sheet 3 (residues K33-N52) partially reversed CCL17-induced changes in Δδ 
and broadening of 15N-CCL5E66S monomer resonances (Fig. S7D). Perturbations at their 
binding interfaces reflect a specific disruption of both CC-type heterodimers (Fig. 
S7C,D). Linear VREY (α-helix residues E54-S68) mimicked heterodimer interactions of 
CCL5 with 15N-CXCL12, as similar resonances at the dimer interface were chemically 
shifted (data not shown). Owing to poor solubility of VREY at pH7 and to improve 
conformational stability [24], we generated a 4-helix bundle version of VREY (TASP-
VREY or [VREY]4, Fig. S8A). Spectral changes in Δδ and a structural perturbation plot 
(Fig. S8B-D) indicated that [VREY]4 interacts with 15N-CXCL12 and can attenuate its 
homo- or heterodimer state, as evident by relevant shifts at the interface (Fig. S8E). 
We validated these findings using SPR where CKEY inhibited the interaction of CCL5 
with CXCL4, but not that with CCL17 or CXCL12; this effect was abrogated in the 
variant CKEYRE by substitutions at key residues R44/E26 crucial for heterodimerization 
(Table S5). Conversely, CAN inhibited the interaction of CCL5 with CCL17 but not that 
with CXCL4 or CXCL12, whereas the N-terminal peptide CCL51-33 blocked both CC-type 
interactions of CCL5 with CXCL4 or CCL17 (Table S5). Finally, [VREY]4 competed with 
CCL5 for binding to CXCL12, but not for that to CCL17 or CXCL4 (Table S5). These data 
evince that chemokine heterodimers can be specifically disrupted by small peptides. 
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Figure 2: Characterization of chemokine interactions by NMR spectroscopy a–f: 1H-15N 
Heteronuclear single quantum coherence (HSQC) spectra were acquired with 128 scans per 
transient and sweep widths of 16 ppm in the 1H (2k points) dimension and 22 ppm in the 15N 
(200 points) dimension. Expansions are shown for 15N-CCL5E66S, either alone (red) or in the 
presence of unlabeled CXCL4 (blue) (a) or unlabeled CCL17 (blue) (b); the molar ratios of 
CCL17:CCL5E66S (1H 850 MHz) and CXCL4:CCL5E66S (1H 700 MHz) were 33:1 (20 µM CCL5E66S) and 
20:1 (30 µM CCL5E66S), respectively. Labels indicate monomers (m), dimers (d), and 15N bleed-
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through from CCL17 (x). The solution contained 25 mM Na-acetate-d3 buffer at pH 4.5 and 37°C. 
The changes in intensity and chemical shift (Δδ) for the 15N-CCL5E66S monomer resonances 
upon binding to CXCL4 (c,e) and CCL17 (d,f) versus those of CCL5E66S are shown. Fractional 
changes in intensity (ΔIntensity) were calculated as described in the methods section (48). g,h: 
Primary CCL5E66S residues binding CXCL4 (g) and CCL17 (h) heterodimer subunits are indicated, 
based on the CCL5 homodimer structure (pdb 1U4L). The broadest resonances within a single 
subunit are in red (> 2 SD above average), orange (between 2 SD and 1 SD), and blue (below 1 
SD). Full view HSQC spectra are displayed in Figure S3. 
Differential function and disruption of heterodimers 
To assess functional effects of chemokine heterodimers, we studied chemotaxis of 
activated T cells, which display a large chemokine-receptor repertoire and 
differentially respond to various chemokines (Fig. S9). Whereas CCL5 plus CCL17 or 
CXCL4 (CC-type), but not the interaction-deficient CXCL4L1 variant, acted 
synergistically to enhance chemotaxis (Fig. 3A-D, Fig. S10A-C), combination with CCL5, 
CXCL4 or CXCL4L1 (CXC-type) inhibited CXCL12-induced chemotaxis (Fig. S10D-F). 
Consistent with a lack of specific interactions, CCL5 plus CCL3 or CXCL10 resulted in 
functionally neutral, i.e. neither synergistic nor inhibitory, effects (Fig. S10G,H). 
Furthermore, combinations preferentially forming CC-type heterodimers (CCL5 plus 
CXCL4, CCL2 or CCL17) acted synergistically to increase monocyte and/or T-cell arrest 
(Fig. 3E,F, Fig. S11A). By contrast, combinations forming CXC-type heterodimers such 
as CXCL4 plus CXCL8 or CCL5 plus CXCL12 exerted inhibitory or less than additive 
effects (Fig. S11B,C). Overall, different types of heterodimeric interactions can have 
opposite functional consequences; namely, CC-type heterodimers are synergistic and 
CXC-type heterodimers are inhibitory. 
In the chemotactic dose-response curve, a left-shift indicated that CCL5 increased the 
potency of CCL17 (Fig. 3A), indicative of increased affinity or receptor 
heteromerization. Synergistic effects of CCL5-CCL17 involved both the CCL17 receptor 
(CCR4) and CCL5 receptors (CCR1, CCR5), as shown by inhibition with the CCR4 
antagonist C021 and the CCL5 receptor antagonist Met-RANTES (Fig. S11D). By 
contrast, CXCL4 increased the efficacy of CCL5 over the entire dose range (Fig. 3B). 
This effect was blocked by Met-RANTES but not by an antibody to the low-affinity 
CXCL4 receptor CXCR3 (Fig. S11E). These data imply that different modes of synergy 
(affecting potency or efficacy) occur through distinct mechanisms. 
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Figure 3: Differential function and specific inhibition of chemokine combinations. (a-d) 
Transwell-filter chemotaxis assays were performed using IL-2- and CD3/C28-activated human T 
cells. The chemotactic index was calculated as the ratio of chemokine-induced versus 
unstimulated migration, as determined by counting cells in the bottom chamber. Combinations 
of CCL5 (1 nM) plus CCL17 at indicated concentrations (a), CXCL4 (4 nM) plus CCL5 at indicated 
concentrations (b) (n=6-12 independent experiments), CCL5 or CCL5MT7 (both 1 nM) plus CCL17 
(0.1 nM) (c) and CCL5 plus CXCL4 (both 4 nM) (d) were added to the bottom chamber. The 
CCL5-peptides CCL51-33 (N-terminal), CAN (CCL5-CCL17 interface), and CKEY (CCL5-CXCL4 
interface) were added at 10-fold molar excess. (e-k) Isolated human blood monocytes were 
perfused over IL-1β-activated human aortic endothelial cells (HAoECs) pre-incubated with 
chemokines and the number of adherent cells per high-power field (HPF) was counted. HAoECs 
were incubated with CCL5 and/or CXCL4 (40 nM each) (e,g), CCL5 and/or CCL2 (4 nM each) (f,h). 
Dashed lines indicate a virtually calculated additive effect (e,f). Monocytes were pre-incubated 
with the CCL5 receptor antagonist Met-RANTES (Met-R, 40 nM), and the peptides CCL51-33, CKEY, 
or CAN (40 nM each) were combined with CCL5 plus CXCL4, (g) or CCL5 plus CCL2 (h) for pre-
incubation with HAoECs. (i) Energy-minimized structure model depicting the CC-type interaction 
of CCL5 (grey) and CXCL4 (blue) trapped via a covalent oxime linkage (magenta), resulting in an 
Obligate Platelet Factor 4-RANTES heterodimer (OPRAH). HAoECs were pre-incubated with 
indicated concentrations of CCL5 plus CXCL4 fixed at 4 nM (CCL5+CXCL4f), indicated 
concentrations of CXCL4 plus CCL5 fixed at 4 nM (CXCL4+CCL5f) or indicated concentrations of 
OPRAH or nOPRAH (N-terminally tethered OPRAH) (j). HAoECS were pre-incubated with CCL5 
plus CXCL4 or OPRAH (4 nM each) with or without CKEY (40 nM) (k). Data represent mean±SEM 
from the indicated number of independent experiments. *p<0.05, **p<0.01, ***p<0.001 versus 
chemokine combinations (cyan), as analyzed by one-way ANOVA (c,e,f) or Kruskal-Wallis-test 
(d,g,h,k). 
Notably, monomeric CCL5MT7 neither formed heterodimers, nor did it support 
functional synergy with CCL17 or CXCL4; whereas the N-terminal peptide CCL51-33 
blocked synergistic effects of CCL5 with CXCL4, CCL17 or CCL2, indicating that N-
terminal motifs are required for CC-type heterodimer formation and activity (Fig. 
3C,D,G,H). Consistent with SPR results (Table S5), CKEY (but not CKEYRE) specifically 
inhibited CCL5-CXCL4 synergy, whereas CAN specifically inhibited CCL5-CCL17 (Fig. 
3C,D,G,H, Fig. S11F). Thus, peptide-targeting of heterodimer interfaces encompassing 
β-strands 2 or 3 with adjacent loops confers specificity for functional inhibition. 
Mimicking effects of CCL5, [VREY]4 (but not the other peptides) inhibited CXCL12 
activity in chemotaxis and arrest (Fig. S11C,H, data not shown). Along with the NMR 
data, this indicates that CCL5 and [VREY]4 induce structural changes in the CXCL12 
dimer, thereby inhibiting CXCL12 activity. 
Based on our modeling, we generated a covalently-linked CC-type CXCL4-CCL5 
heterodimer termed OPRAH (obligate PF4–RANTES heterodimer, Fig.3I) by introducing 
an oxime linker between N-terminal residues of CCL5 (T7) and CXCL4 (L8). The efficacy 
and potency of OPRAH in triggering monocyte arrest were greater than for CCL5 alone 
and for synergistic effects of CCL5 and CXCL4 combined at concentrations that favor 
heterodimer formation (Fig. 3J). CKEY did not inhibit OPRAH-mediated effects (Fig. 3K). 
By contrast, OPRAH with N-termini tethered at the first residues (nOPRAH) failed to 
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enhance function (Fig. 3J), indicating the importance of freely available N-termini. An 
obligate CCL5-CCL17 heterodimer induced T-cell arrest with higher potency and 
efficacy than a combination of CCL17 and CCL5 (Fig. S11I). These data establish that 
heterodimers are responsible for the synergistic effects observed. 
To address underlying mechanisms for synergy, we used an in situ proximity ligation 
assay [25] reporting protein interactions that detect the presence of CCL5-CCL17 
heterodimers formed on cytokine-stimulated endothelial cells after incubation with 
both chemokines (Fig. S12). This approach also allowed detection of endogenous 
heterodimers in mouse lymph nodes (Fig. S12). In dendritic cells, which express both 
CCR4 and CCR5, CCL5-CCL17 heterodimers assembled on the cell surface when adding 
both chemokines, whereas CCR5-CCR4 complexes were constitutively present (Fig. 
4A). The increase in CCL5-CCL17 heterodimers was inhibited by CAN (Fig. 4B), 
revealing that heterodimers can be disrupted by peptides in a cellular context. 
Notably, the number of CCR5-CCR4 complexes and ligand-receptor cross-interactions 
were markedly increased by combining CCL5 and CCL17 but not by either alone (Fig. 
4C, Fig. S13A-D). This effect was impaired by CAN, thus being mediated by CCL5-CCL17 
heterodimers, and disrupted by CCR5-derived peptides spanning transmembrane 1 
and 4 motifs (Fig. 4C), as observed for CCR5 homodimers [26]. Peptide-based 
disruption of CCL5-CCL17 or CCR5-CCR4 impeded synergy in T-cell chemotaxis (Fig. 4D, 
Fig. S13E), substantiating a role of ligand-induced receptor heteromer complexes. 
Binding competition assays further revealed that the affinity of CCL17 for CCR4 was 
higher when adding CCL5 to promote heterodimer formation (Fig. 4E). 
To identify mechanisms underlying CXCL4-mediated synergy, we used the GAG 
binding-impaired mutant CXCL4R>Q, which forms heterodimers with CCL5 (Table S2). 
This mutant did not enhance CCL5-induced monocyte arrest, suggesting that GAG 
binding through CXCL4 may improve presentation of CCL5 to its arrest-triggering 
receptors (Fig. 4F). Indeed, CXCL4 but not CXCL4R>Q increased surface binding of CCL5 
to monocytes, indicating that this was mediated by GAG binding via CXCL4 (Fig. 4G). 
As a consequence, CXCL4 but not CXCL4R>Q prevented CCR1 internalization by CCL5 
(Fig. 4H), without altering the affinity of CCL5 for CCR1 or CCR5 (Fig. S13F,G). Thus, 
CCL5-CXCL4 heterodimers limit rapid internalization of CCR1 from the cell surface, 
where it is retained for active signaling. 
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Figure 4: Mechanisms for synergistic effects of chemokine heterodimers. (a-c) Interactions 
between CCL5, CCL17, CCR4, and CCR5 were detected on the surface of adherent dendritic cells 
(DCs) using a proximity-ligation assay (Duolink®) after cells were incubated with CCL5, CCL17, or 
both (6 nM each) in the presence/absence of CAN (60 nM) or transmembrane (TM) 1+4 CCR5 
peptides (50 µg/ml) known to inhibit CCR5 dimerization (26). Representative images depict the 
presence of CCL5-CCL17 and CCR4-CCR5 heteromers (red dots) on the DC surface (a). Proximity 
ligation signals generated by the interactions of CCL5-CCL17 (b) and CCL5-CCR4 (c) were 
quantified relative to CCL5 alone (control). (d) Transwell-filter chemotaxis assays were 
performed using CD3/CD28-activated primary mouse T cells. Chemotactic index was calculated 
as the ratio of chemokine-induced versus unstimulated migration, as determined by counting 
cells in the bottom chamber. Migration towards CCL5 and/or CCL17 (6 nM each) in the bottom 
chamber was analyzed in the presence/absence of CAN (60 nM) or TM1+4 peptides (50 µg/ml). 
Dashed lines indicate a virtually calculated additive effect (b-d). (e) Binding competition assay; 
CCL17-Alexa647 (2.5 nM) bound to CCR4-expressing HEK transfectants was displaced by 
unlabeled CCL17 in presence or absence of CCL5 (1 nM) (n=6-9 independent experiments). (f) 
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Isolated human monocytes were perfused over IL-1β-HAoECs pre-incubated with CCL5 and 
CXCL4 or the GAG binding-deficient mutant CXCL4R>Q (4 nM each), and the number of adherent 
cells per high power field (HPF) was counted. (g) Deposition of exogenous CCL5, either alone or 
in combination with CXCL4 or CXCL4R>Q (100 nM each) on the surface of primary human 
monocytes was detected by flow cytometry and given as specific mean fluorescence intensity 
(MFI). (h) CCR1 surface expression on human monocytes was detected by flow cytometry after 
treatment with CCL5 (4 nM), either alone or in combination with CXCL4 or CXCL4R>Q (each at 
40 nM). Data represent mean±SEM from the indicated number of independent experiments. 
*p<0.05 versus chemokine combinations (cyan), as analyzed by one-way ANOVA (b), Mann-
Whitney-test (c,f,g,h) or unpaired t-test (e). 
Specific targeting of heterodimers in inflammatory disease models 
To confirm the role of heterodimer formation in vivo, we first used the short-term 
model of LPS-induced acute lung injury (ALI), which relies on platelet chemokines for 
neutrophil recruitment. [11] Treatment with CKEY (but not with CKEYRE) dose-
dependently reduced infiltration in the lung, as evidenced by lower intravascular, 
interstitial, bronchoalveolar and total neutrophil counts (Fig. 5A, FIG. S14A-C). 
Conversely, reconstitution of mice carrying Ccl5-/-Cxcl4-/- bone marrow (deficient in 
both heterodimer components) with OPRAH but not CCL5 exacerbated pulmonary 
infiltration, as reflected in higher intravascular neutrophil numbers and a trend 
towards higher total counts (Fig. 5B, FIG. S14D). 
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Figure 5: Inflammatory effects of CCL5-CXCL4 in vivo require heterodimer formation. (a,b) 
Acute lung injury (ALI) in C57/Bl6 mice was induced by LPS inhalation. Intravascular neutrophil 
accumulation was detected by intravenous (i.v.) injection of a FITC-GR1 antibody before lung 
explantation. (a) Mice were injected intraperitoneally (i.p.) with CKEY at a low-dose (LD, 1 
mg/kg) or a high-dose (HD, 10 mg/kg), or with CKEYRE at a HD before LPS challenge. (b) Ccl5-/-
Cxcl4-/- bone marrow-chimeric mice were i.v. injected with CCL5 (150 µg/kg), OPRAH (300 
µg/kg), or vehicle (ctrl) before LPS challenge. (c-e) Atherosclerosis was analyzed in wild-type 
Cxcl4WT/WT mice, homozygous Cxcl4L1/L1 mice with a Cxcl4 knock-out and a knock-in of a mouse 
variant of human CXCL4L1, heterozygous Cxcl4WT/L1 mice, and CXCL4-deficient Cxcl4-/- mice on 
an Apoe-/- background after 12 weeks on a high-fat diet (HFD). Representative images of the 
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aorta stained with oil-red-O are shown (c). The area of the aorta showing oil-red-O-positive 
lesions (d) and the area of Mac2-positive cells in the aortic arch (e) were quantified and 
expressed as percentage of the total area. (f) The lesion area in the aorta of Apoe-/- mice 
expressing a human CXCL4L1 transgene (tg-L1) in addition to CXCL4 was analyzed after 12 
weeks of HFD. (g, h) Cxcl4wt/L1 and Ccl5-/-Cxcl4-/- mice on an Apoe/ background were treated (i.p.) 
with OPRAH (10 µg, twice a week) while on a HFD for 6 weeks. The oil-red-O-positive lesion 
area (g) and the Mac2-positive area in the aortic arch (h) were quantified and expressed as 
percentage of the total area. Data represent mean±SEM from the indicated number of mice. 
*p<0.05, **p<0.01, as analyzed by Kruskal-Wallis-test (a, b, d, e) or Mann-Whitney-test (g, h). 
To unequivocally prove biological relevance of heterodimer interactions, we 
generated Cxcl4L1/L1mice with a CXCL4 knock-out and knock-in of the CXCL4L1 variant 
(which neither exists in mice nor forms heterodimers with CCL5), to study diet-
induced atherosclerosis on an Apoe-/- background (Fig. S15). Notably, Cxcl4L1/L1 mice 
showed a marked reduction of atherosclerotic lesion size in the aorta and the aortic 
arch, comparable to that seen in CXCL4-deficient mice (Fig. 5C,D, FIG. S16A,B). 
Heterozygous Cxcl4L1/+ mice displayed an intermediate gene-dosing effect. Lesion size 
in the aortic root was attenuated in Cxcl4-/- mice but not Cxcl4L1/L1 mice (Fig. S16C,D), 
implying regional differences unrelated to heterodimerization. Except for lower 
macrophage content in Cxcl4L1/L1 mice, plaque composition (i.e. phenotype 
classification, smooth muscle cells, necrotic core, and T-cell content), lipid profiles, 
body weight, and blood cell counts did not differ among all groups (Fig. 5E, Fig. S17, 
Table S6). Platelet-specific expression of a CXCL4L1 transgene in Apoe-/- mice did not 
alter lesion size, indicating that its effects are not dominant-negative but due to a lack 
of interaction (Fig. 5F). Treatment with mouse OPRAH restored lesion formation in the 
aorta including the arch, increased macrophage content in aortic root plaques, but did 
not change other parameters in Ccl5-/-Cxcl4-/-Apoe-/- mice and heterozygous 
Cxcl4L1/wtApoe-/- mice expressing non-interacting CXCL4L1 (Fig. 5G,H, Fig. S18, Table 
S7). 
The atheroprotective homeostasis of regulatory T cells (Tregs) is suppressed by DC-
derived CCL17, a phenotype not replicated in Ccr4-deficient mice [3, 27, 28], possibly 
implicating other chemokine receptors or heterodimers. Indeed, we detected CCL5-
CCL17 heteromers in aortic root lesions of Apoe-/- mice (Fig. 6A), in the intima and 
adventitia of human coronary arteries with advanced atherosclerosis but not in 
undiseased vessels/segments (Fig. 6B). Notably, combined interference with 
CCR4/CCR5 using the CCR5 antagonist DAPTA in CCR4-deficient Apoe-/- mice increased 
Treg numbers in the para-aortic lymph nodes, and marginally in peripheral blood (Fig. 
6C,D). Similar results were obtained by treatment with CAN (for 6 weeks), which also 
reduced lesion size in the aortic root (Fig. 6C-F), thus phenocopying effects of CCL17 
deficiency. [27] These findings may be due to limiting CCL17-mediated recruitment of 
naïve CD3+ T cells, in which Treg conversion or maintenance is suppressed via 
subsequent CCL17-dependent pathways involving other receptors. 
Mapping the chemokine interactome 
 
111 
 
6 
To exploit inhibitory interactions exemplified by the CXC-type heterodimer CCL5-
CXCL12, we tested whether [VREY]4 inhibits CXCL12-depedent platelet aggregation, as 
relevant to atherothrombosis. Notably, CXCL12 facilitated platelet aggregation, as 
tamoxifen-induced deletion of CXCL12 in blood of CreERT2Cxcl12fl/flApoe-/- showed 
reduced multi-parameter platelet activity and thrombus scores in vitro (Fig. 6G,H). 
Treating Apoe-/- mice with [VREY]4 afforded a comparable inhibition of platelet activity 
(Fig. 6G,H). Likewise, [VREY]4 inhibited CXCL12-induced human platelet aggregation 
and CXCR4 activation in HEK transfectants, likely due to conformational effects on 
CXCL12 (Fig. 6I,J). Thus, CXCL12-targeting peptides may be useful as novel anti-
platelet therapeutics. 
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Figure 6: Specific peptides Inhibit atherogenic CCL5-CCL17 and CXCL12-driven platelet activity. 
(a,b) Interactions of CCL5-CCL17 (red dots indicated by arrows in representative image, left) 
were detected in the adventitia (adv) and intima/media (I/M) of human coronary arteries with 
(diseased) or without (healthy) atherosclerotic lesions (a, quantification, right) or in aortic root 
sections from Apoe/ mice fed a high-fat diet (HFD) for 12 weeks (b) using a proximity-ligation 
assay (Duolink®). (c,d) Wild-type or Ccl4-/- bone marrow chimeric Apoe/ mice were injected 
intraperitoneally (i.p.) with the CCR5 inhibitor DAPTA or CAN (each at 1 mg/kg 3-times a week) 
for 2 weeks and the number of Foxp3+CD4+ Tregs in peripheral blood (C, relative to CD4+ T cells) 
and in para-aortic lymph nodes (d, per lymph node/ln) was determined by flow cytometry. (e,f) 
Apoe/ mice were injected (i.p.) with CAN (1 mg/kg 3-times per week) while on a HFD for 2 
weeks. Oil-red-O-positive lesion areas in the aortic root were quantified and expressed as 
percentage of the total area (e). Representative images of aortic root stained with oil-red-O are 
shown (f). (g,h) Blood from Apoe/ mice treated with or without the CCL5-peptide [VREY]4 or 
from CreERT2Cxcl12fl/flApoe/ following tamoxifen-induced deletion of CXCL12 was perfused over 
collagen for 4 min at 1000s-1. (g) Multi-parameter assessment of thrombus formation using 
distinct surfaces (a: vWF-BP+Laminin. b: vWF-BP+Laminin+Rhodocytin, c: collagen I) was 
performed and depicted in a heatmap (59). Parameters were assessed by bright-field and 
subsequent tri-color fluorescence microscopy: 1 Morphological score, 2 Platelet deposition 
(surface area coverage, SAC), 3 Thrombus contraction score, 4 Multilayer thrombus score, 5 
Multilayered thrombus (%SAC), 6/7 Phosphatidylserine exposure (%SAC or platelet count/field), 
8 CD62P expression (%SAC), 9 αIIbβ3 activation (%SAC). Heatmaps for all microspots 
(normalized per parameter) and genotype/perturbation were colored as increased (red) or 
decreased (green) based on statistical significance versus controls. The multilayered thrombus 
score is exemplified in (h). (i) Platelet aggregation in human blood treated with combinations of 
CXCL12 (100 nM), [VREY]4 (500 nM) and CCL5 (1 µM) was measured by impedance using a 
Multiplate® analyzer. (j) cAMP signaling was analyzed in Glosensor- and CXCR4-transfected HEK 
cells 15 min after stimulation with CXCL12 (40 nM) in the presence/absence of [VREY]4 (100 
nM). Shown is the decrease of the specific Rluc signal over baseline. Data represent mean±SEM 
from the indicated number of independent experiments. *p<0.05, **p<0.01, as analyzed by 
Mann-Whitney-test (b,c), unpaired t-test (d,e,j) or Kruskal-Wallis-test (h,i). 
Discussion 
The comprehensive map of all heteromeric chemokine interactions obtained by 
immuno-ligand blotting and SPR contributes to a completion of the binary human 
protein interactome network. [29, 30] We found that inflammatory and non-
homeostatic chemokines, e.g. platelet-derived atherogenic CCL5 and CXCL4, favor 
interactions, whereas homeostatic chemokines are generally less interactive. This may 
correspond to the need to amplify, fine-tune, and resolve chemokine activity at 
inflammatory sites through heteromeric interactions, whereas the stand-alone 
functions of non-interacting chemokines appear sufficient for organogenesis, immune 
architecture and surveillance, or anti-microbial activity. For example, CXCL4-deficient 
mice are normal in the absence of challenge (with a largely unaltered immuno-
phenotype), whereas CXCL12 deficiency entails embryonic lethality and CXCL13 
deficiency shows its essential role for lymph node development and natural immunity. 
[31, 32] 
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Structure-function analysis revealed an interesting dichotomous pattern wherein CC-
type hetero-dimers promote synergy and CXC-type heterodimers cause inhibition. Use 
of obligate heterodimers such as OPRAH provided conclusive proof that CC-type 
heterodimers mediate functional synergy. Functional inhibition with a CCL5-derived 
N-terminal peptide supports a more general role of the N-terminus in CC-type 
heterodimer formation and synergy. The spacing and shapes adopted by CC-type 
homodimers can vary with minimal changes in N-terminal sequence.[16] Functional 
synergy indeed involved flexible N-termini, as illustrated by a tethered version of the 
obligate heterodimer OPRAH, and could be ascribed to addressing receptor 
heteromers (increasing potency of CCL5-CCL17) or to auxiliary GAG binding and 
impaired receptor internalization (increasing efficacy of CCL5-CXCL4). 
Chemokine-receptor activation follows a two-site binding mechanism involving 
interactions of the chemokine N-loop/core with the receptor N-terminus (site I) and of 
the chemokine N-terminus with extracellular/transmembrane residues (site II). The 
modeled structure for binding of the atypical CC chemokine vMIP-II to CXCR4 appears 
to support findings that CC chemokine homodimers cannot bind or activate receptors, 
as the dimerization interface largely coincides with an intermediate recognition site 
[33-35]; however, this may not extend to all chemokine-receptor interactions, as N-
terminal and core structures in a CC-type heterodimer, e.g. OPRAH, may be differently 
presented to receptors. Instead, binding may involve receptor complexes enabling 
synergy. Concomitant peptide-based disruption of CCL5-CCL17 and CCR4-CCR5 
formation/function supported that CC-type heterodimers can prompt formation of 
corresponding receptor complexes, requiring CCR5 transmembrane regions. 
The conserved GP motif in CXCL8 can couple sites I and II, dictating both substrates 
and cross-talk between sites to control receptor activity. [36] Conformational coupling 
was corroborated by a CC mutant of CXCL8 that retained binding via N-loop-site I 
interactions for CXCR1 activation. [37] Moreover, a disulfide-trapped CXCL8 dimer had 
reduced affinity for CXCR1 due to perturbed binding at N-loop residues, giving rise to 
a model where binding of a CXC-type dimer triggers conformational changes leading 
to release and high-affinity receptor binding of a monomer [38]. Whether this applies 
to CC-type heterodimers is unclear; however, findings with OPRAH indicate that 
dissociation is not essential for function. Conversely, some receptors, e.g. CXCR2, are 
permissive for dimer binding [39]. Macrophage migration-inhibitory factor 
(resembling a CXCL8 dimer) features site I and II-binding to CXCR2 without typical N-
termini. [40, 41] Thus, N-termini may not need to fit fully into the site II-pocket. 
The increased efficacy of CCL5-bearing heterodimers may be explained by several 
aspects. CCR5 antagonists inhibited both CCL5-CXCL4- and CCL5-CCL17-induced arrest. 
Thus, CC-type heterodimers can modulate CCR5 functionality, converting it into an 
arrest receptor such as CCR1 (requiring CCL5 homo-oligomers and extracellular loop 3 
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to sense heteromers). [42-44] As revealed by GAG binding-impaired CXCL4, synergy 
with CCL5 relies on increased cell surface presentation, impeding CCR1 internalization 
to sustain its signaling activity. The structural basis for CCL5 oligomerization and GAG 
binding has been elaborated. [45] Polymerization creates distinctive grooves that 
increase GAG avidity; besides the BBXB motif, CCL5 uses another positively charged 
motif, KKWVR, which supports CCR5 function. [42] Models further predict that CXCL4 
can assemble hetero-oligomers with CCL5 featuring an altered surface charge 
distribution that facilitates GAG binding. [45] 
Regarding inhibitory effects of CXC-type heterodimers, it is remarkable that a 
constitutively homo-dimeric CXCL12 variant bridged by N-terminal CXCR4 peptides 
induces calcium signaling but inhibits chemotaxis, whereas a monomeric variant 
remains chemotactic, indicating that dimerization limits monomer-induced 
chemotaxis [46]. Related mechanisms may apply to CXC-type heterodimers, whereby 
functional activity is impeded by more stable β-sheet interactions attenuating 
monomer release. Alternatively, CXC-type heterodimeric interactions may cause 
conformational alterations, e.g. by aligning the α-helices. [12] Consistent with spectral 
changes, the α-helical peptide [VREY]4 inhibited CXCL12 function, mimicking effects of 
full-length CCL5. 
Several lines of evidence support the functional relevance of heteromer formation in 
disease models. First, obligate CC-type heterodimers show high efficacy/potency in 
recruitment assays, e.g. OPRAH exacerbating LPS-induced ALI as well as chronic 
macrophage-rich atherosclerosis. Second, knocking-in of CXCL4L1 (not interacting 
with CCL5) was similarly effective in protecting from atherosclerosis as CXCL4 
deficiency, indicating that heterodimer formation with CCL5 was essential for 
atherogenic activity. Finally, the inhibition of Treg-dependent atherosclerosis by CAN 
extends findings that CKEY limits atherosclerosis and ALI [7, 11] by interfering with 
residues crucial for heterodimerization. 
Notably, structural information regarding the type of interaction and precise location 
of the interface can be exploited to design peptide inhibitors selectively blocking CC-
type heterodimers (exemplified by CKEY targeting CCL5-CXCL4 and CAN targeting 
CCL5-CCL17). By contrast, [VREY]4 mimics inhibitory effects of CXC-type interactions 
between CCL5 and CXCL12 and could thereby serve to attenuate CXCL12-mediated 
platelet aggregation. These paradigms illustrate strategies for specific targeting of 
heterodimer-mediated functions in the chemokine interactome, and may allow for 
multivalent interference with a diversity of responses in a disease-related chemokine 
microenvironment. The TASP-scaffolding used for [VREY]4 may also be applicable to 
bundle different peptides in a poly-antagonistic approach. Alternatively, sequence-
hybridization could be used to generate mono-molecular poly-antagonists, as 
described for peptide tri-agonists. [47] Our data enable development of peptide 
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therapeutics based on endogenous sequences that are selective in modulating 
heteromeric but not primary receptor interactions of chemokines and would thus lack 
many adverse effects associated with direct receptor-ligand antagonism. 
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Supporting Information 
Ligand blots 
Chemokines (1 µg) were spotted on a nitrocellulose membrane which was immersed 
overnight with the soluble chemokine (1-5 µg/ml) and reacted with biotinylated 
antibodies and streptavidin-conjugated HRP and ECL substrate (Thermo Fisher 
Scientific) essentially as described [48]. The chemiluminescence signal was digitally 
recorded and analyzed by the luminescence image analyzer LAS 3000 and Multigauge 
software (Fuji Photo Film, Düsseldorf, Germany). 
Surface plasmon resonance (SPR) 
SPR was performed on a BIAcore X100 instrument (GE Healthcare Europe GmbH, 
Freiburg, Germany) using neutravidin-modified C1 sensor chips [48]. Biotinylated 
chemokines were immobilized on flow cells to 0.3-1.3x103 response units (RU). 
Screening of chemokine binding was performed at 100 nM in HBS-EP+ buffer at 30 
µl/min after 20 s. Apparent affinities were calculated from on and off rates after 
fitting of the curves obtained from increasing analyte concentrations using a 1:1 
Langmuir interaction model (BIAevaluation software, GE Healthcare). To assess the 
inhibitory capacity of peptides, chemokines were incubated with increasing peptide 
concentrations and binding of chemokine (20 nM) was recorded and calculated as 
percentage inhibition. Half maximal inhibitory concentrations (IC50) were determined 
using a 4-parameter logistic nonlinear regression (GraphPad V5.0). 
Nuclear magnetic resonance (NMR) spectroscopy 
NMR samples were prepared in Wilmad 3 mm NMR tubes (160 µl). Most experimental 
details and solutions conditions of samples are described in the figure legends. 
Typically, chemokine samples were buffer exchanged and concentrated into 25 mM 
Na-acetate-d3 (pH 4.5) containing 0.1 mM EDTA and 0.2 mM sodium azide, through 4 
to 5 ultracentrifugation steps over Amicon (Merck Millipore, Darmstadt, Germany) 
Ultra-4 3 kDa filter devices. Concentration of the final derived stock solutions of 
chemokines was determined based on UV absorbance measured on a NanoDrop 2000 
spectrophotometer (Thermo Scientific, Wilmington, USA). NMR samples of mixtures 
of chemokines at defined molar ratios were prepared from these chemokine stock 
solutions. 5% (v/v) D2O was later added to NMR samples for field locking, together 
with a trace of DSS (4,4-dimethyl-4-silapentane-1-sulfonic acid) as internal chemical 
shift standard. NMR spectra (15N-1H HSQC with flip-back pulse, DIPSI, and NOESY) 
were recorded at 37oC on Bruker (Rheinstetten, Germany) Avance III HD 700 and 
Avance III 850 MHz spectrometers, both equipped with a cryogenically cooled TCI 
probe. Spectra were processed and analyzed using Bruker Topspin 3.2 and Sparky 
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3.114 software (T.D. Goddard and D.G. Kneller, SPARKY 3, University of California, San 
Francisco). 
Resonance assignments of the CCL5E66S and CXCL12 chemokines were carried out by 
2D NOESY and 3D-edited NOESY spectra. Because CCL5E66S show homo-dimers and 
monomers that are in slow exchange on the NMR chemical shift time scale, 
resonances for both dimers and monomers are observed in HSQC spectra and are well 
resolved, allowing assessment of effects on both states [21]. Chemical shift 
differences (δΔ) induced upon binding were calculated as [(Δ1H)2]1/2 + [(0.25Δ15N)2]1/2. 
(in 1H ppm. ΔIntensity was calculated as (1 – Inti/Into), where Inti is the resonance 
intensity of CCL5E66S or CXCL12 resonances in the presence of the other chemokine, 
and Into is the intensity of CCL5
E66S or CXCL12 resonances in the absence of the other 
chemokine. 
Cells and cell culture 
Human CD4 T cells were isolated from whole blood of healthy volunteers after 
separating peripheral blood mononuclear cells (PBMCs) with Biocoll (Biochrom, Merck 
Millipore, Berlin, Germany) using Dynabeads Untouched Human CD4 T Cells kit, 
stimulated with Dynabeads Human T-Activator CD3/CD28 (both Thermo Fisher 
Scientific, Waltham, USA) for 3 days and expanded in the presence of Dynabeads with 
hIL-2 (30 U/mL) for another 3 days. Human monocytes were isolated from PBMCs, and 
purified by negative selection using “Monocyte Isolation Kit II” (Miltenyi Biotec, 
Bergisch Gladbach, Germany). Mouse CD4 T cells were isolated from spleens of mice 
with indicated genotypes using Dynabeads Untouched mouse CD4 Cells Kit and 
activated using Dynabeads Mouse T-Activator, Thermo Fisher Scientific), as above for 
human cells. Mouse dendritic cells were isolated from spleens by positive and 
negative selection using magnetic beads (Pan DC MicroBeads, mouse, Miltenyi Biotec). 
Human aortic endothelial cells (HAoEC) were from PromoCell (Heidelberg, Germany). 
Oligonucleotides were synthesized at MWG-Biotech (Ebersberg, Germany). 
The Flp-In system and Flp-In™ TREx-293 (HEK293) cells were from Invitrogen 
(Karlsruhe, Germany). Plasmids harboring sequences for CCR1, CCR4, CCR5 and CXCR4 
were from Missouri S&T cDNA Resource Center (www.cdna.org). The pGloSensor™-
20F-vector and luciferin-EF were from Promega (Mannheim, Germany). The sequence 
of the luciferase-cAMP binding site fusion protein from the pGloSensor™-20F-vector 
was amplified and ligated into a bicistronic pIRESneo vector (Clontech) to obtain the 
reporter gene plasmid. The pcDNA5/FRT/TO vector (Invitrogen) was used to express 
receptor constructs carrying an N-terminal hemagglutinin-tag or enhanced yellow 
fluorescent protein (eYFP)[49]. HEK293 cells were transfected with the reporter gene 
vector using EcoTransfect (OZBioscience Marseille, France), stable clones were 
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selected as host cell lines for expressing receptor constructs using the Flp-In system 
[49], and re-selected with G418 and hygromycin B. 
Chemokines and peptides 
CCL5 and CXCL12 were recombinantly expressed using codon-optimized genes 
(Genscript, NJ, USA), and pET-24a(+) or -32a(+) vectors, respectively, in E.coli 
BL21(DE3) cells and purified, essentially as described [50]. To generate 15N-labeled 
chemokines, we used Spectra M9 medium (Cambridge Isotope Laboratories, Andover, 
USA). Mass and disulfide bond integrity were examined by UPLC-QTOF mass 
spectroscopy. Biotinylation of chemokines was performed while bound to heparin 
columns. Purified CCL5E26A and the synthesized CCL5MT7 variant were kindly provided 
by Dr. A. Proudfoot [51]. Other chemokines were purchased from Peprotech (Rocky 
Hill, USA) or R&D Systems (Minneapolis, USA). CCL5 and CCL17 C-terminally-
conjugated with AF647 were from ALMAC science (Craigavon, UK). 
The peptides CAN and CKEY were synthetized by Bachem AG (Bubendorf, Switzerland). 
All other peptides (Table S4) were synthesized manually by SPPS on PAM resin or 
thioester (COSR) generating resin using in situ neutralization/HCTU activation for tBoc 
chemistry [52]. Semi-preparative HPLC was performed using Vydac C18 or C4 HPLC 
columns using a Waters Deltaprep system. Peptide analysis was performed on a 
Waters UPLC XEVO-G2QTOF system. The peptide monomer VREY was extended at the 
N-terminus by introducing a glycine spacer to which (Boc-aminooxy) acetic acid (AO) 
was coupled (AO-G-EKKWVREYINSLEMS-COOH). A modified cyclic backbone TASP 
template was used to obtain a parallel 4-helix bundle (H2N-CPKGKGPGKGKG-COSR) 
[24]. TASP-lysines were modified to present a ketone group using 4-acetylbutyric acid 
[52]. TASP was cyclized by native chemical ligation (NCL) [24] and the free cysteine 
was alkylated to prevent dimer formation. Ketone-derivatized TASP and a 2.5-fold 
excess of aminooxy-VREY were reacted to obtain [VREY]4 through oxime linkage. 
The total chemical synthesis of OPRAH (obligate PF4-RANTES heterodimer), nOPRAH 
(n-terminally tethered OPRAH), mOPRAH (mouseOPRAH using the murine orthologs) 
and ORATH (obligate RANTES-TARC heterodimer) comprised the individual synthesis 
of CCL5, CXCL4 or CCL17, which were subsequently folded and coupled by oxime 
chemistry. The individual chemokines were synthesized in three parts that were 
joined by NCL and folded by oxidation [53]. CCL5 N-termini were modified to 
introduce aminooxy moieties for oxime ligation. For both human and mouse CCL51-10, 
Lys(-amino-Alloc) was introduced at position T7 to allow for on-resin aminooxy 
modification. As counterparts in the oxime ligation reactions, ketones (4-acetylbutyric 
acid) were added in the chemokine N-termini by introducing Lys(-amino-Alloc) at 
position L8 of human CXCL4, at position L13 of mouse CXCL4, and at position G7 of 
human CCL17 [54]. The folded N-terminally ketone-derivatized chemokines were 
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reacted with a 2-fold excess of aminooxy-CCL5. The mixture was placed at -20°C for 1 
h to complete the reaction. The covalent heterodimer product was purified using 
HPLC. Detailed information about the synthesis of the heterodimers will be published 
elsewhere (Agten et al., manuscript in preparation). 
Molecular dynamics (MD) simulation and binding free energy calculations 
Chemokine structures were downloaded from the Protein Data Bank (PDB): codes 
1DOK (CCL2), 2L9H (CCL5), 1NR4 (CCL17), 1F9Q (CXCL4), 4UAI (CXCL12). Dimer 
complexes (CC or CXC type) were manually assembled by superimposition onto the 
CC-conformation of CCL5 or the CXC-conformation of CXCL4. The different chemokine 
complexes were subjected to MD simulations as described [55, 56], except applying 
Amber12SB force field and TIP4P-Ew water model. Free MD simulations were 
performed for 100 ns and accelerated molecular dynamics were employed for 
another 30 ns. Snapshots between 100-130 ns were extracted for binding free energy 
calculation using molecular mechanics/generalized Born surface area (MM/GBSA) 
approach and the binding free energies were approximated from enthalpy values as 
described [56]. Default parameters were applied for binding free energy calculation, 
except using generalized Born model 8 to compute the free energy of solvation. 
Transmigration assays 
Transmigration assays were performed using Transwell-96 Permeable Support 
(Corning) with a 5.0 µm (human T cells) and 3.0 µm (mouse T cells) pore size [43]. 
Chemokines were added to the bottom chamber and 105 activated T cells were 
allowed to migrate for 2 h from the top chamber. Receptor antagonists were added to 
the upper chamber, while compounds modulating chemokine interactions were 
added to the bottom chamber at 10x molar excess relative to chemokine. The number 
of cells migrated was analyzed by flow cytometry (FACSCanto II, BD Biosciences, 
Heidelberg, Germany) and FlowJo v.10 software (Tree Star Inc., Ashland, Orgon, USA). 
The chemotactic index was calculated as the ratio of chemokine-stimulated to 
unstimulated migration. 
Arrest assays 
Confluent human aortic endothelial cell (HAoEC) monolayers were activated with IL-
1β for 4 h before incubation with chemokines, synthetic obligate chemokine 
heterodimers and/or peptides for 30 min. Monocytes or T cells (0.7×106/ml) 
pretreated with receptor antagonists (C021, DAPTA, Met-RANTES) were perfused over 
the activated HAoECs in a laminar flow chamber at a shear stress of 1.5 dyn/cm2 for 2 
min. Cells were visualized and recorded by video microscopy (Olympus IX 50, Shinjuku, 
Japan, 20x objective). Firmly adherent leukocytes were counted in 10 high-power 
fields (HPF) per plate. 
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Proximity Ligation Assay 
Proximity ligation was carried out using the Duolink In Situ Red Kit Goat/Rabbit on PFA 
fixated cryo-sections of aortic roots or lymph nodes of Apoe-/- mice, using primary 
polyclonal antibodies to mouse CCL17 (R&D, AF529), mouse CCL5 (Acris, AP20618PU-
N) according to the manufacturer’s instructions. Mouse dendritic cells and SV40-
transformed endothelial cells (SVECs) cultured on collagen-coated cover slips were 
pre-incubated with mouse CCL5, CXCL4 and CCL17 (Biolegend, Fell, Germany) alone or 
incombination with CAN or CCR5-derived transmembrane peptides TM1 and TM4 
known to inhibit CCR5 dimerization[26]. The same kit was used on paraffin sections of 
human coronary arteries using polyclonal antibodies to human CCL5 (AF278-NA, R&D 
Systems) and CCL17 (ab182793, Abcam, Cambridge, UK). The study was under 
approval by the Ethics Committee of the Academic Medical Centre at the University of 
Amsterdam. Anonymous post-mortem coronary artery specimen did not require 
informed consent. 
Flow cytometry 
Whole blood obtained from the retro-orbital plexus of mice was EDTA-buffered and 
subjected to red blood-cell lysis. Lymph nodes and spleens were mechanically 
disrupted and passed through a cell strainer. Leukocytes were counted and analyzed 
by the following antibody cocktail: anti-CD45, anti-CD115, anti-Gr1, anti-CD11b, anti-
CD19 (eBioscience, clone MB19-1) and anti-CD3 (eBioscience, clone 145-2C11). 
Leukocyte subsets were defined using FlowJo software: neutrophils (CD45+CD115-
Gr1high), monocytes (CD45+CD115+), classical monocytes (CD45+CD115+Gr1high), non-
classical monocytes (CD45+CD115+Gr1low) and lymphocytes (CD45+CD3+ and 
CD45+CD19+). Chemokine receptors were analyzed using FITC-anti-Ccr1 (R&D, 
FAB5986F), AF647-anti-Ccr3 (BioLegend, clone TG14/Ccr3), PE-anti-Ccr5 (eBioscience, 
clone HM-CCR5) and PE-anti-Ccr2 (R&D Systems). 
Mice 
All animal experimental procedures were designed and conducted in agreement with 
the German Animal Welfare Legislation and were reviewed and approved by the local 
authorities (Regierung von Oberbayern, Munich, Germany). All mice were housed in 
IVC units and maintained on a 12-h dark/12-h light cycle. B6.129P2-Apoe/J (Apoe-/-) 
and B6.129P2-Ccl5tm1Hso/J (Ccl5-/-) were obtained from The Jackson Laboratory (Bar 
Harbour, USA), C57BL/6J were from Janvier (Le Genest-Saint-Isle, France) and the 
tamoxifen inducible general Cre-deleter C57BL/6-Gt(ROSA)26Sortm9(Cre/ESR1)Arte 
(CreERT2) was from Taconic (TaconicArtemis GmbH, Cologne, Germany). 
Cxcl4L1/L1, Cxcl4tg-L1and Cxcl12-/- mice were generated by laser-assisted (XY-Clone 
Hamilton Thorne) injection of R1/E(129/Sv) cells into 8-cell stage C57Bl/6NCrl 
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embryos. Embryo recipients were Crl:CD1(ICR) mice (Charles River). All manipulations 
were done in the Transgenic Core Facility (TCF) of the MPI-CBG, Dresden. Chimaeras 
were crossed to C57Bl/6NCrl mice and their offspring was screened for germline 
transmission. Details of the targeting constructs used to induce homologous 
recombination and knockin into the Rosa locus are depicted in Fig. S15. 
Bone marrow transplantation 
Apoe-/- mice underwent lethally whole body irradiation (2x5Gy) and were 
reconstituted with donor bone marrow cells from Apoe-/-Ccr4-/- or Apoe-/-Ccl5-/-Cxcl4-/- 
mice, essentially as described [7]. After 4 weeks, animals were injected i.p. with the 
CCR5 antagonist DAPTA (TOCRIS, Bristol, UK) or CAN peptide every second day for 2 
weeks. 
Atherosclerotic lesion formation, quantification and histological analysis 
To induce lesions, 8 week old Apoe-/- mice fed a high-fat diet (HFD, 21% fat, 19.5 % 
casein, 0.15% cholesterol, ssniff, Soest, Germany) for 2 weeks (bone-marrow 
chimeras), 6 weeks (OPRAH injection) or 12 weeks (analysis of Cxcl4-deficient and 
knock-in strains). Mice were anesthetized with ketamine (80 mg/kg) and xylazine (10 
mg/kg) and EDTA-anticoagulated blood was retroorbitally collected. Cell counts were 
determined using an automated hematology analyzer (scil Animal Care, Viernheim, 
Germany). Plasma was used to detect cholesterol and triglyceride levels (CHOD-PAP or 
GPO-PAP kit, Roche, Rotkreuz, Switzerland). After complete bleeding, in situ perfusion 
fixation was performed using 4% buffered formaldehyde (Carl Roth, Karlsruhe, 
Germany) and the heart and entire aorta were excised. The aorta was longitudinally 
opened and stained en face with Oil-Red-O to visualize lipid deposition. The lesion 
area was calculated as percentage of the Oil-Red-O+ stained area normalized to the 
respective aortic area (arch, thoracoabdominal, inner curvature, outer curvature). 
After paraffin-embedding and cutting into 4 µm transverse sections for aortic roots or 
6 µm longitudinal sections for aortic arches, atherosclerotic lesion size was measured 
after Elastica-van Gieson (EVG) staining (Baacklab, Schwerin, Germany). In aortic roots, 
the percentage of lesion area of the aortic valves normalized to the area of the 
internal lumen was determined. In aortic arches, total lesion size was quantified in the 
inner curvature and the three branches. Cellular content was analyzed by 
immunofluorescence staining for macrophages, CD3+ T cells and smooth muscle cells 
(SMCs) using anti-Mac-2 (Cedarlane Labs, Burlington, Canada), anti-CD3 and anti-
αSMA antibodies (Dako; Hamburg, Germany). Nuclei were counterstained with DAPI 
(Vector Laboratories, Burlingame, California, USA). Primary antibodies were visualized 
using DyLight-488, -550 and -650–conjugated secondary antibodies (Abcam, 
Cambridge, UK). Images were recorded with a DM 6000B fluorescence microscope 
(Leica, Solms, Germany), connected to a monochrome digital camera (DFC 365FX) for 
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fluorescent imaging or a DFC425C camera for bright-field microscopy. Mac-2-, CD3- 
and αSMA cells were manually quantified as positive cells per plaque area. Stages of 
atherosclerotic lesions were determined in EVG-stained aortic root sections according 
to the Virmani classification [57]. Necrotic cores were quantified as anuclear crystal-
laden areas of lesions and normalized to the lesion area. 
Acute lung injury 
The acute lung injury (ALI) model was performed as described [11]. ALI was induced in 
8 weeks-old male C57Bl/6mice (Janvier, St Berthevin Cedex, France) or Ccl5-/-CXCL4-/- 
bone marrow chimeric mice by exposure to aerosolized LPS (500 µg/ml) from 
Salmonella enteritidis (Sigma, Munich, Germany) for 30 min. Peptides, chemokines or 
mOPRAH were injected i.v. at indicated doses. Alveolar, interstitial, and intravascular 
neutrophils were analyzed after 4 h. To label intravascular neutrophils, FITC-Ly-6G 
(Gr1) (clone RB6-8L5, eBioscience) was applied by tail vein injection 30 min before 
sacrifice. Broncho-alveolar lavage (BAL) fluid was obtained by repeated injection and 
withdrawal of PBS. The pulmonary vasculature was rinsed with PBS 0.5 mM EDTA. 
Lungs were removed, minced and digested with liberase (Roche Mannheim Germany), 
passed through a cell strainer and neutrophils were analyzed by labeling with anti-
mouse PerCP-Cy5.5-Ly-6G, PE-CD115, APC-Cy7-CD45 antibodies (eBioscience). 
Competitive chemokine receptor-ligand binding 
HEK293 transfectants expressing CCR1, CCR4 or CCR5 were incubated with AF647-
labeled CCL5 or CCL17 (2.5 nM) in presence or absence of unlabeled CCL5 or CCL17 (at 
increasing concentrations) for 1 h at 4°C. After washing, fluorescence intensity was 
measured by flow cytometry (FACSCantoII) and analyzed using FlowJo v.10 software 
(Tree Star Inc., Ashland, Oregon, USA). 
Chemokine binding to monocytes 
Monocytes were incubated with CCL5 in combination with CXCL4 or CXCL4R>Q (each 
100 nM) for 1 h at 4°C. CCL5-binding was reacted with a CCL5-antibody (5 µg/ml, 
Abcam AB9679, Cambridge, UK) and detected with an AF488-conjugated secondary 
antibody (2 µg/ml, Thermo Fisher Scientific). 
Chemokine receptor internalization 
CCR1-, CCR4- or CCR5-expressing HEK transfectants were incubated for 1h at 4°C with 
AF647- labeled CCL5 or CCL17 (2.5 nM) in presence of increasing concentrations of 
unlabeled chemokines. Cells were then washed with cold PBS and fluorescence 
intensity was analyzed by flow cytometry. 
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cAMP signaling 
Levels of cAMP were measured in confluent HEK293 transfectants expressing CXCR4 
after stimulation with CXCL12 using Glosensor technology. After incubation with 
luciferin-EF (2.5 mM) at RT for 2 h, cells were stimulated with CXCL12 in the presence 
or absence of [VREY]4 and luminescence was recorded at indicated time points, and 
after further addition of forskolin (1 µM) and poly-D-lysine. 
Platelet aggregometry and ex vivo thrombus formation 
Human venous blood was collected in hirudin-precoated tubes (Sarstedt, Nürnbrecht, 
Germany). Informed consent was obtained as approved by the Ethics Committee of 
the Faculty of Medicine, LMU Munich. Platelet aggregation in blood was determined 
by multiple electrode aggregometry (MEA) using the Multiplate® device (Roche 
Diagnostics, Mannheim, Germany). Whole blood was diluted with NaCl 1:1 and 
CXCL12, CCL5 or [VREY]4 were added, stirring was started and the increase in electrical 
impedance was recorded continuously for 5 min. The mean value of two independent 
determinations is expressed as area under the curve in arbitrary units (U). 
The multi-parameter assessment of thrombus formation has been described in detail 
for human blood [58, 59]. Mouse blood was collected into 0.1 volume of saline with a 
final concentration of 4 µM PPACK, 4 U/ml fragmin and 5 U/ml heparin. Microspot-
coated coverslips, coated as described with three distinct surfaces (a: VWF + laminin. 
b: VWF + laminin + CLEC-2 ligand. c: collagen type I, Horm), were mounted onto a 
parallel-plate flow chamber and a shear rate of 1000 s-1 was applied. In thrombi, 
platelets were stained with monoclonal antibodies against CD62P (FITC), activated 
integrin αIIbβ3 (PE-JON/A)t, and AF647-annexin-A5. Parameters were assessed by 
bright-field and sub-sequent tri-color fluorescence microscopy. 
Statistical analysis 
Data are expressed as mean ± standard error of the mean (SEM) unless otherwise 
specified. If D'Agostino & Pearson omnibus and/or Shapiro-Wilk normality test 
indicated Gaussian distribution, an unpaired t-test for side-by-side comparisons or 
one-way ANOVA with Newman-Keuls post-test for multiple comparisons were 
performed. Otherwise, Mann-Whitney-tests for side-by-side comparison and Kruskal-
Wallis-test for multiple comparisons were performed using GraphPad Prism version 
5.04 for Windows (GraphPad Software, San Diego, USA). For animal studies, a power 
analysis was performed using BiAS software (version 11.02). We assumed a detectable 
biological difference of at least 50% among up to four groups with a standard 
deviation < 15%, an α of 0.05, and a resultant power of 0.8. The number of biological 
replicates for each data point is included in the figure legends. 
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Figure S1: Representative ligand blot and densitometric values. (a) Chemokines were spotted 
on a nitrocellulose membrane (1 μl, 1 ng) as indicated. In this example, CCL5 served as the 
positive control (orange). (b,c) The membrane was left untreated to test for antibody specificity 
(b) or incubated overnight at 4°C with 100 nM CCL5 (c). CCL5 partners were detected using a 
biotinylated antibody to CCL5 and a HRP-conjugated secondary antibody (c). (d) The absolute 
luminescence signal (area and density) was digitally recorded; background was subtracted and 
expressed relative to the signal of the positive control (CCL5). 
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Figure S2: Interaction of CCL5 with CCL17 analyzed by SPR. To validate chemokine interactions 
of interest, we performed kinetics analyses of their saturation binding curves using surface 
plasmon resonance (SPR). In this example, CCL17 was biotinylated and immobilized onto a 
neutravidin-coated sensor chip C1 (Biacore). CCL5 was perfused at 90 μl/min in running buffer 
(HBS-EP+, pH 7.4) and regenerated with 100 mM NaOH, 0.05% SDS and 30% acetonitrile. On-
rates (κa) and off-rates (κd) were calculated from fitting the curves by non-linear regression 
using the 1:1 Langmuir interaction model. 
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Figure S4:. Chemical shift and resonance intensity changes of CCL5E66S residues. Chemical shift 
(δΔ) and resonance intensity (ΔIntensity) changes for 15N-labeled CCL5E66S (30 μM) in the 
presence of CXCL4K50E or CXCL4 (600 μM) or for 15N-labeled CCL5E66S (20 μM) in the presence of 
CCL17 (650 μM) were quantified and plotted vs the CCL5 amino acid sequence. We denote 
CCL5E66S dimers with “d” and CCL5E66S monomers with the prefix “m”. (a) ΔIntensity values for 
dCCL5E66S plus CXCL4K50E; (b) δΔ values for dCCL5E66S plus CXCL4K50E ; (c) ΔIntensity values for 
dCCL5E66S plus CCL17; (d) δΔ values for dCCL5E66S plus CCL17; (e) ΔIntensity values for mCCL5E66S 
plus CXCL4; (f) δΔ values for mCCL5E66S plus CXCL4; (g) ΔIntensity values for dCCL5E66S plus 
CXCL4; (h) δΔ values for dCCL5E66S plus CXCL4. Solution conditions were 25 mM Na-acetate-d3 
buffer (95% H2O; 5% D2O), pH 4.5, 37°C. 
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Figure S5: Concentration-dependent formation of CC- versus CXC type heterodimers. Changes 
in resonance intensity (ΔIntensity) for 15N-labeled CCL5E66S monomer resonances in the 
presence of increasing concentrations of CCL17 are plotted vs the amino acid sequence of CCL5. 
The final CCL17:CCL5E66S molar ratios were 8:1 (a), 33:1 (b) and 265:1 (c), as indicated. The total 
concentration of CCL5E66S was 20 μM at the two lowest ratios and 10 μM at the 265:1 ratio. 
ΔIntensity was calculated as in Figure S4. Solution conditions were 25 mM Na-acetate-d3 buffer 
(95% H2O; 5% D2O), pH 4.5, 37 °C. (d) ΔIntensity values increasing the most by the highest 
CCL17 concentration are highlighted in red on the X-ray crystal structure of CCL5 (PDB access 
code 1U4L). (e) ΔIntensity values averaged over residues at the CC-type (residues 3-16; 30-35, 
46-50) or CXC-type (residues 24-30, 53-68) heterodimer interfaces are plotted vs the 
CCL17:CCL5E66S molar ratio. 
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Figure S6: CCL5-induced changes in HSQC spectra of CXCL12. (a) 15N-1H heteronuclear single 
quantum coherence (HSQC) spectra (1H frequency of 700 MHz) for 15N-labeled CXCL12 (30 μM) 
in the absence (red contours) and presence (blue contours) of CCL5E66S (315 μM) are overlaid. 
(b) From the HSQC spectra shown in a, δΔ and ΔIntensity values (calculated as in Figure S4) are 
plotted vs the amino acid sequence of CXCL12. (c) 15N-1H HSQC spectra (1H frequency of 700 
MHz) for 15N-labeled CCL5E66S (20 μM) in the absence (red contours) and presence (blue 
contours) of CXCL12 (770 μM) are overlaid. (d) From the HSQC spectra shown in c, δΔ and 
ΔIntensity values (calculated as described in the legend to Figure S4) are plotted versus the 
amino acid sequence of CCL5. (e) From 15N-1H HSQC spectra of 15N-CCL5E66S (20 μM) in the 
absence and presence of CXCL10 (1.0 mM) (data not shown), ΔIntensity values (calculated as in 
Figure S4) are plotted vs the amino acid sequence of CCL5. Solution conditions were 25 mM Na-
acetate-d3 buffer (95% H2O; 5% D2O), pH 4.5, 37 °C. 
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Figure S7: Targeting of chemokine heterodimers by specific peptides. (a,b) Structures of CCL5-
CCL17 (CC-type, a) and CCL5-CXCL12 (CXC-type, b) modelled after MD simulation plus 
minimization (CCL5 in green, CCL17 and CXCL12 in red) are illustrated. (c) 15N-1H heteronuclear 
single quantum coherence (HSQC) spectral expansions for mCCL5E66S residues C10 and Y14 at 
the heterodimer interface are shown to exemplify the inhibitory effect that increasing 
concentrations of CKEY peptide has on the formation of 15N-CCL5E66SCXCL4K50E heterodimers. (d) 
15N-1H HSQC spectral expansions for five residues at the heterodimer interface are shown to 
exemplify the inhibitory effect that CAN peptide has on the formation of 15N-CCL5E66S-CCL17 
heterodimers. Red contour lines show relatively sharp resonances of free CCL5E66S monomer 
peaks, blue contours indicate the corresponding broadened peak caused by heterodimer 
formation with CXCL4K50E or CCL17, while other contours show the reverse trend in linewidth 
and chemical shift on CCL5E66S heterodimer peaks caused by the competitive binding to CKEY or 
CAN. 
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Figure S8: Efficient targeting of CCL5-CXCL12 heterodimer by [VREY]4. (a) Chemical structure of 
4 VREY molecules on a TASP scaffold resulting in [VREY]4. (b) Overlays of 
15N-1H heteronuclear 
single quantum coherence (HSQC) spectral expansions of 10 μM monomeric 15N-CXCL12 in the 
absence (red contours) and presence (blue contours) of 40 μM [VREY]4 peptide. (c) Using these 
HSQC data, δΔ values (calculated as in Figure S4) are plotted versus the amino acid sequence of 
CXCL12. (d) Structural pertubation plot of CXCL12 (monomeric) induced by [VREY]4, as taken 
from the experimental derived delta ppm values. (e) 15N-1H HSQC spectral expansions for five 
residues at the heterodimer interface are shown to exemplify the inhibitory effect that [VREY]4 
has on the formation of 15N-CXCL12-CCL5 heterodimers. Solution conditions were 25 mM 
potassium phosphate buffer (95% H2O; 5% D2O), pH 7.1, 25°C. Poor solubility of [VREY]4 at pH 
values lower than 7 prevents the study of heterodimer formation at standard pH 4.5 buffer 
conditions. 
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Figure S9: Dose-dependency of T-cell chemotaxis elicited by single chemokines. (a-f) 
Chemotaxis assays were performed using IL-2- and CD3/C28-activated human T cells in 3 μm 
Transwell-filter plates. Chemokines were added into the bottom chamber at indicated 
concentrations: CCL5 (a), CCL17 (b), CXCL12 (c), CXCL4 (d), CXCL4L1 (e), CXCL10 (f). The 
chemotactic index was calculated as the ratio of chemokine-induced versus unstimulated 
migration, as determined by counting cells in the bottom chamber. Data represent mean±SEM 
of n=5-20 independent experiments. 
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Figure S10: Differential effects of chemokine combinations on T-cell chemotaxis. (a-h) 
Chemotaxis assays were performed using IL-2- and CD3/C28-activated human T cells in 
Transwell-filter plates. Combinations of CCL5 (1 nM) with CCL17 (0.1 nM), (a), of CXCL4 or 
CXCL4L1 with CCL5 (all at 4 nM) (b,c), of CXCL12 with CCL5, CXCL4, or CXCL4L1 (all at 40 nM) (d–
f) and of CCL5 (1 nM) with CCL3 or CXCL10 (both at 100 nM), (g,h) were added to the bottom 
chamber. The chemotactic index was calculated as the ratio of chemokine-induced versus 
unstimulated migration. Dashed lines indicate a virtually calculated additive effect (a-c, g,h). 
Data represent mean±SEM from the indicated number of independent experiments. *p<0.05, 
as analyzed by Krukal-Wallis-test. 
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Figure S11: Differential effects of chemokine heterodimerization on leukocyte recruitment. (a-i) 
The firm arrest of IL-2- and CD3/C28-activated human T cells (a,f,i) or isolated monocytes (b,c,g) 
perfused over IL-1β-stimulated human aortic endothelial cells (HAoECs) at 1.5 dyne/cm2 was 
analyzed by counting high-power fields (HPF) and chemotaxis assays were performed using IL-2- 
and CD3/C28-activated human T cells in Transwell-filter plates (d,e). For T-cell arrest, CCL5 (1 
nM) and CCL17 (0.1 nM) were immobilized on HAoECs in combination with CAN or CKEY (both 
10 nM) (a,f). For monocyte arrest, HAoECs were pre-incubated with CXCL8 and/or CXCL4 (b) and 
with CCL5 and/or CXCL12 (all at 40 nM) in combination with a 10-fold excess of [VREY]4 (c). The 
effect of CCL5 (1 nM) plus CCL17 (0.1 nM) on T-cell chemotaxis was inhibited by blocking CCR4 
(C021) or CCL5 receptors with Met-RANTES (Met-R) (d). The effect of CCL5 plus CXCL4 (both 4 
nM) on T-cell chemotaxis was inhibited by blocking CCL5 receptors with Met-R (e). Isolated 
human blood monocytes were perfused on IL-1β-activated HAoEC pre-incubated with CCL5 (4 
nM) plus CXCL4 (40 nM) and CKEY or CKEYRE with the substitutions R44A and E26A (both 400 
nM), and arrest was quantified (g). A combination of CXCL12 with or without CCL5 (both 40 nM) 
and a 10-fold excess of [VREY]4 were added to the bottom chamber to assess T-cell chemotaxis 
(h). Arrest of activated T cells on IL-1β -stimulated HAoECs pre-incubated with CCL5 (1 nM) plus 
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CCL17 (0.1 nM) or with covalently bound CCL5-CCL17 heterodimer ORATH (Obligate RAntes 
Tarc Heterodimer) at indicated concentrations (i). Dashed lines indicate a virtually calculated 
additive effect (a,c). Data represent mean±SEM from the indicated number of independent 
experiments. *p<0.05, **p<0.01, ***p<0.001, as analyzed by Kruskal-Wallis-test (a-d,f,g,i) or 
one-way ANOVA (e,h). 
 
Figure S12: Microscopy of chemokine interactions at the cell surface. (a-d) Interactions of 
murine CCL5 with CCL17 or CXCL4 were analyzed using an antibody-based proximity-ligation 
assay (Duolink®). (a,b) Signals indicative of interaction were detected on the surface of mouse 
Simian-virus 40-transformed endothelial cells (SVECs) after incubation with CCL5 in combination 
with CCL17 (a) or CXCL4 (b) (6 nM each) by fluorescence microscopy. The endogenous presence 
of CCL5-CCL17 (c) was detected by proximity ligation in frozen sections of murine para-aortic 
lymph nodes but not in controls (d). 
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Figure S13: Mechanisms for synergy of chemokine heterodimers. (a–d) Interactions between 
CCL5, CCL17, CCR4, and CCR5 were detected on the surface of adherent dendritic cells (DCs) 
using a proximity-ligation assay (Duolink®) after the cells were incubated with CCL5, CCL17, or 
both (all at 6 nM).  The proximity ligation signals generated by the direct or indirect interactions 
between CCL17-CCR4 (a), CCL5-CCR5 (b), CCL5-CCR4 (c), and CCL17-CCR5 (d) were measured. 
Dashed lines indicate a virtually calculated additive effect (a-d). (e) Migration of activated 
primary mouse T cells was elicited by CCL5, CCL17, or both (all at 6 nM) and compared between 
cells from wild-type (WT) or CCR5-deficient (Ccr5-/-) mice, wild-type (WT) mice or cells 
pretreated with C021 (a CCR4 inhibitor). (f,g) Binding competition assays were performed, 
whereby CCL5-Alexa647 (2.5 nM) bound to CCR1-expressing (f) or CCR5-expressing (g) HEK 
transfectants was displaced by unlabeled CCL5 at indicated concentrations in presence or 
absence of CXCL4 (40 nM) (n=5 and n=3, respectively). Data represent mean±SEM from a 
number of independent experiments, as indicated. *p<0.05, **p<0.01, as analyzed by Mann-
Whitney-test (a-d) or two-way ANOVA (e). 
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Figure S14: Relevance of chemokine heterodimer formation in acute lung injury. (a-d) Acute 
lung injury was induced by LPS inhalation of 10 week old female C57/B6 mice and 30 minutes 
before sacrifice a FITC conjugated Ly6G antibody was injected i.v., to discriminate intravascular 
from interstitial neutrophils. (a-c) CKEY was injected i.v. at low dose (1mg/kg, LD) or high dose 
(10 mg/kg, HD), as well as the variant CKEYRE with the substitutions R44A and E26A. Neutrophils 
were counted by FACS from total lungs (a), the interstitial space (b) or bronchoalveolar lavage 
(BAL) fluid (c). (d) Lethally irradiated female C57/B6 mice were transplanted at 10 weeks of age 
with bone marrow from Ccl5-/-Cxcl4-/- mice. Acute lung injury was induced by LPS inhalation and 
CCL5 (150 μg/kg) or the obligate PF4-RANTES heterodimer (OPRAH, 300 μg/kg) were injected 
i.v. Neutrophils from total lungs were counted. Data represent mean±SEM from the indicated 
number of independent experiments. *p<0.05, as analyzed by Kruskal-Wallis-test. 
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Figure S15: Generation of mice deficient in Cxcl4 or Cxcl12 or carrying Cxcl4 variants.  (a-c) 
Targeting strategy to generate Cxcl4l1 knock-in, Cxcl4 knock-out and Cxcl12 knock-out mice. 
The exon-intron structures of the gene loci and the targeting vector (right) and correct targeting 
as evidenced by southern blotting (left) are shown. Green bars indicate the position of the 
probe, grey bars indicate flippase recognition target (frt) sites, black triangles indicate loxP sites. 
(a) Cxcl4L1/L1 mice were generated by homolgous recombination with a targeting vector of 
mutated murine Cxcl4 (Pf4), which included a 2.3 kb 5′ homology arm harboring exon 1, intron 
1-2 and a frt-flanked neomycin selection cassette (Neo). The 3′ recombination arm spanned 3.6 
kb, loxP sites flanked exons 2-3 (the coding part of Cxcl4 gene) substituting prolin P64 by leucin 
(L), lysine K72 by glutamate (E) and isoleucine I73 by histidine (H) to obtain the murine 
orthologue of human CXCL4L1. Cxcl4-/- mice resulted from off-springs of CreERT2-Cxcl4L1/L1 
parents after ubiquitous deletion of Cxcl4 by tamoxifen. Southern blots demonstrated wild-type 
Cxcl4wt/wt and correct targeting of heterozygous Cxcl4wt/L1 and homozygous Cxcl4wt/L1. (b) 
Transgenic Cxcl4tg-L1 mice were generated by inserting the human CXCL4L1 gene into the 
Rosa26 locus. The targeting vector contained a 1.1 kb 5′ arm harboring intron 1-2, a Neo 
selection and Stop cassettes flanked by loxP sites, IRES and eGFP were flanked by frt sites. The 
3′ recombination arm spanned 4.3 kb containing intron 1-2. Southern blots demonstrated 
correctly targeted ES clones (4 and 5). (c) Shown is the mouse Cxcl12 locus and the targeting 
vector consisting of a 1.9 kb 5′ homolgy arm including exon 1 and intron 1-2, frt-flanked Neo, 
loxP-flanked exon 2 and the 3′ recombination arm spanning 6.7 kb. Southern blots show wild-
type (1, 2) and correctly targeted heterozygous (3) ES clones. Cxcl12-/- mice were generated by 
conditional inactivation of Cxcl12 by intercrossing CreERT2 and injecting tamoxifen i.p. 
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Figure S16: Analysis of atherosclerotic lesion in mice expressing Cxcl4 or its variant. (a) 
Overview and zoom-in insets of a longitudinal section through the aortic arch presenting typical 
sites of plaque development (1: brachiocephalic trunc; 2: left common carotid artery; 3: left 
subclavian artery; 4: arch; 5: lesser curvature). (b-d) Apoe-/- mice homozygous for wild-type 
Cxcl4 (wt/wt), heterozygous for Cxcl4 and Cxcl4l1 (wt/L1), homozygous for Cxcl4l1 (L1/L1), or 
deficient for Cxcl4 and Cxcl4l1 (-/-) were fed a HFD for 12 weeks. (c) Shown are representative 
Elastica-van Gieson (EVG) staining of aortic root cross-sections. (d) Quantification of (c). Data 
represent mean±SEM from the indicated number of mice. *p<0.05, **p<0.01 versus wt/wt, as 
analyzed by one-way ANOVA (b,d). 
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Figure S17: Composition of aortic root lesions in mice expressing Cxcl4 or its variant. Apoe-/- 
mice homozygous for wild-type Cxcl4 (wt/wt), heterozygous for Cxcl4 and Cxcl4l1 (wt/L1), 
homozygous for Cxcl4l1 (L1/L1), or deficient for Cxcl4 and Cxcl4l1 (-/-) were fed a HFD for 12 
weeks. Cross-sections of paraffin-embedded roots were analyzed for the content (percentage) 
of smooth muscle cells by staining smooth muscle-actin (SMA) (a), of T cells by staining CD3 (b), 
for necrotic core (c) or for staging the plaque phenotype according to the Virmani classification 
into advanced i.e. fibrous cap atheroma (FCA) or early lesions i.e. pathological intimal 
thickening (PIT) (d). Data represent mean±SEM from the indicated number of mice, as analyzed 
by Kruksal-Wallis-test (a-c). 
 
Figure S18: Obligate chemokine heterodimers mimic natural heterodimers. Apoe-/- mice, 
homozygous for wild-type Cxcl4 (wt/wt), heterozygous for Cxcl4 and Cxcl4l1 (wt/L1), or 
deficient for Cxcl4 and Ccl5 (Ccl5-/-Cxcl4-/-) were fed a HFD for 6 weeks. Atherogenesis was 
exacerbated by injecting i.p. the obligate RANTESPF4 heterodimer (OPRAH) or saline (control) 3 
times a week for 6 weeks. Shown is the lesion size of the aortic arch (a) content of SMA+ 
smooth muscle cells in aortic root plaque (b) and CD3+ T cells (c). Data represent mean±SEM 
from the indicated number of mice. *p<0.05, as analyzed by Mann-Whitney-test). 
Mapping the chemokine interactome 
 
147 
  
6 
 
  
Mapping the chemokine interactome 
 
148 
 
  
Ta
bl
e 
S1
: D
en
sit
om
et
ry
 a
na
ly
sis
 o
f b
id
ire
ct
io
na
l i
m
m
un
o-
lig
an
d 
bl
ot
tin
g.
 C
he
m
ok
in
es
 im
m
ob
ili
ze
d 
on
 n
itr
oc
el
lu
lo
se
 m
em
br
an
es
 a
re
 a
rr
an
ge
d 
in
 ro
w
s, 
ch
em
ok
in
es
 a
dd
ed
 in
 s
ol
ut
io
n 
ar
e 
ar
ra
ng
ed
 in
 c
ol
um
ns
. F
ol
lo
w
in
g 
de
te
ct
io
n 
by
 s
pe
cif
ic
 a
nt
ib
od
ie
s, 
th
e 
de
ns
ity
 a
nd
 a
re
a 
of
 p
os
iti
ve
 r
ea
ct
io
ns
 w
er
e 
de
te
rm
in
ed
 b
y 
de
ns
ito
m
et
ry
, a
nd
 t
he
 r
at
io
 r
el
at
iv
e 
to
 t
he
 r
es
pe
ct
iv
e 
po
sit
iv
e 
co
nt
ro
l i
s 
gi
ve
n.
 R
ea
ct
io
ns
 e
xc
ee
di
ng
 5
%
 o
f t
he
 v
al
ue
 o
f t
he
 p
os
iti
ve
 
co
nt
ro
l w
er
e 
re
ga
rd
ed
 a
s p
os
iti
ve
 a
nd
 a
re
 h
ig
hl
ig
ht
ed
 in
 g
re
en
. M
ea
ns
 w
er
e 
ca
lcu
la
te
d 
fr
om
 2
-4
 in
de
pe
nd
en
t i
m
m
un
o-
lig
an
d 
bl
ot
s. 
Mapping the chemokine interactome 
 
149 
  
6 
  
Ta
bl
e 
S1
 (
co
nt
in
ue
d)
: 
De
ns
ito
m
et
ry
 a
na
ly
sis
 o
f 
bi
di
re
ct
io
na
l i
m
m
un
o-
lig
an
d 
bl
ot
tin
g.
 C
he
m
ok
in
es
 i
m
m
ob
ili
ze
d 
on
 n
itr
oc
el
lu
lo
se
 m
em
br
an
es
 a
re
 
ar
ra
ng
ed
 in
 ro
w
s, 
ch
em
ok
in
es
 a
dd
ed
 in
 s
ol
ut
io
n 
ar
e 
ar
ra
ng
ed
 in
 c
ol
um
ns
. F
ol
lo
w
in
g 
de
te
ct
io
n 
by
 s
pe
cif
ic
 a
nt
ib
od
ie
s, 
th
e 
de
ns
ity
 a
nd
 a
re
a 
of
 p
os
iti
ve
 
re
ac
tio
ns
 w
er
e 
de
te
rm
in
ed
 b
y 
de
ns
ito
m
et
ry
, a
nd
 th
e 
ra
tio
 re
la
tiv
e 
to
 th
e 
re
sp
ec
tiv
e 
po
sit
iv
e 
co
nt
ro
l i
s 
gi
ve
n.
 R
ea
ct
io
ns
 e
xc
ee
di
ng
 5
%
 o
f t
he
 v
al
ue
 o
f 
th
e 
po
sit
iv
e 
co
nt
ro
l w
er
e 
re
ga
rd
ed
 a
s p
os
iti
ve
 a
nd
 a
re
 h
ig
hl
ig
ht
ed
 in
 g
re
en
. M
ea
ns
 w
er
e 
ca
lc
ul
at
ed
 fr
om
 2
-4
 in
de
pe
nd
en
t i
m
m
un
o-
lig
an
d 
bl
ot
s. 
Mapping the chemokine interactome 
 
150 
 
Chemokine ka (M
-1s-1)x104 kd (s
-1)x10-4 KD (nM) 
CCL5 chip 
CCl2 1.5 ± 0.6 15 ± 6.1 95 ± 40 
CCL11 286 ± 115 1450 ± 667 51 ± 11 
CCL17 169 ± 25 161 ± 35 9.6 ± 1.5 
CXCL4 45 ± 19 18 ± 6.4 4.1 ± 1.8 
CXCL4R>Q 30 ± 17 11 ± 0.1 4.5 ± 2.6 
CXCL4L1 0 - - 
CXCL7 11 ± 2.2 30 ± 18 27 ± 16 
CXCL10 24 ± 1.5 21 ± 3.2 8.8 ± 1.9 
CXCL12 1.6 ± 0.1 94 ± 5.8 578 ± 61 
CXCL4 chip 
CCL5 20 ± 14 7.7 ± 2.7 5.2 ± 2.8 
CCL5E66S 3.2 ± 0.1 2.2 ± 0.1 6.7 ± 0.5 
CCLMT7 0 - - 
CCL5E26A 9.2 ± 5.2 499 ± 110 678 ± 365 
CCL544AANA47 0 - - 
CXCL7 0 - - 
CXCL8 0.3 ± 0.1 2.9 ± 0.4 105 ± 11 
CXCL12 33 ± 9.1 113 ± 28 35 ± 8.6 
CXCL12 chip 
CXCL4 2.2 ± 0.7 4.6 ± 2.9 20 ± 7.4 
CXCL4L1 10 ± 6.1 12 ± 5.7 13 ± 6.1 
CCL5 4.9 ± 1.2 159 ± 80 298 ± 119 
CCL5E66S 42 ± 29 1415 ± 1217 319 ± 60 
CCL17 chip 
CCL5 16 ± 3.3 14 ± 2.1 8.6 ± 1.8 
CCL5E66S 69 ± 4.8 27 ± 4.5 3.9 ± 0.4 
CCLMT7 0.8 ± 0.2 11 ± 2.2 145 ± 64 
CCL5E26A 49 ± 0.8 20 ± 3.9 4.1 ± 0.8 
CCL544AANA47 8.5 ± 1.4 25 ± 2.9 30 ± 5.5 
 
Table S2: Kinetics analysis of chemokine binding by surface plasmon resonance. Biotinylated 
CCL5, CXCL4, CXCL12 and CCL17 were immobilized on neutravidin-coated C1 sensor chips. 
Analytes were injected over the 2 flow cells at flow rates and concentrations described in 
Online Methods. All kinetic rate analyses were performed in running buffer, pH 7.4 at 25°C 
(n=3). Responses from analyte injections were overlaid with the fit of a 1:1 interaction model to 
determine on-rates (ka), off-rates (kd), and dissociation constants (KD). 
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 ΔIntensity 
(top 10) 
ΔIntensity 
(all) 
Ratio 
(10/all) 
Dimer 
type 
preferred 
ΔG for 
CC-
type 
ΔG for 
CXC-
type 
CCL5E66S/CCL17 0.85 0.37 2.3 CC   
CCL5/CCL17    CC -61.3 -45.7 
CCL5E66S/CXCL4 0.25 0.11 2.3 CC -53.2 -40.3 
CCL5/CXCL4    CC -62.6 -44.9 
CCL5E66S/CCL12 0.48 0.37 1.3 CC/CXC   
CCL5/CCl12    CC -56.8 -34.6 
CCL5E66S/CXCL12 0.15 0.11 1.4 CXC/CC -7.9 -44.5 
CCL5/CXCL12    CXC -7.5 -31.5 
CXCL4/CXCL12    CXC -3.0 -67.7 
CCL5E66S/CCL3 0.7 0.61 1.1 none   
 
Table S3: Weighted averaging of ΔIntensity changes and MDS-based in silico modeling. The 
changes in resonance intensity (ΔIntensity) of 1H-15N resonances in heteronuclear single 
quantum coherence spectra of 15N-CCL5E66S in the presence of indicated CXC and CC 
chemokines were recorded and calculated as 1 minus the ratio presence/absence of any given 
chemokine. Average ΔIntensity values are shown; “top 10” indicates the average of the 10 
resonances showing the greatest reduction in intensity; “all” means the average over all 
resonances. Free energies (ΔG) for various pairs of chemokines were calculated from molecular 
dynamics simulations (MDS) of pre-constructed CC-type or CXC-type heterodimers, as 
indicated. Values assessed using data from 100-130 ns of MD simulation. ΔG values are given in 
kcal/mol. 
Peptide Sequence Configuration CCL5 origin 
CCL51-33 SPYSSDTTPCCFAYIARPLPRAHIKEYFYTSGK Linear 1-33 
CKEY CKEYFYTTSGKCSNPAVVFITRC Cyclic 25-45 
CKEYRE CKAYFYTTSGKCSNPAVVFITAC Cyclic 25-45 
CAN CKSSNPAVVFVTRKNRQVSANC Cyclic 33-53 
VREY EKKWVREYINSLEMS Linear 54-68 
[VREY]4 [TASP]*+ 4x [EKKWVREYINSLEMS] branched 54-68 
 
Table S4: Sequence and origin of peptide inhibitors. * The synthetic unprotected pro-helical 
VREY αCOSH peptide was reacted with a templateassembled synthetic protein (TASP) molecule 
resulting in a 4-helix TASP. 
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Peptide Inhibitor Ligand (immobilized) Analyte (soluble) IC50 (µM) 
CCL51-33 CCL5 CXCL4 1.7 
CCL17 CCL5 0.24 
CXCL12 CCL5 2.4 
CKEY CCL5 CXCL4 1.9 
CCl17 CCL5 ND 
CXCL12 CCL5 ND 
CKEYRE CCL5 CXCL4 ND 
CAN CCL5 CXCL4 ND 
CCL17 CCL5 0.27 
CXCL12 CCL5 ND 
[VREY]4 CCL5 CXCL4 ND 
CCL17 CCL5 ND 
CXCL12 CCL5 2.7 
 
Table S5: CCL5 derived peptides specifically inhibit heterodimer formation of CCL5. Chemokines 
were biotinylated and immobilized on neutravidin-coated C1 sensor chips. The RU signal of the 
soluble chemokine was obtained at 50 nM. The inhibition of chemokine heterodimerization by 
the peptides CCL51-33, CKEY, CKEYRE, CAN, and [VREY]4 was tested at increasing concentrations 
and is indicated by IC50 values (n=3). Owing to aggregation of peptides, IC50 values > 5.0 μM 
could not be determined (ND). 
CXCL4 genotype CXCL4wt/wt CXCL4wt/L1 CXCL4L1/L1 CXCL4-/- P-value 
Cholesterol (mg/dl) 1048 ± 202 1088 ± 146 1152 ± 177 1017 ± 88 ns 
Triglycerides (mg/dl) 394 ± 179 426 ± 144 256 ± 120 379 ± 159 ns 
Body weight (g) 22.9 ± 1.7 26.1 ± 4.4 25.9 ± 3.1 25.3 ± 2.5 ns 
      
RBC (106/µL) 9.1 ± 0.4 8.9 ± 0.6 8.9 ± 0.5 9.5 ± 0.4 ns 
WBC (103/µL) 4.5 ± 1.4 4.5 ± 1.3 5.3 ± 1.8 4.5 ± 1.5 ns 
      
Lymphocytes (103/µL) 3.1 ± 1.1 3.2 ± 1.0 4.0 ± 1.3 3.2 ± 1.2 ns 
Neutrophils (103/µL) 1.3 ± 0.7 1.2 ± 0.4 1.1 ± 0.6 1.2 ± 0.4 ns 
Platelets (103/µL) 1019 ± 204 844 ± 242 868 ± 280 937 ± 229 ns 
 
Table S6: Lipid parameters and peripheral blood counts of different CXCL4 genotypes. Wild-type 
mice (wt/wt), homozygous Cxcl4L1/L1mice with a CXCL4 knock-out and knock-in of the human 
variant CXCL4L1, heterozygous Cxcl4L1/+ mice and Cxcl4-deficient Cxcl4-/- mice on a Apoe-/- 
genetic background were fed a high-fat diet for 12 weeks. Lipid parameters, body weight and 
differential peripheral blood counts were determined using standard methodology. Data 
represent mean±SEM from 8-15 mice, analyzed by Kruskal-Wallis-test (ns; not significant). 
  
Mapping the chemokine interactome 
 
153 
  
6 
Genotype  Wt/wt CXCL4L1/wt CXCL4L1/wt CCL5-/-
CXCL4-/- 
CCL5-/-
CXCL4-/- 
P-
value 
Treatment ctrl ctrl OPRAH ctrl OPRAH  
       
Cholesterol 
(mg/dl) 
1019 ± 
182 
905 ± 103 969 ± 169 968 ± 124 754 ± 239 ns 
Triglycerides 
(mg/dl) 
140 ± 50 121 ± 28 105 ± 20 152 ± 56 93 ± 66 ns 
Body weight (g) 25.2 ± 2.6 23.0 ± 1.9 23.6 ± 2.6 31.7 ± 2.2 31.8 ± 4.6 ns 
       
RBC (106/µL) 9.1 ± 0.2 8.6 ± 1.2 9.1 ± 0.3 9.1 ± 0.5 8.2 ± 1.1 ns 
WBC (103/µL) 4.2 ± 0.8 3.7 ± 0.9 3.8 ± 0.8 4.0 ± 0.9 3.6 ± 0.4 ns 
       
Lymphocytes 
(103/µL) 
3.0 ± 0.6 2.5 ± 0.7 2.7 ± 0.6 2.8 ± 0.9 2.4 ± 0.4 ns 
Neutrophils 
(103/µL) 
1.1 ± 0.2 1.1 ± 0.3 1.0 ± 0.2 1.2 ± 0.3 1.1 ± 0.2 ns 
Platelets 
(103/µL) 
822 ± 97 777 ± 194 821 ± 86 1102 ± 45 1213 ± 
319 
ns 
 
Table S7: Effect of OPRAH on lipid parameters and peripheral blood counts. Wild-type mice 
(wt/wt), heterozygous Cxcl4L1/wt mice and Ccl5-/-Cxcl4-/- mice on an Apoe-/- genetic background 
were fed a high-fat diet for 6 weeks and were treated (i.p.) with vehicle (ctrl) or OPRAH (10 μg, 
twice a week). Lipid parameters, body weight and differential peripheral blood counts were 
determined using standard methodology. Data represent mean±SEM from 5-6 mice, analyzed 
by Kruskal-Wallis-test (ns; not significant). 
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Abstract  
We present the site-specific modification of a thrombolytic drug, recombinant tissue 
plasminogen activator (tPA). A main disadvantage of the current tPA thrombolytic 
therapy is the risk on bleeding. To partly overcome this, a tPA molecule with very high 
affinity for fibrin would be required. We therefore modified tPA with the A14 peptide 
derived from the N-terminus of α2-antiplasmin. The A14 peptide is covalently linked to 
fibrin polymers by factor XIIIa and can thus be used to exclusively site-direct tPA to its 
target by covalent coupling to the fibrin-stabilized blood clot. Site specific 
modification of the large serine protease was achieved by oxidation of the N-terminal 
serine followed by oxime ligation of the resulting glyoxyloyl protein with an 
aminooxyacetyl functionalized A14 peptide. We showed that other groups prone to 
oxidation (glycosylated amino acids) were not affected by the oxidation strategy. The 
activity of the synthesized chimera proteins was tested both in static conditions as 
well as under flow in a plasma clot lysis assay. Chimera proteins showed no difference 
in activity compared to tPA, which was explained by potential restricted mobility of 
the protease on the fibrin mesh by the covalent attachment to the clot. Although the 
activity of tPA was not enhanced, the protein was successfully site-specifically 
modified using N-terminal serine oxidation showing the selective efficacy of 
modification of large post-translationally modified proteins. 
Introduction 
Clinically approved drugs can be modified to improve their mode of action and 
decrease their side effects. Thrombolytic drugs dissolve blood clots by activating 
plasminogen to plasmin that subsequently cleaves fibrin clots into soluble 
components.[1, 2] Clinically used thrombolytic drugs are alteplase (recombinant tissue 
plasminogen activator, tPA), reteplase (single chain, unglycosylated mutant of tPA), 
tenecteplase (recombinant tissue plasminogen activator mutated at three positions) 
and urokinase (uPA). Both tPA and uPA are large serine proteases (527 aa and 411 aa) 
that are used to treat different thrombolytic events.[1, 3-6] While tPA is widely used 
to treat for example acute myocardial infarction and cerebral stroke, uPA is mainly 
used in case of pulmonary embolisms.[7, 8]  
Although recombinant tPA has been approved for clinical use since 1984 it has some 
disadvantages. The efficacy of tPA is limited which results in requirement of high 
doses and consequently the main side effect is an increased bleeding tendency.[1, 4] 
Modification of tPA could improve its efficacy and decrease the risk of bleeding 
complications. Our hypothesis is that this can be achieved by coupling of a peptide 
derived from the N-terminus of α2-antiplasmin (α2-AP); a serine protease inhibitor 
that inhibits plasmin.[9] The N-terminus of α2-AP is covalently linked to fibrin by FXIIIa 
during clot formation.[10] In this way, fresh clots that prevent blood loss are 
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protected against early lysis by plasmin. A chimera of tPA and the N-terminus of α2-AP 
(A14) can thus target tPA to pathological fibrin clots and covalently attach tPA to the 
clot. This may lead to a higher efficacy of tPA resulting in lower doses of tPA and a 
decrease in bleeding tendencies during thrombolytic therapy. A similar recombinant 
chimera of α2-antiplasmin and uPA has been reported, however no benefit was seen 
in vivo.[11] A possible explanation for this observation is that attachment of the α2-
antiplasmin sequence to uPA compromised the folding and activity of the uPA part of 
the hybrid. Therefore, the aim of the current study was to modify a native, correctly 
folded thromobolytic enzyme, tPA, with a fibrin crosslinking sequence derived from 
α2-antiplasmin by specific coupling to the N-terminus and to assess of the fibrinolytic 
activity of this chimeric protein.  
Site specific modification of large and complex proteins is most often a difficult task to 
achieve since proteins contain many functional groups. In the case of tPA two 
locations for site specific modification were available, the first was a free cysteine to 
which maleimides can be coupled (cysteine-83), and the second was an N-terminal 
serine that can be oxidized to form a glyoxyloyl-protein which can subsequently be 
modified using oxime ligation (Scheme 1).[12, 13] 
 
Scheme 1: Schematic representation of the oxidation of the N-terminal serine of tPA followed 
by the reaction of the resulting glyoxyloyl-peptide with an aminooxy to form an oxime. 
The oxime ligation is particularly useful since it can be performed using unprotected, 
folded  proteins because of the orthogonal nature of oxime chemistry.[14] Moreover, 
tPA’s free cysteine was found to be partially blocked as it exists in a mixed disulfide 
bond with glutathione and a free cysteine making modification more difficult.[15] 
Therefore, the chosen approach was to modify tPA via the N-terminal serine. Peptides 
were used to model the oxidation reaction after which tPA was conjugated to A14 
moieties. tPA chimeras were characterized by mass spectrometry and in various clot 
lysis assays. 
Results 
Site specific oxidation of model peptides 
The size of tPA directly correlates with the number of functional groups present in the 
protein and the number of groups prone to oxidation. tPA contains 35 cysteine 
residues forming 17 disulfide bonds, 5 methionine residues, 4 glycosylation sites and 
evidence for a hydroxylysine has been found (Figure 1).[1, 6, 16] All these groups can 
be oxidized and thus complicate the modification of tPA via N-terminal serine 
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modification. However, since this is still an attractive approach for the site specific 
modification of large, complex and unprotected proteins, a method for site specific 
oxidation was explored. 
 
Figure 1: Primary sequence of tPA; showing the N-terminal serine and cysteine-83 involved in 
the mixed disulfide. Disulfides and N- and O-linked glycosylation sites are indicated in blue and 
pink, respectively. Figure adapted from Collen.[1] 
First, a test peptide was synthesized to optimize experimental conditions of the 
ligation reaction. The test peptide H2N-SYQVWK-NH2 contained the first four amino 
acids of tPA followed by tryptophan to facilitate UV quantification and a C-terminal 
lysine to improve aqueous solubility. Conversion of the N-terminal serine into an 
aldehyde was readily achieved using periodate treatment (Figure 2). The reaction was 
performed in phosphate buffer (pH 7.3) using 1.5 equiv. of periodate for 30 min after 
which the reaction was quenched by the addition of 3 equiv. of glycerol. Upon analysis 
of the quenched reaction mixture, we found remaining starting product, along with 
glyoxyloyl-peptide and hydrated glyoxyloyl-peptide (Figure 2). The choice for 
incomplete conversion was deliberate and intended to increase the probability of site-
specific modification at the N-terminus without side reactions at any other residue in 
the protein. Low amounts of reaction at other residues were expected to be very 
difficult to detect in a complex protein. However, selectivity for N-terminal serine 
oxidation was still achieved because a 2-amino alcohol is considerably more reactive 
towards periodate treatment when compared to diols as are present in the glycosyl 
groups.[17] 
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Figure 2: MALDI-TOF spectra of the test-peptide (SYQVWK). a: MALDI-TOF spectra of test-
peptide before oxidation. b: MALDI-TOF spectra of test-peptide after oxidation using sodium 
periodate. Mass 809.5 (1H+) corresponds with the non-oxidized peptide (1), 778.4 (1H+) with 
the oxidized peptide (2). Mass 796.4 (1H+) corresponds with the hydrated form of the oxidized 
peptide (3).  
Site specific oxidation of tPA 
Full length tPA was oxidized using varying concentrations of NaIO4. The oxidation 
reaction was followed by MALDI-TOF mass spectrometry. Small aliquots of the 
reaction mixture were removed at regular time intervals, subjected to a short trypsin 
treatment and analyzed. Under these conditions, only limited trypsinolysis occurred 
and the N-terminal fragment of tPA could be studied (Figure 3). Precise detection of 
the mass change induced by the oxidation of the N-terminal serine in full length tPA 
by MALDI-TOF analysis was not possible due to heterogeneity (glycosylation) of the 
tPA molecule. 
In order to prevent over-oxidation of tPA, methionine was added to the reaction 
mixture and the reaction again was quenched using glycerol. All experiments with full 
length tPA were performed in an arginine containing buffer to prevent solubility 
problems. Although the oxidation of the N-terminal serine could easily be followed by 
using limited proteolysis (Figure3), it was more difficult to assess whether oxidation 
had occurred at any other positions in the molecule, thereby possibly giving rise to 
additional aminooxy-reactive functional groups. 
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Figure 3: MALDI-TOF spectra of the N-terminus of tPA. a: MALDI-TOF spectrum of the N-
terminus of tPA after limited digestion by trypsin of the full length protein before oxidation. 
Mass 3404.8 (1H+) corresponds to the non-oxidized N-terminus of tPA. b: MALDI-TOF spectrum 
of the N-terminus of tPA after oxidation using NaIO4, Mass 3374.5 (1H
+) corresponds to the 
oxidized N-terminus of tPA. 
A14 modification of tPA 
To challenge over-oxidation and subsequent multiple A14 ligation, an excess of 
aminooxy modified A14 peptide (Scheme 2) was subjected to oxime ligation with the 
oxidized tPA. The C-terminal two lysine residues of the A14 peptide were modified 
with an aminooxy group for oxime ligation and a biotin moiety to enable detection or 
quantification. 
Mass analysis showed an increase in mass in agreement with that of the peptide but 
analysis was complicated by the fact that recombinant tPA has different degrees of 
glycosylation of the protein. Therefore tPA was deglycosylated using anhydrous 
hydrofluoric acid before analysis.[18] Mass analysis showed two main peaks (62.5 kDa; 
64,1 kDa: 1H+) for native tPA (Figure 4A) and a single peak (60.3 kDa: 1H+) for the 
deglycosylated protein (Figure 4B). The mass differences with the glycosylated tPA 
range between 2.2-3.8 kDa. 
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Figure 4: MALDI-TOF spectra of tPA constructs. a: Full length tPA before deglycosylation. b:  Full 
length tPA before deglycosylation. c: Over-oxidized (2 equiv. NaIO4) oxime ligated A14-tPA 
before deglycosylation. d: Over-oxidized oxime ligated A14-tPA after deglycosylation. e: Optimal 
oxidized (1.35 equiv. NaIO4) oxime ligated A14-tPA. f: Optimal oxidized oxime ligated A14-tPA 
after deglycosylation. Indicated are 3H+; 2H+; 1H+ states representing 1/3; 1/2, and full mass of 
the protein, respectively. Dashed line in B; D; E represents deglycosylated mass of unmodified 
tPA. 
It was now possible to determine the degree of oxidation in the full protein and 
determine the optimal conditions for oxidation. tPA was oxidized using increasing 
concentrations of periodate and then modified with the A14 peptide. The protein was 
subsequently deglycosylated. It was observed that oxidation using 2 equiv. of NaIO4 
followed by oxime ligation led to a mass increase of approximately 2 kDa (Figure 4C). 
Deglycosylation of the chimeric protein however, did not lead to a single peak as 
expected for a single modification, but showed a minor second peak indicating 
multiple peptides had been coupled to tPA (Figure 4D).  In addition, preservation of 
double A14 ligation after deglycosylation suggests that most or all coupling had 
occurred at the protein part rather than the carbohydrate part of tPA (Figure 4D). 
Since the modified proteins are expected to express very similar physicochemical 
properties, integration of peaks on the MALDI spectra was used to determine a ratio 
of 70/30 for the single and double modified tPA. These tests led to an optimal 
stoichiometry of 1.35 equiv. of NaIO4 per equiv. of tPA. This ensured only the N-
terminal serine to be affected, but did not lead to a complete conversion to the 
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glyoxylyl-protein. Using these optimal conditions with subsequent oxime ligation led 
to the desired mono A14-tPA construct (Figure 4E; 4F). Furthermore, the use of L-
methionine to prevent unwanted oxidation and the neutral pH at which the reaction 
is performed, led to a selective oxidation of the N-terminal serine governed by the 
high reactivity of the 2-amino alcohol to periodate treatment.[12, 17] The chosen 
conditions led to a ~70% conversion to the A14 modified-protein (Figure 4F).  
SDS-PAGE and Western blot analysis of tPA constructs 
Two variants of the α2-AP N-terminal peptide (A14) were prepared: a peptide 
containing the native α2-AP motif and a Q3A mutant representing a glutamine to 
alanine replacement, the latter becoming nearly unreactive in the FXIIIa-catalyzed 
fibrin crosslinking reaction. This resulted in 2 chimeric protein constructs to be used 
for biological studies, one with a native A14 sequence (A14-tPA) and the other with 
the Q3A mutation (nA14-tPA), which was used as a negative control. The covalent 
linkage of A14 to tPA was confirmed by SDS-PAGE and Western blot analysis (Figure 5).  
 
Scheme 2: Schematic representation of A14 peptide modified with an aminooxy group for 
oxime ligation (green) and a biotin moiety for detection. The active glutamine residue involved 
in FXIIIa-mediated coupling to fibrin is highlighted in red. 
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Figure 5: SDS-PAGE and Western blot analysis of tPA constructs, a: SDS-PAGE analysis of tPA 
and chimera proteins in reducing and non-reducing conditions (CBB staining).  b: Western blot 
analysis of SDS-PAGE from Panel A using streptavidin-HRP detecting exclusively chimera 
proteins that contain a biotinylated A14 moiety. 
The SDS-PAGE gel and Western blot show both non-reduced (lane 3 to 5) and reduced 
(lane 7 to 9) tPA constructs. Unmodified tPA (lane 3 and 7) shows a band around the 
expected mass of 67 kDa and a band corresponding to dimerized tPA around 130 kDa. 
When reduced, the dimer is no longer detected and a band around 30 kDa becomes 
apparent corresponding to the two-chain variant of tPA, which is also observed for the 
A14 modified constructs (lane 8 and 9). Western blot analysis of these samples with 
streptavidin-HRP detected the A14 modified constructs only, since these contain a 
biotin. A14 coupling to tPA is confirmed as both A14-tPA and nA14-tPA (lanes 4, 5 and 
8, 9) are detected and show bands around 130 kDa for the tPA-dimer, around 67 kDa 
for the monomer and two bands around 30 kDa for the two-chain variant of tPA. The 
double band pattern at 30 kDa is caused by heterogeneous glycosylation of tPA which 
results in two variants of the detected N-terminal fragment. 
A14-tPA fibrin cross-linking 
We determined the ability of A14-tPA to be covalently crosslinked to fibrin by FXIIIa. 
A14-tPA was incubated with fibrinogen, thrombin and FXIII during which thrombin 
cleaves fibrinopeptides A and B off fibrinogen to initiate fibrin formation. 
Simultaneously FXIII is activated, after which a fibrin D domain is crosslinked with one 
E domain and A14-tPA is covalently attached to lysine-303 on the Aα chain of fibrin. 
[19, 20] By taking advantage of the biotin tag present on A14- and nA14-tPA we could 
visualize the covalent linkage between tPA and fibrin (Figure 6). The SDS-PAGE gel 
shows the fibrinogen α, ß and γ chains (lane 2), which after fibrin formation result in 
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α-α and γ-γ crosslinks (lane 4, 6).[21]  Western blot analysis once again detects A14-
tPA (lane 3) and nA14-tPA (lane 5), but also shows covalent crosslinking of A14-tPA to 
the Aα-chain of fibrin resulting in a main band around 130 kDa and higher molecular 
weight aggregates (lane 4). Efficient crosslinking of A14-tPA to fibrin was thus 
observed, resulting in a high molecular weight product, whereas nA14-tPA shows no 
covalent attachment to fibrin (lane 6).  
 
Figure 6: SDS-PAGE and Western blot analysis of tPA crosslinking to fibrin a: SDS-PAGE gel 
analysis of cross-linking of A14-tPA to fibrin. b: Western blot analysis using streptavidin-HRP 
showing covalent attachment of A14-tPA to fibrin. 
A14-tPA plasma clot lysis 
The activity of the chimera tPA proteins was evaluated using multiple in vitro clot lysis 
assays. First, the activity of tPA and tPA chimeras was measured using a tPA specific 
chromogenic substrate. Activities of the different tPA preparations were normalized 
on basis of their activities in order to perform subsequent assays with comparable 
activities. Compared to freshly reconstituted tPA; chimeric tPA activities varied 
between 105-150% (data not shown). 
Subsequently, the lysis time of a plasma clot in the presence of increasing 
concentrations of tPA was determined in an in vitro plasma clot lysis assay.[22] Plasma 
clot formation was performed in presence of tPA; the turbidity of the mixture at 405 
nm was taken as a measure for clot density. In this assay both clot formation and 
fibrinolysis are monitored, after which the half-life of clot lysis time was determined 
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and plotted against plasminogen activator concentration (Figure 7A). When 
comparing tPA to the 2 chimeric proteins, no differences in clot lysis time were 
observed. However, the experimental setting under static conditions allowed all tPA 
variants to remain in the well, unaffected by physiological blood flow conditions. 
Therefore, in order to mimic fibrinolysis under more physiological conditions, we used 
a microfluidic flow assay. In this assay a clot is formed by flowing recalcified citrated 
whole blood to which fluorescent fibrinogen was added over a collagen surface, which 
contains a microspot of tissue factor (TF) to trigger coagulation. In the beginning 
platelets will adhere to the surface, which will gradually form more stable aggregates 
after which they are surrounded by a fibrin mesh (Figure 7B). Subsequently, the 
formed fibrin mesh is broken down by switching to a buffer containing tPA 
variants.[23] The degradation of the fibrin mesh is monitored and is a direct 
measurement for the activity of the tPA constructs (Figure 7C). Results show a dose 
dependent decrease in clot lysis time with increasing tPA concentration, but no 
difference is observed when comparing the different constructs. 
 
Figure 7: The effect of tPA chimeras on plasma clot lysis assays. a: plasma clot lysis under static 
conditions. b: Representative images of clot lysis under flow followed over time. Fluorescent 
signal of fibrin and platelets are monitored. c: Real time monitoring of fibrinolysis by tPA 
chimeras compared to tPA. Degradation of fluorescent fibrin over time, with varying indicated 
concentrations of plasminogen activator added.  
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Discussion 
We were able to site-selectively modify tPA via oxidation of the N-terminal serine 
residue followed by oxime ligation with an aminooxy modified α2-AP N-terminal 
peptide, named A14. We could show a single modification was present in a complex 
protein molecule. Selective labeling of the N-terminus of tPA was obtained by a slight 
under oxidation (70%) of the N-terminal serine followed by reaction with an excess of 
A14 peptide. A14-modified tPA effectively cross-linked to fibrin, in contrast to the 
negative control nA14-tPA, in which the crucial glutamine-3 residue was replaced by 
alanine. In spite of the selective cross-linking activity, both the static and the flow 
plasma clot lysis assays did not show an enhanced fibrinolytic activity of the A14-tPA 
compared to native tPA.  
An explanation for the observed results would be that the introduced A14 moiety is 
unstable. The covalent attachment of A14 to tPA was first shown by MALDI-TOF mass 
spectrometry (Figure 4) and confirmed with SDS-PAGE and Western blot analysis by 
making use of the biotin tag present in A14 (Figure 5). Furthermore, no evidence was 
observed for loss of the A14 moiety, since low molecular weight fragments were not 
detected on SDS PAGE analysis.  
Since the A14 moiety behaves as predicted, an explanation may be found in the tPA 
part of the chimera protein. Covalent crosslinking of tPA to fibrin might sterically 
hinder tPA function. For example, the inside of the blood clot might be less accessible 
for A14-tPA because it is retained at the periphery of the clot. This should, however, 
lead to clear observed differences between A14-tPA and nA14-tPA, which are not 
apparent from either of the plasma clot lysis assays. It remains unclear though if 
multiple effects cancel each other out. Under flow conditions, non-bound 
plasminogen activator will be washed away. Covalent crosslinking of tPA to fibrin will 
lead to increased concentrations at the site of the fibrin clot. If steric hindrance, 
however, leads to a decreased efficiency of plasminogen to plasmin conversion the 
net effect will be less obvious. This decreased efficiency of conversion can be 
explained by enhanced plasminogen activation by tPA when it is bound to fibrin. It 
was found that a ternary complex is formed when tPA binds to fibrin followed by 
addition of plasminogen, which leads to strongly promoted plasminogen 
activation.[24] The tPA binding sites on fibrin are identified to be Aα148-160 and 
γ312-324, where the latter is an exclusive binding site for tPA.[25-27] However, the 
crosslinking site of A14 to fibrin is identified to be Aα303 lysine, which, although 
crystal structures are inclusive about this region, is probably located far from the tPA 
binding site.[19, 20] Covalent crosslinking of tPA to fibrin Aα303 would thus lead to 
tPA being unable to bind to its natural binding site. 
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In conclusion, we have shown that tPA can be selectively modified using an 
oxidation/oxime linking strategy leading to an efficient cross linking of A14-tPA to a 
fibrin clot. The linker length used in this study may have constrained the enzyme away 
from its natural binding site, leading to a lower efficiency of plasminogen conversion. 
However, fibrinolytic activity was unchanged when compared to unmodified tPA. It 
remains to be investigated if chimeric proteins in which A14 is linked to tPA by a 
longer linker will lead to an enhancement of fibrinolytic function. 
  
Crosslinking tPA to fibrin 
 
168 
 
References 
1. Collen, D. and H.R. Lijnen, The tissue-type plasminogen activator story. Arterioscler 
Thromb Vasc Biol, 2009. 29(8): 1151-1155. 
2. Collen, D. and H.R. Lijnen, Thrombolytic agents. Thromb Haemost, 2005. 93(4): 627-
630. 
3. Astrup, T. and P.M. Permin, Fibrinolysis in the animal organism. Nature, 1947. 
159(4046): 681. 
4. DeMers, G., W.J. Meurer, R. Shih, S. Rosenbaum, and G.M. Vilke, Tissue Plasminogen 
Activator and Stroke: Review of the Literature for the Clinician. The Journal of 
Emergency Medicine, 2012. 43(6): 1149-1154. 
5. Holmes, W.E., D. Pennica, M. Blaber, M.W. Rey, W.A. Guenzler, G.J. Steffens, and H.L. 
Heyneker, Cloning and Expression of the Gene for Pro-urokinase in Escherichia coli. 
Nat Biotech, 1985. 3(10): 923-929. 
6. Pennica, D., W.E. Holmes, W.J. Kohr, R.N. Harkins, G.A. Vehar, C.A. Ward, W.F. 
Bennett, E. Yelverton, P.H. Seeburg, H.L. Heyneker, D.V. Goeddel, and D. Collen, 
Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. 
Nature, 1983. 301(5897): 214-221. 
7. Tow, D.E., H.N. Wagner, R.A. Holmes, K.S. Harrison, U. Scheffel, J.K. Langan, and R. 
Longo, Urokinase in Pulmonary Embolism. New England Journal of Medicine, 1967. 
277(22): 1161-1167. 
8. Kwiatkowski, T.G., R.B. Libman, M. Frankel, B.C. Tilley, L.B. Morgenstern, M. Lu, J.P. 
Broderick, C.A. Lewandowski, J.R. Marler, S.R. Levine, and T. Brott, Effects of Tissue 
Plasminogen Activator for Acute Ischemic Stroke at One Year. New England Journal of 
Medicine, 1999. 340(23): 1781-1787. 
9. Wiman, B. and D. Collen, Purification and characterization of human antiplasmin, the 
fast-acting plasmin inhibitor in plasma. Eur J Biochem, 1977. 78(1): 19-26. 
10. Miserus, R.J., M.V. Herias, L. Prinzen, M.B. Lobbes, R.J. Van Suylen, A. Dirksen, T.M. 
Hackeng, J.W. Heemskerk, J.M. van Engelshoven, M.J. Daemen, M.A. van Zandvoort, S. 
Heeneman, and M.E. Kooi, Molecular MRI of early thrombus formation using a 
bimodal alpha2-antiplasmin-based contrast agent. JACC Cardiovasc Imaging, 2009. 
2(8): 987-996. 
11. Lijnen, H.R., J.M. Stassen, H.J. Rapold, H. Nakamura, Y. Kobayashi, and D. Collen, 
Biochemical and Biological Properties of a Recombinant Chimera Consisting of Amino-
Acids Asn-1 to Lys-12 of Alpha-2-Antiplasmin (Fibrin Cross-Linking Site) and Amino-
Acids Leu-4 to Leu-411 of Single Chain Urokinase-Type Plasminogen-Activator. 
Fibrinolysis, 1992. 6(2): 87-98. 
12. Dixon, H.B.F., N-terminal modification of proteins—a review. J Protein Chem, 1984. 
3(1): 99-108. 
13. Geoghegan, K.F. and J.G. Stroh, Site-Directed Conjugation of Nonpeptide Groups to 
Peptides and Proteins Via Periodate-Oxidation of a 2-Amino Alcohol - Application to 
Modification at N-Terminal Serine. Bioconjugate Chem, 1992. 3(2): 138-146. 
14. Canne, L.E., A.R. Ferre- D'Amare, S.K. Burley, and S.B.H. Kent, Total Chemical Synthesis 
of a Unique Transcription Factor-Related Protein: cMyc-Max. Journal of the American 
Chemical Society, 1995. 117(11): 2998-3007. 
15. Wu, S.-L., H. Jiang, W.S. Hancock, and B.L. Karger, Identification of the Unpaired 
Cysteine Status and Complete Mapping of the 17 Disulfides of Recombinant Tissue 
Plasminogen Activator Using LC−MS with Electron Transfer DissociaƟon/Collision 
Induced Dissociation. Analytical Chemistry, 2010. 82(12): 5296-5303. 
Crosslinking tPA to fibrin 
 
169 
 
7 
16. Molony, M.S., S.-L. Wu, L.K. Keyt, and R.J. Harris, The unexpected presence of 
hydroxylysine in non-collagenous proteins, in Techniques in Protein Chemistry, W.C. 
John, Editor 1995, Academic Press. p. 91-98. 
17. Gaertner, H.F., K. Rose, R. Cotton, D. Timms, R. Camble, and R.E. Offord, Construction 
of protein analogues by site-specific condensation of unprotected fragments. 
Bioconjugate Chem, 1992. 3(3): 262-268. 
18. Mort, A.J. and D.T.A. Lamport, Anhydrous hydrogen fluoride deglycosylates 
glycoproteins. Analytical Biochemistry, 1977. 82(2): 289-309. 
19. Kimura, S. and N. Aoki, Cross-linking site in fibrinogen for alpha 2-plasmin inhibitor. J 
Biol Chem, 1986. 261(33): 15591-15595. 
20. Tamaki, T. and N. Aoki, Cross-linking of alpha 2-plasmin inhibitor and fibronectin to 
fibrin by fibrin-stabilizing factor. Biochim Biophys Acta, 1981. 661(2): 280-286. 
21. Ariens, R.A., H. Philippou, C. Nagaswami, J.W. Weisel, D.A. Lane, and P.J. Grant, The 
factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and 
affects cross-linked fibrin structure. Blood, 2000. 96(3): 988-995. 
22. Mutch, N.J., L. Thomas, N.R. Moore, K.M. Lisiak, and N.A. Booth, TAFIa, PAI-1 and α2-
antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots. 
Journal of Thrombosis and Haemostasis, 2007. 5(4): 812-817. 
23. Whyte, C.S., F. Swieringa, T.G. Mastenbroek, A.S. Lionikiene, M.D. Lance, P.E. van der 
Meijden, J.W. Heemskerk, and N.J. Mutch, Plasminogen associates with 
phosphatidylserine-exposing platelets and contributes to thrombus lysis under flow. 
Blood, 2015. 125(16): 2568-2578. 
24. Hoylaerts, M., D.C. Rijken, H.R. Lijnen, and D. Collen, Kinetics of the activation of 
plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem, 1982. 
257(6): 2912-2919. 
25. Schielen, W.J., H.P. Adams, K. van Leuven, M. Voskuilen, G.I. Tesser, and W. 
Nieuwenhuizen, The sequence gamma-(312-324) is a fibrin-specific epitope. Blood, 
1991. 77(10): 2169-2173. 
26. Schielen, W.J., H.P. Adams, M. Voskuilen, G.I. Tesser, and W. Nieuwenhuizen, The 
sequence A alpha-(154-159) of fibrinogen is capable of accelerating the t-PA catalysed 
activation of plasminogen. Blood Coagul Fibrinolysis, 1991. 2(3): 465-470. 
27. Yonekawa, O., M. Voskuilen, and W. Nieuwenhuizen, Localization in the fibrinogen 
gamma-chain of a new site that is involved in the acceleration of the tissue-type 
plasminogen activator-catalysed activation of plasminogen. Biochem J, 1992. 283 ( Pt 
1): 187-191. 
 
  
Crosslinking tPA to fibrin 
 
170 
 
Supporting Information 
Reagents. 2-(6-Chloro-1H-Benzotriazol-1-yl)-1,1,3,3-tetramethylaminium 
hexafluorophosphate (HCTU) and Boc-Trp(Hoc)-OH were obtained from Peptides 
International. Boc-Leu-OH, Boc-Phe-OH, Boc-Asp(OcHx)-OH, Boc-Ser(Bzl)-OH, Boc-Pro-
OH, Boc-Gly-OH, Boc-Tyr(BrZ)-OH, Boc-Cys(4-MeBzl)-OH, Boc-Glu(OcHx)-OH, Boc-
Lys(Fmoc)-OH, Boc-Val-OH and Boc-Ala-OH were obtained from Nova Biochem. Boc-
Lys(ClZ)-OH, Boc-Asn(Xan)-OH, Boc-His(Dnp)-OH, Boc-Arg(Tos)-OH.EtOAc were 
purchased from Midwest Bio-tech Inc. Boc-Gln(Xan)-OH, Boc-Thr(Bzl)-OH and Boc-
Lys(Boc)-OH.DCHA were obtained from Bachem. The 0.63 meq/g MBHA-polystyrene 
resin was obtained from ChemPep Inc. N,N-Diisopropylethylamine (DIPEA), N,N-
dimethylformamide (DMF), dichloromethane, diethylether and acetonitrile were 
purchased from Biosolve. Methanol, Boc-β-Ala-OH, and hydrogen fluoride were from 
Fluka. α-cyano-4-hydroxycinnamic acid, and p-cresol were from Sigma-Aldrich. 
Anhydrous acetic acid and ethylenedinitrilotetraacetic acid disodium salt dihydrate 
(EDTA) were obtained from Merck and trifluoroacetic acid (TFA) from Halocarbon 
Biograde. All solvents were analytical grade (p.a.) and were used as received. 
HPLC Analysis and Purification. Analytical HPLC was performed using a Vydac C18 
HPLC column (4.6 mm x 150 mm, 1 mL/min flow rate) connected to a Varian Prostar 
system consisting of two Varian Prostar 215 delivery modules and a Varian Prostar 
320 UV/Vis detector (λ = 214 nm). A linear gradient of 0-67 % buffer B in buffer A over 
30 minutes was used, where buffer A = 0.1 v-% TFA in H2O and buffer B = 0.1 v-% TFA, 
10 v-% H2O in CH3CN. 
Semi-preparative HPLC was performed using Vydac C18/C4 HPLC columns (10 mm x 
250 mm, 5 mL/min flow rate or 22 mm x 250 mm, 10 mL/min flow rate) connected to 
a Waters Deltaprep System consisting of a Waters Prep LC Controller and a Waters 
2487 Dual wavelength Absorbance Detector (λ = 214 nm). Peptides were eluted using 
a shallow gradient of B in A, based on an exploratory analytical HPLC run (vide supra). 
Product containing fractions were analyzed by Electrospray Ionization Mass 
Spectrometry (ESI-MS) (vide infra), pooled, and lyophilized. 
Electrospray Mass Spectrometry. ESI-MS was performed on an Applied Biosystems 
SCIEX API 150 EX electrospray ionization quadrupole (ESI-Q) mass spectrometer. 
Peptide masses were calculated from the experimental mass to charge (m/z) ratios of 
all the protonation states observed in the ESI-MS spectrum of a peptide using Analyst 
1.4.2 software (Sciex). 
MALDI Mass Spectrometry. MALDI-MS was performed on an Applied Biosystems 
4800 MALDI TOF/TOF analyzer. Samples were prepared in CH3CN (45 v-%) in H2O + 
0.1 % TFA and mixed with α-Cyano-4-hydroxycinnamic acid (CHCA) (1:1) as matrix. 
Reflective positive mode was used to measure samples with an expected mass 
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between 1000 and 5000 Da, linear high mass mode was used to measure samples 
with an expected mass above 20000 Da.   
Synthesis of  biotinylated A14 peptides. Ac-Gly-Asn-Gln-Glu-Gln-Val-Ser-Pro-Leu-Thr-
Leu-Leu-Lys(aminooxyacetyl)-Lys(Gly-Gly-Gly-biotin)-NH2 
Following the general peptide solid phase methods described above, Fmoc-Lys(Boc)-
OH was coupled to MBHA resin (0.6 mmol). After deprotection of the lysyl-Nε-Boc 
group, three glycine residues were introduced following standard SPPS methods. After 
removal of the Glycine-Nα-Boc group, biotin was attached by reacting the resin bound 
peptide with 2.2 mmol of biotin, 1.0 mL of DIPEA and 2.0 mmol of HCTU in DMF (4.0 
mL). This step was repeated once. The resin-bound Fmoc-Lys(Gly-Gly-Gly-biotin)-
MBHA (0.3 mmol) was Nα-Fmoc deprotected (4x3 min treatment with 20% piperidine 
in DMF) and used for the synthesis of Boc-Glu(OcHx)-Gln-Val-Ser-Pro-Leu-Thr(OBzl)-
Leu-Leu-Lys(aminooxyacetyl)-Lys(Gly-Gly-Gly-biotin)-MBHA. 2/3 of this product was N-
terminally extended, acetylated, coupled with Boc-aminooxyacetic acid, subjected to 
HF acidolysis and purified, resulting in 2.1 mg (1.0 µmol) of Ac-Gly-Asn-Gln-Glu-Gln-
Val-Ser-Pro-Leu-Thr-Leu-Leu-Lys(aminooxyacetyl)-Lys(Gly-Gly-Gly-biotin)-NH2. ESI-MS 
showed a mass of 2066.24 ± 1.21, fitting well between the calculated monoisotopic 
mass (2065.06) and the average mass (2066.34). 
The remaining 1/3 of Boc-Glu(OcHx)-Gln-Val-Ser-Pro-Leu-Thr(OBzl)-Leu-Leu-
Lys(aminooxyacetyl)-Lys(Gly-Gly-Gly-biotin)-MBHA was N-terminally extended, 
acetylated, coupled with Boc-aminooxyacetic acid, subjected to HF acidolysis and 
purified, resulting in 1.2 mg (1.0 µmol) of Ac-Gly-Asn-Ala-Glu-Gln-Val-Ser-Pro-Leu-Thr-
Leu-Leu-Lys(aminooxyacetyl)-Lys(Gly-Gly-Gly-biotin)-NH2. ESI-MS showed a mass of 
2008.99 ± 1.42, fitting well between the calculated monoisotopic mass (2008.04) and 
the average mass (2009.29). 
N-terminal serine oxidation of tPA. Full length recombinant tPA (Actilyse) (15 μM, 1.0 
equiv.) was dissolved in 0.5 M arginine phosphate buffer (pH 7.3) containing 1.5 mM 
L-methionine (100 equiv.) and 0.01% polysorbate-80. NaIO4 (20 μM, 1.35 equiv.) was 
added and left to react for 30 min at 0 °C after which the reaction was quenched with 
glycerol (75 μM, 5 equiv.). The resulting product was purified using a Sephadex G-50 
size exclusion column eluting with 0.1 M CH3COOH. 
Glyoxylyl-tPA oxime ligation with A14. Glyoxylyl-t-PA (150 μM, 1 equiv.) was 
dissolved in 0.4 M arginine acetate buffer (pH 4.0) and reacted with A14 (750 μM, 5 
equiv.) for 24h at RT. The resulting product was purified using a Sephadex G-50 size 
exclusion column eluted with 0.5 M arginine phosphate buffer (pH 7.2) containing 
0.01% tween-80 
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Short trypsin digestion of tPA. tPA (13 µM) was dissolved in 0.1 M Tris.HCl buffer (pH 
8) containing 0.8 mM DTT, 0.74 mM CaCl2 and 0.9 M Gn.HCl. 1.6 µM bovine TPCK-
trypsin was added. A sample was taken within seconds after addition of trypsin.  
Deglycosylation of tPA using anhydrous HF. To 200 µg of lyophilized tPA, 10 mL of 
anhydrous HF was added. The mixture was left to react for 1h at 0 °C without stirring. 
After reaction, the HF was slowly evaporated; the protein was dissolved in 300 µL 
CH3CN (45 v-%) in H2O + 0.1 % TFA and analyzed using MALDI mass spectrometry. 
tPA activity via chromogenic substrate. Activity of the different tPA constructs was 
evaluated using chromogenic substrate S2288 (Chromogenix) or T2943 (Sigma). To 
each well of a 96 well plate 25 µL S2288, 125 µL tPA (0.5-5 nM) and 100 µL buffer (50 
mM Tris pH 7.9, 175 mM NaCl, 20 mM EDTA, 0.5 mg/mL ovalbumin) was added. 
Substrate conversion was followed over time. The construct with the highest activity 
was set to 100%, concentration of the other constructs was adjusted to the same level 
of activity accordingly. 
FXIIIa mediated crosslinking of A14-tPA to fibrin. Lyophilized human fibrinogen was 
obtained from Kordia (Stago). Before use it was resuspended in water, and 
subsequently dialyzed against Hepes-buffered saline (25 mM Hepes, 175 mM NaCl, pH 
7.7 at room temperature) and quantified spectrophotometrically. Fibrinogen (6.1 µM) 
was incubated with hFXIII-A2 (0.1 µM, Zedira), thrombin (40 nM, ) and A14-tPA (500 
nM) in buffer (10 mM CaCl2, 50 mM Tris, 150 mM NaCl, pH 7.4). Formed fibrin clots (2 
minute incubation) were dissolved in SDS sample buffer (40 mM Tris, 3.33% SDS, 6.25% 
ß-mercaptoethanol, 50% glycerol, pH 6.7). Samples were analyzed on gel and with 
western blot. Western blot analysis was performed using streptavidin-HRP. 
Plasma clot lysis. To each well of a 96 well plate 20 µL CaCl2 (53 mM in H2O) was 
added. A dilution series of tPA (5 µL, final concentrations 791 pM -158 pM) in buffer 
(45 µL) (10mM Tris-HCl, 0.01% tween-20 pH 7.5) was added to plasma (30 µL) which 
was subsequently added to CaCl2 mix to reach a final volume of 100 µL (20 µL + 80 µL). 
The mixtures were briefly mixed and placed in a plate reader. Absorbance was 
measured every minute at 630 nm and 405 nm at 37 °C. 
Fibrinolysis under flow. Thrombus formation and fibrinolysis under flow were 
performed as previously described. [23] Basically, recalcified citrate-anticoagulated 
whole blood was perfused over a collagen/tissue factor coated surface and following 
thrombus formation fibrin lysis was monitored by as the disappearance of 
fluorescently labeled fibrin(ogen). Quantification of this process was performed using 
FIJI (open source). 
 
  
 
 
 
 
 
 
Chapter 8 
Discussion 
  
Discussion 
 
174 
 
Site-selective modification in proteins and peptides remains a difficult task, and the 
complexity with the high number of functional groups has led to a wide range of 
methods all with their respective advantages and drawbacks. Highly selective 
reactions have been developed that can be employed with completely unprotected 
proteins, such as the widely used copper catalyzed click reaction (CuAAC) or 
derivatives thereof.[1, 2] The reactive moieties required (azide, alkyne) are, however, 
not easily introduced in a protein and often require multiple steps or an unspecific 
labelling step to thiols or amines. An alternative orthogonal approach is found in the 
reaction between a ketone or aldehyde with an aminooxy to form an oxime. In 
contrast to the azide or alkyne required for CuAAC, a ketone can be introduced in a 
protein using a variety of methods most of which are site-selective and do not require 
protecting group chemistry (Chapter 2). While this is an obvious advantage, the oxime 
is often overlooked because the reaction is known to be a slow reaction. 
Improvements in oxime ligation reaction rates have been achieved through the 
introduction of nucleophilic catalysis by aniline and derivatives (Chapter 2), but little 
research was performed regarding the reactive moieties.  
We found that a widely used keto acid, levulinic acid, was not suitable for introduction 
of a ketone moiety in proteins when subsequent oxime ligation was required. When 
coupled to an amine the levulinoyl moiety is prone to an intramolecular cyclization 
reaction that leads to a pyrrolidone ring which is unable to react with an aminooxy to 
an oxime (Chapter 3). Although levulinic acid has been used extensively, this 
cyclization reaction has gone largely unnoticed. We believe the main reason for this 
are the high concentrations of the two reactants used in previous studies, which led to 
acceptable oxime yields and minor side product formation. However, when the same 
reaction is performed at lower concentrations, typically with protein modifications, 
intramolecular cyclization will appear more predominantly, as it is independent of the 
concentration used.. We investigated alternative keto acids to replace levulinic acid 
and found that none of the alternatives show an intramolecular cyclization reaction 
(Chapter 3). However, a difference was observed when using aromatic ketones as 
opposed to aliphatic ketones. The aromatic ketone reacted 5-fold slower than the 
aliphatic ketones, most likely because the reactive carbocation is stabilized in this case. 
The use of alternative ketones drastically increased reaction yields, but the reaction 
still required nucleophilic catalysis by aniline to reach acceptable reaction rates.  
While studying oxime formation we encountered an interesting chance finding. An 
instrument failure led to a delay in measurement of the first time point in an oxime 
reaction that was expected to reach completion within 10 hours. In an attempt to 
save this measurement, the sample was frozen with the idea that this would slow 
down the reaction. Surprisingly, the oxime reaction was near completion after 1 hour 
at -20 °C. We followed up upon this phenomenon and found that slow freezing greatly 
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catalyzes oxime formation, especially at neutral pH (Chapter 4). More specifically, we 
found the freezing process to be vital, since a similar reaction mixture that contained 
methanol, and thus did not freeze, saw no rate enhancement when reacted at -20 °C. 
In addition, the freezing rate proved to be an important factor. Increasing the freezing 
rate by lowering the temperature to -80 °C or -196 °C did not result in catalysis of 
oxime formation. We believe that slow freezing, by expelling reactants from growing 
ice crystals, leads to a large concentrations in the remaining liquid phase, which will 
lead to a faster than expected oxime formation. In contrast, increasing freezing rates 
will either snap freeze the status quo of reaction concentrations, or allow a shorter 
time for oxime formation in the liquid state before the reaction mixture is fully frozen, 
explaining why no rate increase is observed. At this point it remains unclear if catalysis 
by freezing can be employed to increase the reaction rates of other chemical reactions. 
Similar effects have been earlier, mainly in relation to the food industry although 
some studies have found other reactions to proceed faster in frozen aqueous 
solutions.[3] We hypothesize that other reactions, especially those performed in 
water, can be catalyzed by slow freezing of the reaction mixture. However, a real 
benefit will only be obtained with reactions known to occur with a low reaction rate. 
Freeze “catalysis” has some advantages over nucleophilic catalysis with aniline. With 
freezing no purification steps after ligation are required and the detrimental effects of 
aniline on some proteins can be avoided. Notably, freeze catalysis is not suitable for 
every purpose; some proteins do not tolerate repeated freezing. 
While we managed to improve oxime yields and reaction rates, some aspects of the 
oxime have remained underexposed in this thesis. We have focused mainly on the use 
of ketones, despite the fact that aldehydes react much faster, most likely due to 
decreased steric hindrance. This was a deliberate choice, since ketoximes are more 
stable compared to aldoximes and the intended applications required stable 
constructs. Furthermore, optimization of the aminooxy group required for oxime 
formation was not performed while its current use certainly has some drawbacks. The 
aminooxy group is highly reactive which leads to potential by-product formation that 
can occur during oxime formation.[4] Most of these by-products arise from reactions 
of the aminooxy moiety with carbonyls present in solvents, such as formaldehyde, 
acetaldehyde or acetone. In our studies we have observed these side reactions, but 
were unable to completely abolish them. Minute formaldehyde contaminations 
proved to be very difficult to avoid, and were the major cause of incomplete oxime 
reactions. In addition, a major side-product observed in our studies was the 
degradation of the α-aminooxy group into the corresponding unreactive alcohol. In 
some cases it was possible to separate the desired compound from the alcohol, but 
this side-reaction also occurred during oxime ligation and therefore led to incomplete 
oxime reactions. In future studies these problems should be tackled to achieve higher 
yields. Degradation of the aminooxy to the alcohol is likely caused by acidic hydrolysis 
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and can therefore occur during TFA treatment with peptide synthesis, during HF 
cleavage or during HPLC purification with solvents containing TFA. Fmoc-based 
peptide synthesis could potentially avoid multiple TFA- and HF-treatments and would 
thus be a viable alternative. Hydrolysis during HPLC purification may be avoided by 
choosing an alternative additive to the mobile phase, i.e. triethylamine instead of TFA.  
To apply our oxime formation optimization to a more translational setting, we 
synthesized a covalent heterodimer of 2 chemokines involved in atherosclerosis, 
namely RANTES and PF4 (Chapter 5). Many processes in inflammatory diseases are 
governed by small chemotactic cytokines named chemokines. These small proteins 
have become interesting pharmaceutical targets accordingly. Previous research has 
shown that chemokines RANTES and PF4 play a pivotal role in the initiation and 
progression of atherosclerosis through formation of heterodimers. With the synthesis 
of a covalent heterodimer, we have shown that physical formation of a heterodimer is 
responsible for initiation and progression of atherosclerosis, as opposed to combined 
receptor stimulation of the separate chemokines that could explain previous 
observations. Moreover, while performing oxime ligations of RANTES to PF4, we 
observed a stimulatory effect of the native protein-protein interaction between 
RANTES and PF4, on the rate of oxime formation, confirming the affinity these 
chemokines have for each other.  
Subsequently, the full spectrum of chemokine interactions was investigated, and 
chemical protein synthesis and oxime ligation were applied to synthesize a different 
covalent heterodimer as well as peptide inhibitors of chemokine interactions (Chapter 
6). New protocols developed in previous chapters were applied; the ketone 
functionality was introduced using one of the alternative keto acids and oxime 
ligations were frozen to accelerate the reaction. Although all protein and peptide 
targets were synthesized successfully, the overall yields of chemical protein synthesis 
were typically low. This was mainly due to the need of multiple purification steps, 
which were required after every ligation step and oxidative folding of the chemokines. 
This approach is therefore not suitable for large scale production of these target 
molecules. Preliminary studies have started to investigate if a semi-synthetic approach 
could improve yields in chemokine heterodimer synthesis.  
In the final chapter of this thesis such a semi-synthetic approach is used to synthesize 
an improved thrombolytic agent, tissue plasminogen activator (tPA), with a novel 
fibrin crosslinking functionality (Chapter 7). Recombinantly expressed tPA is used to 
treat patients suffering from ischemic stroke to break down pathological blood clots 
to regain blood circulation in the brain. We synthesized a hybrid protein consisting of 
a fibrin crosslinking tag derived from α2-antiplasmin (A14), which was covalently 
linked to the N-terminus of recombinantly expressed tPA using oxime ligation. We 
could show that A14 was covalently attached to tPA, but it remained difficult to assess 
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whether other sites prone to oxidation were affected by treatment with periodate. 
Furthermore, no enhancement of function was observed when the synthesized hybrid 
was compared to unmodified tPA. We believe this is mainly due to the crosslinking 
position on fibrin (Aα Lys-303), which is located far away from the natural binding site 
of tPA (γ312-324 and Aα148-160). The exact distance is difficult to estimate, because 
the C-terminal end of the Aα chain is not resolved in the crystal structure, but we 
estimate it to be approximately 100 Å. These results are currently being followed up 
with the synthesis of a hybrid protein that contains a long linker, which will allow 
crosslinking to fibrin but will not restrict tPA in binding to its natural position from 
which it can optimally degrade fibrin. 
Overall, we have made improvements to the use of the oxime ligation and have 
shown its utility in various protein and peptide targets. The improvements and 
applications in respect to oxime chemistry presented in this thesis and its publications 
might further boost the interest and use of oximation in chemical biology and 
translational chemistry.   
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The work in this thesis established novel approaches to site directed bioconjugation of 
chemically (semi-) synthesized proteins and their use in deciphering mechanisms and 
optimizing therapy in cardiovascular disease. In Chapter 1 of this thesis state of the art 
chemical protein synthesis and bioconjugation by oxime chemistry is explained and 
research objectives are set.  
In Chapter 2 methods for introducing ketone or aldehyde functionalities in peptides 
and proteins are reviewed. Modifications in proteins can be made site specifically 
using oxime chemistry, but the necessary ketones or aldehydes are normally not 
found in proteins. Introduction of this carbonyl moiety in a protein is therefore the 
first step towards oxime ligation. Several methods are highlighted where a distinction 
between 5 main methods is made. These include chemical treatment, enzymatic 
modification, genetic methods, glycan modification and chemical synthesis. In 
addition, the nucleophilic catalysis of aniline and its more recently developed 
derivatives are reviewed.  
Chapter 3 deals with the optimization of oxime formation in peptides and proteins. 
Levulinic acid was widely used to introduce a ketone functionality in biological 
molecules by reaction with a free amine present on lysine residues or the N-terminus 
of a protein. However, its use was frequently marked by low yields and slow reactions. 
We explained low yields by the formation of an intramolecular cyclic species of the 
levulinoyl moiety that is unable to react with an aminooxy to form an oxime. Aside 
from elucidation of this mechanism, we also proposed alternative keto-acids that do 
not exhibit this intramolecular cyclization and can thus be used to introduce stable 
ketone functionalities in proteins and peptides.  
Chapter 4 reports on an unexpected method of catalysis of oxime formation. It was 
found that slow freezing of the reaction mixture leads to a large increase in reaction 
rate. A model system was used to obtain more insight into the mechanism by which 
this is achieved; the reaction mixture was frozen at 3 different temperatures; -20 °C, -
80 °C. and -196 °C, which showed that slow freezing to -20 °C was a definite 
requirement. In comparison to aniline-catalyzed reactions, the most pronounced 
improvement by slow freezing was observed for reactions performed at neutral pH 
and low concentrations. Finally, the method was applied to the fluorescent labeling of 
a small protein.   
In Chapter 5 the optimization of ketone incorporation and improved oxime catalysis 
were employed to synthesize a covalent heterodimer of chemokines RANTES (CCL5) 
and PF4 (CXCL4). A combination of native chemical ligation (NCL) and oxime ligation 
was used to link two fully folded proteins. The heterodimer obtained by total chemical 
synthesis was subsequently evaluated structurally using NMR and biological activity 
was studied using a monocyte arrest assay. In addition, the natural affinity between 
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chemokines RANTES and PF4 was luminously illustrated by the observation that 
chemokine PPIs catalyze oxime ligation. We could show that synergistic enhancement 
of function of the chemokine combination was caused by physical formation of a 
heterodimer.  
Chapter 6 establishes the “Chemokine Interactome”, a functional interplay between 
different chemokines to modulate or modify function. This was investigated using 
immuno-ligand blotting and surface plasmon resonance. Two covalently linked 
chemokine pairs were synthesized by solid phase peptide chemistry, native chemical 
ligation, and oxime chemistry, and functionally and structurally characterized. 
Functional interactions involved in atherosclerosis were followed up upon in vitro by 
chemotactic and arrest assays and in vivo in different mouse models. Moreover, 
peptide inhibitors for chemokine heterodimerization were developed and evaluated. 
With this extensive study, insight is gained in the formation of functional chemokine 
heterodimers that can be exploited for therapeutic targeting.  
In Chapter 7 the oxime bond is used to modify recombinant tissue plasminogen 
activator (tPA), which is used as a thrombolytic agent to treat stroke, with a fibrin 
crosslinking sequence (A14) derived from α2-antiplasmin, aiming at an improved, 
more efficient thrombolytic agent. Current use of tPA often leads to bleeding 
complications, because of high required doses. Modification of tPA is achieved by a 
combination of oxidation of the N-terminal serine followed by oxime ligation with A14. 
Different A14-tPA constructs were evaluated in plasma clot lysis assays both in static 
conditions and under flow. We could show that modification of tPA could be achieved 
site specifically; an improvement in function was, however, not observed. In this 
ongoing project optimized constructs are currently being developed which may lead 
to a more efficient thrombolytic agent. 
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Het werk in dit proefschrift presenteert nieuwe methodes voor de plaats specifieke 
bioconjugatie van (semi-) gesynthetiseerde eiwitten. Hiermee kunnen hun 
werkingsmechanismes ontcijferd worden en therapieën gebruikt voor de behandeling 
van hart- en vaat ziekten geoptimaliseerd worden. In Hoofdstuk 1 van dit proefschrift 
worden chemische eiwit synthese en bioconjugatie met behulp van oxime chemie 
geïntroduceerd en de doelstellingen van het onderzoek bekend gemaakt. 
 In Hoofdstuk 2 worden methodes besproken die gebruikt kunnen worden voor de 
introductie van een keton of aldehyde in peptiden en eiwitten. Modificaties in 
eiwitten kunnen namelijk plaats specifiek gemaakt worden met behulp van oxime 
chemie, maar de benodigde ketonen en aldehyden komen van nature niet voor in 
eiwitten. Meerdere methodes worden besproken, waar een onderscheid tussen 5 
hoofd groepen wordt gemaakt. Deze omvatten chemische behandeling, enzymatische 
modificatie, genetische methodes, sacharide modificatie en chemische synthese. 
Verder wordt de nucleofiele katalyse van aniline en de meer recent ontwikkelde 
derivaten besproken. 
Hoofdstuk 3 behandelt de optimalisatie van oxime chemie in peptiden en eiwitten. 
Levulinezuur werd frequent gebruikt voor de introductie van een keton in biologische 
moleculen. Het ketozuur werd gereageerd met een vrije amine zoals die voorkomen 
op de zijketens van lysine of de N-terminus van een eiwit. Het gebruik hiervan leidde 
echter vaak tot lage opbrengsten en langzame reacties. Wij ontdekten dat dit 
verklaard kan worden door de formatie van een intramoleculair gevormde cyclische 
variant van levulinezuur, die niet meer in staat is te reageren met een aminooxy om 
een oxime te vormen. Naast het ontrafelen van dit reactiemechanisme, hebben we 
ook alternatieven onderzocht die deze cyclische variant niet vormen en dus gebruikt 
kunnen worden om stabiele ketonen in eiwitten en peptiden te introduceren. 
In Hoofdstuk 4 rapporteren we een onverwachte methode van katalyse van de oxime 
reactie. Langzaam bevriezen van het reactiemengsel bleek te zorgen voor een grote 
toename in reactiesnelheid. Vervolgens werd een model systeem gebruikt om meer 
inzicht te krijgen in het mechanisme van deze toename. Het reactiemengsel werd 
bevroren bij 3 verschillende temperaturen (-20 °C, -80 °C en -196 °C), waarbij bleek 
dat langzaam vriezen bij -20 °C een absoluut vereiste was. In vergelijking met aniline 
gekatalyseerde reacties, werd de grootste toename in reactiesnelheid gevonden bij 
neutrale pH en lage concentraties. Uiteindelijk werd de methode gebruikt voor het 
fluorescent labelen van een groter eiwit.  
In Hoofdstuk 5 werd de optimalisatie van het keton en de vernieuwde oxime katalyse 
toegepast voor de synthese van een covalente heterodimeer van de chemokines 
RANTES (CCL5) en PF4 (CXCL4). Een combinatie van natieve chemische ligatie (NCL) en 
oxime ligatie werd gebruikt om de volledig gevouwen eitwitten met elkaar te 
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verbinden. De structuur van de nieuw gevormde heterodimeer werd geëvalueerd met 
behulp van NMR en de biologsiche activiteit werd gemonitord met een monocyten 
arrest assay. Verder konden wij aantonen dat de affiniteit tussen de twee chemokines 
aanwezig is doordat de chemische ligatie versneld werd door eiwit-eiwit interacties. 
Uiteindelijk konden we aantonen dat de functieversterking van het chemokine paar 
wordt veroorzaakt door de fysieke formatie van een heterodimeer.  
In Hoofdstuk 6 wordt het “Chemokine Interactoom” geïntroduceerd, een functionele 
interactie tussen verschillende chemokines om hun functie te moduleren of 
modificeren. Het interactoom werd onderzocht met immuno-ligand blotting en 
surface plasmon resonance. Twee covalent gelinkte chemokine paren werden 
gesynthetiseerd met behulp van vaste fase peptide chemie, native chemische ligatie 
en oxime ligatie. Deze heterodimeren werden functioneel en structureel 
gekarakteriseerd. Functionele interacties die van belang zijn in atherosclerose werden 
verder opgevolgd in vitro met chemotactische en arrest assays en in vivo in 
verschillende muizen modellen. Verder werden peptide inhibitoren voor chemokine 
heterodimerisatie ontwikkeld en getest. Met deze uitgebreide studie is inzicht 
verkregen in de formatie van chemokine heterodimeren die gebruikt kan worden voor 
therapeutische toepassingen.  
In Hoofdstuk 7 wordt de oxime gebruikt voor de modificatie van recombinant tissue 
plasminogeen activator (rtPA), dat gebruikt wordt voor de trombolytische 
behandeling van hersenbloedingen, met een fibrine crosslinking sequentie (A14) 
afgeleid van α2-antiplasmine, gericht op een verbeterd, meer efficiënt trombolyticum. 
Het huidige gebruik van rtPA leidt vaak tot bloedingsneigingen als gevolg van de hoge 
gebruikte dosis. De modificatie van rtPA wordt bereikt door de oxidatie van de N-
terminale serine gevolgd door oxime ligatie met A14. Verschillende A14-tPA 
constructen werden getest in plasma clot lysis assays in zowel statische als flow 
condities. We konden aantonen de modificatie van rtPA plaats specifiek gedaan kon 
worden, een verbetering in functie werd echter niet waargenomen. In dit lopende 
project worden geoptimaliseerde constructen ontwikkeld die uiteindelijk moeten 
leiden tot een efficiënter trombolyticum. 
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Over the past few years an increasing interest is shown in valorization of research 
performed in an academic setting. Research should have a societal impact and a clear 
utilization. One of the definitions of valorization is: 
“The process of value-creation out of knowledge, by making this knowledge suitable 
and available for economic or societal utilization and to translate this into high-
potential products, services, processes and industrial activity.” 
This thesis describes the development of a chemical reaction (oximation) and the 
subsequent (cardiovascular) applications for which it can be used. While it is difficult 
at first to see a direct benefit to society of this fundamental research, the applications 
for which it has been used in later chapters already provide a hint towards potential 
products. 
The first chapters (1 and 2) of this thesis discuss the formation and catalysis of the 
oxime bond. This so-called oximation reaction has long been overlooked in the 
bioconjugation field, but has received increasing attention over the past few years. 
With this ever increasing interest, more knowledge is gained about the usefulness of 
this technique in for example the development of novel medicines. The oxime bond is 
formed by reaction of a ketone with an aminooxy; both of these functionalities are 
normally not present in a protein. We have shown that a frequently used keto-acid, 
levulinic acid, is not suitable for introduction of a ketone in proteins and leads to low 
yields when performing subsequent oxime ligations. Interestingly, the postulated 
demise of levulinic acid (Chapter 3) does not hold true for other fields of chemistry. 
Levulinic acid, a 5-carbon building block, is suggested to be useful for a range of 
applications and could potentially become the next big biobased chemical. This 
furthermore shows that although an application might not be immediately apparent, 
fundamental research is necessary to eventually find these applications.  
Optimization of the ketone involved in oxime ligation led to the accidental discovery 
of reaction rate acceleration by freezing. While we did not test this mechanism with 
other reactions in aqueous systems, we expect a similar result. Optimization of a 
chemical reaction reduces possible side reactions, increases yield and with that 
decreases cost and the environmental strain.    
After optimization of the oximation process, the focus changed to applying the 
acquired knowledge to important questions in cardiovascular research. 
Atherosclerosis is a major health problem and can lead to serious conditions such as 
myocardial infarction or stroke. Remarkably, a cause of the disease is not known, and 
current treatment is mostly based on lifestyle changes (i.e. reducing cholesterol levels) 
and surgical interventions in late stage disease. Our research focused on the initiation 
of atherosclerosis. In early stages of disease development leukocytes (predominantly 
monocytes) play an important role and are attracted to a site of inflammation where 
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they differentiate into macrophages. This process is governed by small chemotactic 
cytokines known as chemokines. More than 40 different chemokines exist in the 
human body, each with its own function and expression pattern. Recent research has 
shown that these chemokines do not act alone, interactions between chemokines 
occur to modulate their function. In the process of atherosclerosis an interaction 
between two chemokines (CCL5 and CXCL4) was hypothesized, because of an 
increased monocyte arrest when the 2 chemokines were mixed. It was unclear, 
however, if this effect was a result of the formation of a heterodimer or a result of 
combined receptor activation. With the synthesis of a covalent heterodimer we could 
show that the increased monocyte arrest can be attributed to the formation of a 
heterodimer of chemokines CCL5 and CXCL4. With the synthesis of this heterodimer 
we have synthesized a molecule that can induce a disease state, the exact opposite of 
what would be beneficial for the general society. However, this molecule has provided 
us with insights into its mechanism of action, which can subsequently be used for the 
development of inhibitors. This study was followed up by an extensive mapping of all 
possible chemokine interactions. Subsequently, interactions with an atherogenic 
effect where further investigated and eventually led to the development of inhibitors 
of these interactions. First results show that this approach can inhibit monocyte arrest 
in vitro and atherosclerosis in an in vivo mouse model, and thus may be a viable 
therapeutic approach to inhibit plaque formation in an early stage. In order to develop 
these inhibitors into approved pharmaceuticals more research is required, but a first 
step is taken. 
A different application of oximation was found in the modification of an existing drug. 
Tissue plasminogen activator (tPA) is currently being used to dissolve blood clots in 
stroke patients. The treatment is effective but often leads to bleeding complications 
as a result of the high required dose. We attempted to overcome this problem by 
modifying tPA to result in a molecule with a very high affinity for fibrin, which would 
decrease the required effective dose. We used an oxime bond to link a peptide that is 
covalently crosslinked to fibrin. Although current constructs show no improvement 
over unmodified tPA, we are confident that this approach will be beneficial when 
further improvements are made. Moreover, this method is useful for the modification 
of other (large) proteins currently being used as treatment for various diseases. 
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Na 200 pagina’s wetenschappelijk onderzoek zijn we dan uiteindelijk aangekomen bij 
het (voor sommigen) belangrijkste en meest gelezen deel van een proefschrift. Ik ga 
ervan uit dat een ieder die hier aan belandt is, zich ook door de rest van het 
proefschrift geworsteld heeft. Het is een cliché, maar het gepresenteerde werk is 
uiteraard niet door mij alleen uitgevoerd. In dit hoofdstuk wil ik graag iedereen 
bedanken die deel heeft uitgemaakt van het onderzoek.  
Allereerst mijn promotor, prof. dr. Tilman Hackeng. Beste Tilman, binnen enkele 
minuten van mijn sollicatiegesprek voelde ik me op mijn plaats op de afdeling 
biochemie. Het was voor mij dan ook geen moeilijke keuze om mijn PhD project 
binnen jouw groep uit te voeren. Ik heb genoten van de afgelopen 4 jaar die helemaal 
niet als “echt werk” aanvoelden en kan alleen maar hopen dat ik eenzelfde sfeer en 
werkomgeving ergens anders ook kan vinden. Jouw deur stond altijd open en ik ben er 
zeker van dat ik dit resultaat zonder jouw supervisie nooit had bereikt. Ook wil ik je 
speciaal bedanken voor het onmiddellijk betrekken van mij in het project in 
samenwerking met München, dat mij extreem gemotiveerd en veel geleerd heeft. 
Daarnaast mijn co-promotor, dr. Rory Koenen. Beste Rory, biochemie kan niet meer 
bestaan zonder biologische toepassingen. In mijn eerste project werd dit al meteen 
duidelijk, en jij hebt mij geïntroduceerd in de wondere wereld van cel cultuur en 
microscopie. Jouw enthousiasme om elk project aan te pakken zijn een inspiratie voor 
een ieder. 
Members of the assessmentcommittee; prof. dr. C.G. Schalkwijk, prof. dr. C. F. W. 
Becker, prof. dr. P. Timmerman en prof. dr. E.A.L. Biessen. I would like to thank you all 
for the time and attention spent for the assessment of my thesis. 
Dennis, vanaf mijn eerste dag op het lab was jij onmisbaar voor mij. Zonder jou was 
mijn eerste zuivering al compleet gefaald. We hebben samen meerdere congressen 
bezocht en natuurlijk een weekje pretparken in Orlando. Bedankt voor de geweldige 
samenwerking. 
Hans, bedankt voor het begrijpbaar en soms onbegrijpbaar maken van de NMR data in 
al mijn projecten.  
I would also like to thank my collaborators in the chemokine interactome project. Prof. 
dr. Christian Weber, dr. Philipp von Hundelshausen, prof. dr. Kevin Mayo and dr. Hans 
Ippel thank you for the fruitful collaboration and the nice visits to Munich and 
Maastricht. 
Mijn kamergenoten, sommige al een tijdje vertrokken anderen met wie ik bijna 4 jaar 
een kamer heb gedeeld; Pieter bedankt voor de begeleiding in mijn eerste jaar, je 
hebt een grote indruk op me gemaakt. Ik kon bij jou met elke synthetische vraag 
terecht. Ingrid, bedankt voor de prettige samenwerking en veel succes met de rest 
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van je carrière. Kristien, bedankt voor de gezellige korte tijd dat wij een kantoor 
deelden. Farida en Tanja bedankt voor alle leuke gesprekken, sommigen niet helemaal 
voor mij bedoeld, en alle hulp bij mijn vragen, werk gerelateerd of totaal niet. Ik neem 
aan dat jullie dit ook wel in het Nederlands kunnen lezen. Nahla, thank you for all the 
sweets and pleasant company. Stepan, good luck with the remainder of your PhD 
period. 
Tevens wil ik mijn mede-PhD studenten en collega’s bedanken voor het creëren van 
een geweldige sfeer op de afdeling met vele feestjes, filmavonden, congressen en 
uitstapjes. In het bijzonder Stella, altijd enthousiast en positief en dat heb je zeker op 
mij overgedragen. Bedankt: Roy, Danielle, Armand, Rick, Kanin, Annemiek, Linda, 
Alexandra, Peter, Jelle, Jens, Suzanne, Frauke, Niko, Hans, Bogac.  
In het bijzonder wil ik nog de Biochemical Brothers bedanken, Jelle en Niko, bedankt 
dat jullie samen met mij de uitdaging zijn aangegaan en IRONMAN Maastricht tot een 
goed einde hebben gebracht. Ik hoop dat dit een terugkerend event gaat worden op 
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Ook wil ik graag mijn trainingsmaatjes bij Zv Kimbria bedanken, waar ik iedere avond 
even mijn hoofd kon leegmaken. 
Verder wil ik iedereen bedanken die mij (moreel) gesteund heeft tijdens mijn PhD 
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en dat was niet zonder reden, thuis is voor mij nog altijd bij jullie. Papa en mama 
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